<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9607835</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20545</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Molecular psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">1359-4184</issn>
<issn pub-type="epub">1476-5578</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26390828</article-id>
<article-id pub-id-type="pmc">4684728</article-id>
<article-id pub-id-type="doi">10.1038/mp.2015.141</article-id>
<article-id pub-id-type="manuscript">NIHMS703456</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular Substrates of Schizophrenia: Homeostatic Signaling to Connectivity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Landek-Salgado</surname>
<given-names>Melissa A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faust</surname>
<given-names>Travis E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sawa</surname>
<given-names>Akira</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, John Hopkins University School of Medicine, Baltimore, MD, USA</aff>
<aff id="A2"><label>2</label>Department of Neuroscience, John Hopkins University School of Medicine, Baltimore, MD, USA</aff>
<author-notes>
<corresp id="CR1"><bold>Corresponding author</bold> Akira Sawa, M.D., Ph.D., Johns Hopkins Hospital, 600 N. Wolfe Street, Meyer 3-166, Baltimore, MD 21287, Telephone Number: 410-955-4726, Fax Number: 410-614-1792, <email>asawa1@jhmi.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>7</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>9</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>5</month>
<year>2016</year>
</pub-date>
<volume>21</volume>
<issue>1</issue>
<fpage>10</fpage>
<lpage>28</lpage>
<!--elocation-id from pubmed: 10.1038/mp.2015.141-->
<permissions>
<license xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">
<license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
</license>
</permissions>
<abstract>
<p id="P1">Schizophrenia (SZ) is a devastating psychiatric condition affecting numerous brain systems. Recent studies have identified genetic factors that confer an increased risk of SZ and participate in the disease etiopathogenesis. In parallel to such bottom-up approaches, other studies have extensively reported biological changes in patients by brain imaging, neurochemical and pharmacological approaches. This review highlights the molecular substrates identified through studies with SZ patients, namely those using top-down approaches, while also referring to the fruitful outcomes of recent genetic studies. We have sub-classified the molecular substrates by system, focusing on elements of neurotransmission, targets in white matter-associated connectivity, immune/inflammatory and oxidative stress-related substrates, and molecules in endocrine and metabolic cascades. We further touch on crosstalk among these systems and comment on the utility of animal models in charting the developmental progression and interaction of these substrates. Based on this comprehensive information, we propose a framework for SZ research based on the hypothesis of an imbalance in homeostatic signaling from immune/inflammatory, oxidative stress, endocrine and metabolic cascades that, at least in part, underlies deficits in neural connectivity relevant to SZ. Thus, this review aims to provide information that is translationally useful and complementary to pathogenic hypotheses that have emerged from genetic studies. Based on such advances in SZ research, it is highly expected that we will discover biomarkers that may help in the early intervention, diagnosis or treatment of SZ.</p>
</abstract>
<kwd-group>
<kwd>Schizophrenia</kwd>
<kwd>neurotransmission</kwd>
<kwd>white matter</kwd>
<kwd>inflammation</kwd>
<kwd>oxidative stress</kwd>
<kwd>endocrine and metabolism</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Schizophrenia (SZ) is one of the most devastating mental conditions with a lifetime prevalence of about 0.7-1%.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> If we include the prevalence of subclinical psychotic experiences and symptoms, which are likely to share similar biological mechanisms with SZ, the prevalence increases to about 8%.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> The cross-sectional clinical manifestations and course of SZ are heterogeneous with a complex phenomenology. However, even among clinical psychiatrists, a more simplified sub-classification of clinical symptoms is frequently used to facilitate biological and translational studies<sup><xref ref-type="bibr" rid="R3">3</xref></sup>: positive symptoms (e.g., hallucinations, delusions, and disorganized thoughts and speech), negative symptoms (e.g., apathy, affective flattening, social withdrawal), and cognitive dysfunction (e.g., deficits in working memory, verbal memory). Although SZ typically manifests in the second decade of life, abnormal neurodevelopmental processes are thought to begin during prenatal and perinatal stages.<sup><xref ref-type="bibr" rid="R4">4</xref></sup></p>
<p id="P3">Several ‘biological’ hypotheses of SZ were originally proposed because of the effects of drugs. The dopamine hypothesis of SZ evolved from multiple observations and studies including findings that antipsychotic drugs used for SZ block dopamine D2 receptors.<sup><xref ref-type="bibr" rid="R5">5</xref>-<xref ref-type="bibr" rid="R7">7</xref></sup> Years later the glutamatergic hypothesis of SZ was proposed based on observations that phencyclidine or ketamine mimic SZ-like manifestations, even including some aspects of negative symptoms and cognitive dysfunction, by blocking N-methyl-D-aspartate receptors (NMDAR).<sup><xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R9">9</xref></sup></p>
<p id="P4">SZ is now considered a polygenic condition;<sup><xref ref-type="bibr" rid="R10">10</xref>-<xref ref-type="bibr" rid="R12">12</xref></sup> many candidate susceptibility genes have been identified, however, individual effect sizes are modest in sporadic cases. Single nucleotide polymorphisms (SNP), copy number variations, and <italic>de novo</italic> mutations have been implicated in conferring risk of SZ.<sup><xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref></sup> In addition, in the contexts of both common and rare variants, susceptibility factors that have been suggested for SZ confer risk for other mental conditions, such as bipolar disorder and autism.<sup><xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R15">15</xref>-<xref ref-type="bibr" rid="R18">18</xref></sup> This is reasonable given that the current diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), emphasize clinical reliability and utility rather than etiological validity.<sup><xref ref-type="bibr" rid="R19">19</xref></sup></p>
<p id="P5">In addition to genetic studies (bottom-up approach), years of research with clinical subjects and biospecimens have implicated multiple molecular targets of SZ. In this review, we discuss the different ‘molecular’ substrates of SZ that have been identified primarily through human (patient) studies, namely those using top-down approaches, and sub-classify them by biological system (<bold><xref ref-type="table" rid="T1">Table 1</xref></bold>): neurotransmission, white matter-associated connectivity, immune/inflammatory response and oxidative stress, endocrine system, and metabolic cascades. For each system, we focus on evidence from brain imaging, neurochemical, postmortem, genetic, and clinicopharmacological studies (<bold><xref ref-type="table" rid="T2">Table 2</xref></bold>). Lastly, we describe the possible integration of these systems and additional evidence from animal models of SZ under an overall perspective of an in-depth understanding of the disease pathology and translational application.</p>
<p id="P6">The goal of this review article is to provide comprehensive information that is translationally useful and complementary to pathogenic hypotheses that have recently emerged from genetic studies. To address this goal, we propose a framework for SZ research based on the hypothesis of an imbalance in homeostatic signaling that, at least in part, underlies deficits in neural connectivity relevant to SZ. More concretely, we describe how inflammatory, oxidative stress, endocrine, and metabolic homeostatic signaling processes mediate and pathologically modulate neurotransmission and myelinated tracks. Given that many comprehensive review articles on psychiatric genetics and animal models have been published recently,<sup><xref ref-type="bibr" rid="R20">20</xref>-<xref ref-type="bibr" rid="R24">24</xref></sup> we only touch on the critical conceptual viewpoints in these areas.</p>
<p id="P7">By referring to the information from genetic studies, we can address the question of whether molecular substrates identified through human patient studies are primary or secondary. In particular, molecular studies in first episode psychosis and individuals with high genetic risk of SZ combined with convergent evidence from genetic and animal models can help determine the central disease processes. The successful integration of pathogenic-oriented (bottom-up) and patient phenotype-oriented (top-down) research has precedence in many other diseases, such as cancer, metabolic syndrome and Alzheimer's disease.<sup><xref ref-type="bibr" rid="R25">25</xref>-<xref ref-type="bibr" rid="R29">29</xref></sup></p>
</sec>
<sec id="S2">
<title>Neurotransmission</title>
<sec id="S3">
<title>Dopamine</title>
<p id="P8">Molecular brain imaging studies have provided useful insights into dopamine, glutamate, and γ-aminobutyric acid (GABA) neurotransmission in SZ. The majority of the molecular imaging studies using positron emission tomography (PET) and single photon emission computerized tomography (SPECT) have suggested that presynaptic striatal dopamine is elevated and dopamine release is increased in subjects with SZ. PET studies have found that striatal L-[β-<sup>11</sup>C]DOPA or [<sup>18</sup>F]DOPA uptake is elevated in subjects with SZ as well as subjects showing prodromal symptoms of SZ, suggesting an elevation in presynaptic striatal dopamine in SZ (<bold><xref ref-type="fig" rid="F1">Figure 1</xref></bold>).<sup><xref ref-type="bibr" rid="R30">30</xref>-<xref ref-type="bibr" rid="R34">34</xref></sup> A PET study using [<sup>11</sup>C]raclopride and SPECT studies using [<sup>123</sup>I]IBZM found significantly greater amphetamine-induced reductions in the binding potential of the radiotracers in the striatum of subjects with SZ compared to controls, suggesting that there is enhanced dopamine release in SZ.<sup><xref ref-type="bibr" rid="R35">35</xref>-<xref ref-type="bibr" rid="R37">37</xref></sup> However, it has been suggested that the elevated dopamine observed in SZ is linked to psychosis rather than the disease itself.<sup><xref ref-type="bibr" rid="R38">38</xref></sup></p>
<p id="P9">It has been further shown that subjects with SZ have a significant increase in dopamine D2 receptor (D2R) availability in the associative striatum, specifically in the precommissural dorsal caudate, but not in the ventral or the sensorimotor striatum, after dopamine depletion.<sup><xref ref-type="bibr" rid="R39">39</xref></sup> A meta-analysis of 13 studies using PET and SPECT found a significant, but small, elevation in striatal D2R density in subjects with SZ.<sup><xref ref-type="bibr" rid="R40">40</xref></sup> Studies analyzing D2R availability in the thalamus, anterior cingulate cortex and temporal cortex have found both decreased and unaltered D2R availability in SZ.<sup><xref ref-type="bibr" rid="R41">41</xref></sup> Additionally, a recent genome-wide association study (GWAS) found that the <italic>D2R</italic> gene is within a SZ-associated locus.<sup><xref ref-type="bibr" rid="R42">42</xref></sup></p>
<p id="P10">Results of PET studies using [<sup>11</sup>C]SCH23390 and [<sup>11</sup>C]NNC112 to image prefrontal cortex dopamine D1 receptor (D1R) binding are contradictory, reporting reduced, unaltered and increased receptor binding in SZ patients.<sup><xref ref-type="bibr" rid="R43">43</xref>-<xref ref-type="bibr" rid="R45">45</xref></sup> A meta-analysis of seven postmortem studies and one PET study did not find an elevation in D1R in SZ.<sup><xref ref-type="bibr" rid="R46">46</xref></sup> Studies measuring levels of homovanillic acid, a metabolite of dopamine, in the cerebrospinal fluid (CSF) of subjects with SZ are inconsistent; some report no difference between SZ and control subjects but others report lower levels in SZ.<sup><xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R48">48</xref></sup></p>
<p id="P11">Abnormalities in dopamine neurotransmission have also been suggested by postmortem studies. Changes in the density and mRNA levels of some classes of dopamine receptors have been suggested in the prefrontal cortex, striatum, and hippocampus of SZ subjects.<sup><xref ref-type="bibr" rid="R49">49</xref>-<xref ref-type="bibr" rid="R51">51</xref></sup> Reductions in the density of tyrosine hydroxylase, an enzyme involved in dopamine synthesis, and the density of dopamine membrane transporter immunoreactive axons in the prefrontal cortex have been reported in SZ.<sup><xref ref-type="bibr" rid="R52">52</xref></sup> A reduced density of tyrosine hydroxylase immunoreactive axons in the entorhinal cortex has also been reported.<sup><xref ref-type="bibr" rid="R53">53</xref></sup></p>
<p id="P12">In summary, the main finding on dopaminergic neurotransmission is that a state of overstimulation of D2R in the associative striatum exists in SZ starting early in the prodromal phase and corresponds with psychosis as well as with the therapeutic response to antipsychotics.<sup><xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R54">54</xref></sup> Other symptom domains are thought to relate to deficits in dopamine transmission in cortical and extrastriatal regions, but conclusive evidence for this has not emerged yet.<sup><xref ref-type="bibr" rid="R55">55</xref></sup></p>
</sec>
<sec id="S4">
<title>Serotonin</title>
<p id="P13">Most typical antipsychotics are D2R antagonists, whereas several atypical antipsychotic drugs also target serotonin receptors, in particular the 5HT<sub>2A</sub> receptor, for antipsychotic efficacy.<sup><xref ref-type="bibr" rid="R56">56</xref></sup> Furthermore, indoleamine hallucinogens such as psilocybin, can elicit SZ-like symptoms that can be blocked by 5HT<sub>2</sub> antagonists.<sup><xref ref-type="bibr" rid="R57">57</xref></sup> Postmortem studies have shown a reduction in the density of 5HT<sub>2A</sub> receptors in the prefrontal and frontal cortex in SZ.<sup><xref ref-type="bibr" rid="R58">58</xref></sup> These results suggest involvement of serotonin in the pathophysiology of SZ, or at least in psychotic manifestations.</p>
</sec>
<sec id="S5">
<title>Glutamate</title>
<p id="P14">Pharmacological evidence has also implicated glutamate neurotransmission in SZ. Acute administration of NMDAR antagonists, such as phencyclidine (PCP) or ketamine, transiently induces symptoms typically associated with psychosis, including positive, negative and cognitive deficits.<sup><xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R60">60</xref></sup> This observation led to a hypothesis for NMDAR glutamate dysregulation as a prominent pathophysiological feature of SZ. Studies using autopsied brains have shown reduced numbers of dendritic spines on pyramidal neurons in SZ.<sup><xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R62">62</xref></sup> Furthermore, analysis of GWAS and genetic and gene expression studies have indicated the significance of genes involved in glutamate receptor signaling.<sup><xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R42">42</xref>, <xref ref-type="bibr" rid="R63">63</xref></sup> These include the NMDAR subunit gene <italic>GRIN2A</italic>, glutamate receptor, ionotropic, AMPA 1 (GRIA1), and genes involved in the activity-regulated cytoskeleton-associated protein (ARC) signaling complex.</p>
<p id="P15">Many <sup>1</sup>H magnetic resonance spectroscopy (MRS) studies have measured glutamate, glutamine or the sum of glutamate and glutamine (Glx) in subjects with SZ; some studies also include GABA in the measurement.<sup><xref ref-type="bibr" rid="R64">64</xref></sup> Several reports have indicated that glutamatergic levels in the medial prefrontal cortex and anterior cingulate cortex are elevated in medication-naïve and unmedicated SZ subjects; however, studies also report that glutamatergic levels tend to decrease during the disease course, possibly reflecting treatment response and/or disease progression (<bold><xref ref-type="table" rid="T3">Table 3</xref></bold>).<sup><xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R64">64</xref>-<xref ref-type="bibr" rid="R68">68</xref></sup> A recent review summarizes the findings of many MRS studies with an emphasis on regional specificity: medication-naïve and unmedicated SZ subjects have elevated glutamatergic levels in the medial prefrontal cortex, but not in the dorsolateral prefrontal cortex and hippocampus, while studies on the thalamus report more variable effects with unaltered, increased or decreased glutamatergic levels (<bold><xref ref-type="table" rid="T3">Table 3</xref></bold>).<sup><xref ref-type="bibr" rid="R64">64</xref>, <xref ref-type="bibr" rid="R69">69</xref></sup> Meanwhile, studies with CSF have shown that the levels of glutamate are similar between control and medicationnaïve or unmedicated SZ subjects.<sup><xref ref-type="bibr" rid="R70">70</xref>-<xref ref-type="bibr" rid="R72">72</xref></sup> Lastly, some studies have explored a role for glutamate in SZ pathophysiology:<sup><xref ref-type="bibr" rid="R73">73</xref>, <xref ref-type="bibr" rid="R74">74</xref></sup> ketamine administration to rodents elicited hypermetabolism in the CA1 sub-region of the hippocampus, while repeated exposure shifted the hippocampus to a hypermetabolic basal state with concurrent atrophy. Similarly, hypermetabolism of the hippocampus, in particular the CA1 sub-region, has also been seen in SZ patients, which may be a predictive factor of hippocampal atrophy.<sup><xref ref-type="bibr" rid="R73">73</xref>, <xref ref-type="bibr" rid="R74">74</xref></sup></p>
<p id="P16">In addition, reports of patients who have autoantibodies to the NMDAR (anti-NMDAR encephalitis) and show psychotic symptoms including visual or auditory hallucinations and paranoid thoughts have supported the involvement of glutamate and NMDAR in the pathophysiology of SZ and psychosis.<sup><xref ref-type="bibr" rid="R75">75</xref>-<xref ref-type="bibr" rid="R78">78</xref></sup> The causality of the autoantibody to psychosis, at least in this specific disease condition, has been demonstrated in cases where an ovarian teratoma is present: tumor removal and intravenous immunoglobulin or intravenous steroids can reverse the psychiatric symptoms within weeks.<sup><xref ref-type="bibr" rid="R79">79</xref>, <xref ref-type="bibr" rid="R80">80</xref></sup> Collectively, these pharmacological, clinical, genetic, and autoimmune studies have repeatedly implicated glutamate dysfunction in SZ.</p>
</sec>
<sec id="S6">
<title>GABA</title>
<p id="P17">There is still a technical debate about measuring GABA consistently in different scanners and institutions. However, one group found reduced GABA concentrations in the basal ganglia, but not in the frontal lobe, in early stage SZ subjects.<sup><xref ref-type="bibr" rid="R81">81</xref></sup> In contrast, another group has reported that GABA levels were elevated in the medial prefrontal cortex in unmedicated SZ subjects.<sup><xref ref-type="bibr" rid="R66">66</xref></sup> As for chronic SZ, studies have reported unaltered GABA concentrations in the basal ganglia, reduced concentrations in the visual cortex, and elevated levels in the parieto-occipital cortex.<sup><xref ref-type="bibr" rid="R82">82</xref>-<xref ref-type="bibr" rid="R84">84</xref></sup> Unaltered and elevated GABA concentrations in the anterior cingulate cortex have been reported in chronic SZ, while a more recent study found reduced GABA concentrations in the anterior cingulate of older subjects with chronic SZ (<bold><xref ref-type="table" rid="T3">Table 3</xref></bold>).<sup><xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R84">84</xref>, <xref ref-type="bibr" rid="R85">85</xref></sup> Recently, a study using MRS and magnetoencephalography (MEG) to measure resting GABA and glutamate concentrations and stimulus-induced gamma oscillations in the occipital cortex of healthy subjects, reported that there was no correlation between GABA, glutamate, or the GABA/glutamate ratio and gamma peak frequency or gamma amplitude.<sup><xref ref-type="bibr" rid="R86">86</xref></sup> In addition, several studies have measured GABA levels in the plasma and CSF of unmedicated SZ patients and reported no major differences between SZ and controls, however, one report found a significant decrease in mean CSF GABA levels after neuroleptic treatment.<sup><xref ref-type="bibr" rid="R87">87</xref>-<xref ref-type="bibr" rid="R89">89</xref></sup> One study reported significantly lower CSF GABA levels in patients whose duration of illness was 4 years or less compared to subjects whose duration of illness was greater than 4 years.<sup><xref ref-type="bibr" rid="R90">90</xref></sup> However, another study reported similar GABA levels between acute SZ subjects and controls but increased CSF GABA levels in chronic SZ subjects.<sup><xref ref-type="bibr" rid="R91">91</xref></sup> In general, MRS studies on GABA in SZ are scarce and show inconclusive results at this time.</p>
<p id="P18">Postmortem studies have provided convincing evidence of GABAergic changes in SZ.<sup><xref ref-type="bibr" rid="R92">92</xref>, <xref ref-type="bibr" rid="R93">93</xref></sup> These studies have consistently reported alterations in GABAergic interneurons in the prefrontal cortex. These alterations include decreased glutamic acid decarboxylase 67 (GAD67) and parvalbumin (PV).<sup><xref ref-type="bibr" rid="R94">94</xref>-<xref ref-type="bibr" rid="R98">98</xref></sup> Additionally, some potassium channels (Kv3.1 and KCNS3) that are predominately expressed in PV positive neurons, are decreased in the prefrontal cortex in SZ.<sup><xref ref-type="bibr" rid="R99">99</xref>, <xref ref-type="bibr" rid="R100">100</xref></sup> PV positive neurons are fast spiking, synchronize pyramidal neuron firing and play a role in the generation of gamma oscillations.<sup><xref ref-type="bibr" rid="R101">101</xref></sup> Thus, deficits in this population of neurons may contribute to the cognitive deficits observed in SZ.<sup><xref ref-type="bibr" rid="R101">101</xref></sup> Decreased somatostatin and cholecystokinin mRNA levels have also been reported in SZ.<sup><xref ref-type="bibr" rid="R102">102</xref></sup></p>
</sec>
<sec id="S7">
<title>α7-nicotinic receptor</title>
<p id="P19">A high percentage of SZ patients smoke cigarettes. It has been shown that cigarette smoking improves sensory gating, P50 inhibition, and prepulse inhibition in SZ.<sup><xref ref-type="bibr" rid="R103">103</xref>-<xref ref-type="bibr" rid="R105">105</xref></sup> The P50 sensory deficit observed in SZ might be genetically linked to the locus of the α7-nicotinic acetylcholine receptor gene, <italic>CHRNA7</italic>, on chromosome 15q14.<sup><xref ref-type="bibr" rid="R106">106</xref></sup> Multiple linkage studies have also supported this evidence.<sup><xref ref-type="bibr" rid="R107">107</xref>, <xref ref-type="bibr" rid="R108">108</xref></sup> Postmortem studies using [<sup>125</sup>I]alpha-bungarotoxin have shown fewer nicotinic receptors in the hippocampus, the reticular nucleus of the thalamus, and the cingulate cortex of subjects with SZ.<sup><xref ref-type="bibr" rid="R109">109</xref>-<xref ref-type="bibr" rid="R111">111</xref></sup> Brain imaging studies to validate this hypothesis using [<sup>123</sup>I]5-IA-85380 and 2-[<sup>18</sup>F]FA, radiotracers for high affinity nicotinic acetylcholine receptors, are under way.<sup><xref ref-type="bibr" rid="R112">112</xref>, <xref ref-type="bibr" rid="R113">113</xref></sup></p>
</sec>
<sec id="S8">
<title>Synaptic assembly</title>
<p id="P20">As described above in the context of glutamate, some genetic susceptibility factors for SZ have distinct synaptic functions in a broader sense.<sup><xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R42">42</xref>, <xref ref-type="bibr" rid="R114">114</xref></sup> Some of the genes involved in synaptic function and plasticity that have been identified within SZ-associated loci include potassium channel tetramerization domain containing 13 (KCTD13), contactin 4 (CNTN4), p21 protein-activated kinase 6 (PAK6), neuroligin 4, X-linked (NLGN4X), and genes related to the postsynaptic ARC complex.<sup><xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R42">42</xref></sup> Functional studies of such candidates, including disrupted in schizophrenia 1 (DISC1) and p21 protein-activated kinase 7 (PAK7), also support synaptic roles.<sup><xref ref-type="bibr" rid="R115">115</xref>-<xref ref-type="bibr" rid="R117">117</xref></sup> Microarray analysis of the prefrontal cortex found that the expression of genes related to the presynaptic secretory machinery [for example, N-thylmaleimide sensitive factor (<italic>NSF)</italic> and synapsin II (<italic>SYN2)</italic>] were decreased in SZ.<sup><xref ref-type="bibr" rid="R118">118</xref></sup> Although brain imaging studies of synaptic changes in SZ are lacking, the field awaits the development of new techniques to assess synaptic changes in SZ.</p>
<p id="P21">As described, multiple lines of evidence suggest that multiple types of neurotransmission, in particular dopaminergic, glutamatergic, and GABAergic neurotransmission, are altered in the brains of SZ patients. However, at this time it is unclear if the reported changes are causal or secondary, but in either case, the changes are critical for the pathophysiology.</p>
</sec>
</sec>
<sec id="S9">
<title>White matter-associated connectivity</title>
<p id="P22">Neurotransmitters play a role in cell-cell communication in the brain, but distant communication is also dependent on proper transduction of action potentials along axon tracts. White matter regions contain long-range axonal connections insulated by myelin, a lipid-dense material produced by oligodendrocytes. Signaling between oligodendroyctes and axons mediates the formation of nodes of Ranvier (NoR) and internodal myelin sheathes.<sup><xref ref-type="bibr" rid="R119">119</xref></sup> The myelin sheathes increase electrical resistance, allowing for faster propagation of electrical signals along axons. Dysmyelination can affect neuronal connectivity; decreased white matter integrity has been correlated with functional deficits in demyelinating diseases.<sup><xref ref-type="bibr" rid="R120">120</xref></sup> Although there is no robust demyelination in the brain in SZ, many reports have indicated a deficit in white matter associated connectivity.<sup><xref ref-type="bibr" rid="R121">121</xref></sup></p>
<p id="P23">Diffusion tensor imaging (DTI) with MRI can measure the diffusion of water molecules along white matter bundles. Fractional anisotropy (FA), a metric of the rate of diffusion along axons and a measure of myelin integrity, is reduced in SZ patients.<sup><xref ref-type="bibr" rid="R121">121</xref>-<xref ref-type="bibr" rid="R123">123</xref></sup> Deep white matter tracts in the frontal and temporal lobes interconnecting to the thalamus, cingulate gyrus, amygdala, insula, hippocampus, and occipital lobe are reportedly those most affected in SZ.<sup><xref ref-type="bibr" rid="R124">124</xref></sup> Changes are observed in chronic, first episode, and adolescents with early onset SZ as well as subjects in prodromal stages and adolescents at high clinical risk for developing SZ.<sup><xref ref-type="bibr" rid="R125">125</xref>, <xref ref-type="bibr" rid="R126">126</xref></sup> A longitudinal study in SZ patients also found heterogeneous decreases in white matter volume (total cerebral, frontal, temporal, parietal) over the disease course, primarily at the onset of the disorder.<sup><xref ref-type="bibr" rid="R127">127</xref></sup> Notably, the regions that are prominently affected are those still undergoing myelination during late adolescence. Furthermore, functional MRI (fMRI) studies now suggest altered connectivity in SZ patients. Recently, it was reported that the global brain signal (the average signal across all voxels in the brain derived from fMRI) is altered in SZ subjects, but not in subjects with bipolar disorder.<sup><xref ref-type="bibr" rid="R128">128</xref></sup> Time series of resting-state fMRI suggest that patients with SZ have reduced functional network strength and altered brain network topology.<sup><xref ref-type="bibr" rid="R129">129</xref>-<xref ref-type="bibr" rid="R131">131</xref></sup> Also, recent investigations have documented robust and replicable dysconnectivity in thalamocortical systems in chronic SZ.<sup><xref ref-type="bibr" rid="R132">132</xref>, <xref ref-type="bibr" rid="R133">133</xref></sup> Patients with SZ also show impaired task-dependent communication between brain regions including reduced suppression of default network activity and weaker activation of task-associated regions.<sup><xref ref-type="bibr" rid="R134">134</xref>-<xref ref-type="bibr" rid="R136">136</xref></sup> Several recent studies combining functional and structural imaging have found correlations between reduced FA and altered brain activity in specific neural circuits.<sup><xref ref-type="bibr" rid="R137">137</xref></sup> Collectively, these structural and functional investigations repeatedly point to profound alterations in major neural systems related to executive control.<sup><xref ref-type="bibr" rid="R138">138</xref>, <xref ref-type="bibr" rid="R139">139</xref></sup></p>
<p id="P24">Postmortem tissue analyses of SZ brains have found abnormalities in oligodendrocytes, the brain's source of myelin.<sup><xref ref-type="bibr" rid="R140">140</xref></sup> For example, a report indicated a decrease in the number and density of oligodendrocytes in the grey and white matter of Brodmann area 9.<sup><xref ref-type="bibr" rid="R141">141</xref></sup> Additionally, microarray and real-time quantitative polymerase chain reaction (qPCR) studies identified changes in the expression of oligodendrocyte and myelin-related genes such as proteolipid protein 1 (PLP1), myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG), and oligodendrocyte transcription factor 2 (OLIG2) in the prefrontal cortex.<sup><xref ref-type="bibr" rid="R142">142</xref>, <xref ref-type="bibr" rid="R143">143</xref></sup> Similar studies have noted expression changes in myelination-related genes in additional brain areas including the temporal cortex, cingulate cortex, and the hippocampus.<sup><xref ref-type="bibr" rid="R144">144</xref>-<xref ref-type="bibr" rid="R146">146</xref></sup></p>
<p id="P25">Furthermore, a number of myelin-related genes have been genetically linked to an increased risk of SZ.<sup><xref ref-type="bibr" rid="R147">147</xref></sup> These include genes encoding neuregulin-1 (NRG1), receptor tyrosine-protein kinase erbB-4 (ERBB4), reticulon 4 (RTN4/NOGO), PLP1, MAG, MOG, OLIG2, 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP1) and ankyrin-3 (ANK3).<sup><xref ref-type="bibr" rid="R147">147</xref>-<xref ref-type="bibr" rid="R156">156</xref></sup> Several of the molecules that are genetically associated with SZ also have altered expression in the SZ brain, such as PLP1, MAG, MOG and OLIG2. While no myelin-related genes reached significance in a large GWAS set for SZ,<sup><xref ref-type="bibr" rid="R11">11</xref></sup> a few (<italic>NRG1, ERBB4, ANK3</italic>) had sub-threshold associations (p-value &lt; 5 × 10<sup>−5</sup>), and broader pathway analysis revealed a significant association for genes in myelination-related pathways and those with specific glial cell-type functions.<sup><xref ref-type="bibr" rid="R157">157</xref>, <xref ref-type="bibr" rid="R158">158</xref></sup> NRG1 and its erbB receptors are important signaling molecules for axon guidance and myelination.<sup><xref ref-type="bibr" rid="R150">150</xref></sup> Unaffected subjects carrying a risk allele for NRG1 have reduced white matter density.<sup><xref ref-type="bibr" rid="R159">159</xref></sup> ANK3 is an axonal protein that helps form the scaffolding for NoR and has also been identified as one of the most significant genetic risk factors shared between SZ and bipolar disorder.<sup><xref ref-type="bibr" rid="R156">156</xref></sup> Another recent study identified several NoR proteins affected in SZ, including ANK3 and its interactors.<sup><xref ref-type="bibr" rid="R160">160</xref></sup> These results highlight the importance of neuron-glia interactions at the NoR in psychiatric illness.<sup><xref ref-type="bibr" rid="R161">161</xref></sup> In addition, while not traditionally identified as myelin/oligodendrocyte-associated genes, several susceptibility genes for SZ that encode the zinc finger binding protein 804A (ZNF804A), L-type voltage-dependent calcium channel CAV1.2 (CACNA1C), DISC1, and microRNA-137 (MIR137) have been associated with white matter phenotypes in SZ patients, as well as, control subjects that carry risk alleles.<sup><xref ref-type="bibr" rid="R161">161</xref>, <xref ref-type="bibr" rid="R162">162</xref></sup></p>
<p id="P26">Lastly, we refer to some interesting aspects of clinicopharmacology. Studies have suggested that treatment with antipsychotics, lithium, antidepressants, and electroconvulsive therapy may share common myelin-protective signaling mechanisms.<sup><xref ref-type="bibr" rid="R163">163</xref></sup> One study found that higher white matter integrity in first episode SZ was predictive of responsiveness to antipsychotics.<sup><xref ref-type="bibr" rid="R164">164</xref></sup></p>
<p id="P27">In summary, data from imaging and postmortem studies have suggested the presence of abnormal myelination in SZ. Genetic studies have suggested the importance of neuron-oligodendrocyte interactions. Given that the typical onset of SZ coincides with the final stages of myelination in the frontal and temporal cortices, aberrant myelin development may contribute to the presentation of symptoms in patients.</p>
</sec>
<sec id="S10">
<title>Immune/inflammatory response and oxidative stress</title>
<p id="P28">Epidemiological studies have suggested that prenatal infections with viruses, bacteria, or parasites increases the risk of their offspring developing SZ in adulthood.<sup><xref ref-type="bibr" rid="R165">165</xref></sup> Given that the full onset of SZ is frequently in late adolescence and young adulthood, addressing mechanisms and mediators of the long pathological trajectory from initial predisposition to disease onset remains a central question of SZ research.<sup><xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R166">166</xref></sup></p>
<sec id="S11">
<title>Cytokines</title>
<p id="P29">An imbalance in the cytokine/chemokine network may be an explanation for why multiple infections can increase the risk of SZ; the disturbance of this network during the neonatal period may alter fetal brain development.<sup><xref ref-type="bibr" rid="R165">165</xref></sup> In accordance with this hypothesis, studies on serum levels of cytokines in SZ suggest that IL-1β, IL-6, TNF-α and IL-2 are increased in SZ.<sup><xref ref-type="bibr" rid="R167">167</xref>-<xref ref-type="bibr" rid="R171">171</xref></sup> However, it should be noted that there are also studies that report unaltered serum levels of IL-1β, IL-6, TNF-α and IL-2 in SZ.<sup><xref ref-type="bibr" rid="R167">167</xref>, <xref ref-type="bibr" rid="R169">169</xref>, <xref ref-type="bibr" rid="R172">172</xref>, <xref ref-type="bibr" rid="R173">173</xref></sup> A recent meta-analysis also found that serum levels of IL-1β, the soluble IL-2 receptor (sIL-2R), IL-6 and TNF-α were increased in drug-naïve first episode psychosis (SZ, schizophreniform disorder, delusional disorder and brief reactive psychosis), however, IL-2, IL-4 and IFN-γ levels were not altered.<sup><xref ref-type="bibr" rid="R174">174</xref></sup> A meta-analysis of antipsychotic-induced cytokine changes in SZ found that antipsychotic treatment increased IL-12 and sIL-2R and reduced IL-1β and IFN-γ plasma levels, with treatment duration having no effect.<sup><xref ref-type="bibr" rid="R175">175</xref></sup> Additionally, two studies found an association between maternal cytokine levels (TNF-α and IL-8) and increased risk of SZ in the offspring.<sup><xref ref-type="bibr" rid="R176">176</xref>, <xref ref-type="bibr" rid="R177">177</xref></sup> Studies that compare such inflammatory mediators in the CSF of controls and SZ subjects (and prodromal subjects) are also available. In particular, a recent study that purely utilized unmedicated first onset SZ and prodromal subjects supports alterations of inflammatory mediators in psychotic subjects, including the IL-6 cascade and IL-8.<sup><xref ref-type="bibr" rid="R178">178</xref></sup></p>
</sec>
<sec id="S12">
<title>Microglia</title>
<p id="P30">Chronically activated T cells, macrophages and microglia produce cytokines that may impact brain development.<sup><xref ref-type="bibr" rid="R167">167</xref>, <xref ref-type="bibr" rid="R179">179</xref>, <xref ref-type="bibr" rid="R180">180</xref></sup> The potential involvement of microglia is of particular interest from a mechanistic viewpoint since recent studies have indicated a role for microglia in synaptic pruning and maintenance.<sup><xref ref-type="bibr" rid="R181">181</xref>-<xref ref-type="bibr" rid="R183">183</xref></sup> Aberrant synaptic pruning in adolescence is one of the important working hypotheses in SZ pathology.<sup><xref ref-type="bibr" rid="R184">184</xref></sup> Furthermore, a study using <italic>in vivo</italic> two-photon imaging has shown that blockade of excess synaptic pruning in late adolescence ameliorates deficits in prepulse inhibition, at least in an animal model that may model some SZ manifestations.<sup><xref ref-type="bibr" rid="R116">116</xref></sup> Taken together, reactivation during adolescence of microglia pathologically primed in early development may be a likely scenario to account for the mechanism. Some postmortem studies have found an increase in the density or activation of microglia in SZ: however, other studies found no difference between controls and subjects with SZ.<sup><xref ref-type="bibr" rid="R179">179</xref>, <xref ref-type="bibr" rid="R185">185</xref>-<xref ref-type="bibr" rid="R189">189</xref></sup> A more recent study that used next generation sequencing and Western blotting has shown that microglial markers are upregulated in the dorsolateral prefrontal cortex of SZ.<sup><xref ref-type="bibr" rid="R190">190</xref></sup> Furthermore, immunohistochemistry for the human leukocyte antigen (HLA) class II molecules (HLA-DP, -DQ and –DR), which are expressed on antigen-presenting cells, revealed more positive cells in the white matter of subjects with SZ; the authors also indicated that these positive cells morphologically resembled microglia.<sup><xref ref-type="bibr" rid="R190">190</xref>, <xref ref-type="bibr" rid="R191">191</xref></sup></p>
<p id="P31">Although these studies provide promising evidence for the involvement of microglia and the inflammatory cascade in SZ, we also need to be prudent in interpreting data from the autopsied brain because confounding factors exist and the plausibility of detecting adolescent pathology from typically aged autopsied brains is unknown. Validation of ‘brain’ inflammation in SZ at the time of psychosis has recently been pursued using PET imaging with tracers that target molecules changed in neuroinflammation. In particular, radioligands that target the translocator protein (TSPO) (previously known as the peripheral benzodiazepine receptor) have been frequently used.<sup><xref ref-type="bibr" rid="R192">192</xref></sup> Activation of microglia results in an increase in the number of mitochondria per cell and an increase in the density of the peripheral benzodiazepine receptor in the outer mitochondrial membrane.<sup><xref ref-type="bibr" rid="R193">193</xref>, <xref ref-type="bibr" rid="R194">194</xref></sup> Two PET studies found an increase in the regional binding potential of [<sup>11</sup>C]PK11195, a classic TSPO tracer, in subjects with a psychotic disorder or SZ.<sup><xref ref-type="bibr" rid="R195">195</xref>, <xref ref-type="bibr" rid="R196">196</xref></sup> Given the limitations in the [<sup>11</sup>C]PK11195 tracer, such as high nonspecific binding, high lipophilicity and poor signal-to-noise ratio, recently new PET tracers (e.g., [<sup>11</sup>C]PBR28 and [<sup>11</sup>C]DPA713) have been developed and are beginning to be used.<sup><xref ref-type="bibr" rid="R197">197</xref>, <xref ref-type="bibr" rid="R198">198</xref></sup> A general limitation of TSPO brain imaging to test neuroinflammation is that this protein can also be influenced by mitochondrial deficits and oxidative stress that may also occur in SZ.<sup><xref ref-type="bibr" rid="R199">199</xref></sup> Assessment of brain inflammation in SZ using radioligands that target other inflammatory markers will shed further light on the role of inflammation in this disease.</p>
</sec>
<sec id="S13">
<title>Autoimmunity</title>
<p id="P32">Multiple combinations of environmental stressors and genetic factors contribute to SZ pathology.<sup><xref ref-type="bibr" rid="R165">165</xref>, <xref ref-type="bibr" rid="R200">200</xref>-<xref ref-type="bibr" rid="R202">202</xref></sup> Aberrant activation and an imbalance of immune/inflammatory cascades are likely due to both environmental influences and host susceptibility. Epidemiological data linking autoimmune diseases and SZ has recently been reviewed: celiac disease, autoimmune thyroiditis, Graves’ disease, type 1 diabetes, multiple sclerosis, autoimmune hepatitis, psoriasis, and Sjögren's syndrome are all associated with SZ, whereas, there is a very unique and negative association with rheumatoid arthritis.<sup><xref ref-type="bibr" rid="R203">203</xref>, <xref ref-type="bibr" rid="R204">204</xref></sup> The increased co-morbidity of SZ with many autoimmune diseases supports the idea that SZ has an intrinsic susceptibility to the immune/inflammatory response. This notion is further supported by GWAS, which found an association of SZ with the major histocompatibility complex (MHC) region.<sup><xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R42">42</xref>, <xref ref-type="bibr" rid="R205">205</xref>, <xref ref-type="bibr" rid="R206">206</xref></sup> Additionally, as discussed in the neurotransmission section, in some cases of anti-NMDAR encephalitis the presence of the autoantibody appears to be related to the psychiatric symptoms.<sup><xref ref-type="bibr" rid="R79">79</xref>, <xref ref-type="bibr" rid="R80">80</xref></sup></p>
</sec>
<sec id="S14">
<title>Oxidative Stress</title>
<p id="P33">The inflammatory response is interconnected with oxidative stress.<sup><xref ref-type="bibr" rid="R207">207</xref></sup> The significance of oxidative stress in SZ pathology is that the stress can lead to synaptic deterioration, abnormal myelination and interneuron deficits.<sup><xref ref-type="bibr" rid="R207">207</xref>, <xref ref-type="bibr" rid="R208">208</xref></sup> Oxidative stress occurs when antioxidant defense mechanisms fail to counterbalance reactive oxygen species (hydrogen peroxide, superoxide radicals, and hydroxyl radicals). Imbalances in the oxidative and antioxidant defense systems have been reported in SZ.<sup><xref ref-type="bibr" rid="R208">208</xref>, <xref ref-type="bibr" rid="R209">209</xref></sup> Studies with biospecimens (autopsied brain, olfactory cells, CSF and blood) have indicated changes in glutathione (GSH), microsomal glutathione <italic>S</italic>-transferase 1 (MGST1), superoxide dismutase (SOD), and catalase.<sup><xref ref-type="bibr" rid="R209">209</xref>-<xref ref-type="bibr" rid="R214">214</xref></sup> A recent report indicates a significant reduction in CSF SOD-1 from recent onset SZ compared with matched controls, however, there was no difference in the level of SOD-1 in chronic SZ.<sup><xref ref-type="bibr" rid="R212">212</xref></sup> The most reproducible evidence may be a reduction of GSH in the blood. Because access to biospecimens from unmedicated first onset SZ and prodromal subjects have become more frequently available, the validation of peripheral signs of oxidative stress with such subjects is awaited.</p>
<p id="P34">Several studies have investigated ‘brain’ oxidative stress by directly measuring GSH in the brain of living SZ patients. Although the measurement of GSH via MRS is a promising approach, the data thus far are inconsistent.<sup><xref ref-type="bibr" rid="R208">208</xref></sup> An initial study found a 52% reduction in the GSH level in the medial prefrontal cortex of drug-free subjects with SZ.<sup><xref ref-type="bibr" rid="R215">215</xref></sup> Two subsequent studies, focusing on the anterior cingulate and the posterior medial frontal cortex, did not find a difference in the GSH level in medicated subjects with SZ.<sup><xref ref-type="bibr" rid="R216">216</xref>, <xref ref-type="bibr" rid="R217">217</xref></sup> Finally, another study reported an increase in GSH levels in the medial temporal lobe of subjects with first episode psychosis.<sup><xref ref-type="bibr" rid="R218">218</xref></sup></p>
<p id="P35">In summary, many clinical and epidemiological studies have supported immunological deficits in SZ, which are mediated, at least in part, by microglia. Such immuno-inflammatory changes are interconnected with deficits in antioxidant cascades and may affect neural connectivity.</p>
</sec>
</sec>
<sec id="S15">
<title>Endocrine system</title>
<p id="P36">Although there are contradictory reports, multiple types of studies have suggested that the hypothalamic-pituitary-adrenal (HPA) axis is affected in first episode psychosis and SZ.<sup><xref ref-type="bibr" rid="R219">219</xref></sup> An MRI study comparing first episode and chronic SZ subjects to controls found increased and reduced pituitary volumes in first episode and chronic SZ, respectively.<sup><xref ref-type="bibr" rid="R220">220</xref></sup> Additional MRI studies support the finding of an increased pituitary volume in first episode SZ, as well as, an increased pituitary volume in subjects at high risk for developing psychosis (i.e., at-risk mental state).<sup><xref ref-type="bibr" rid="R221">221</xref>, <xref ref-type="bibr" rid="R222">222</xref></sup> However, other studies have not found a change in pituitary volume in first episode or chronic SZ.<sup><xref ref-type="bibr" rid="R223">223</xref>-<xref ref-type="bibr" rid="R225">225</xref></sup> A smaller pituitary volume in unmedicated SZ has also been reported.<sup><xref ref-type="bibr" rid="R226">226</xref></sup> Findings from studies analyzing the volume of the hypothalamus in SZ are inconsistent and report both an increased volume as well as no change.<sup><xref ref-type="bibr" rid="R227">227</xref>-<xref ref-type="bibr" rid="R230">230</xref></sup></p>
<p id="P37">Consistent with some brain imaging reports, a fraction of unmedicated, medicated, or chronic SZ patients have displayed elevated baseline adrenocorticotropic hormone (ACTH) and cortisol levels.<sup><xref ref-type="bibr" rid="R231">231</xref>-<xref ref-type="bibr" rid="R234">234</xref></sup> ACTH is secreted from the anterior pituitary gland in response to the hypothalamus releasing corticotropin-releasing hormone (CRH). Higher mean ACTH and cortisol levels have also been shown in first episode unmedicated SZ.<sup><xref ref-type="bibr" rid="R219">219</xref>, <xref ref-type="bibr" rid="R235">235</xref></sup> Furthermore, the North American prodrome longitudinal study reported higher baseline cortisol levels in prodromal (i.e., at-risk mental state) subjects and found that baseline cortisol levels correlated with symptom progression: prodromal subjects who transitioned to psychotic level symptoms had significantly higher baseline cortisol levels compared to controls and prodromal subjects in remission.<sup><xref ref-type="bibr" rid="R236">236</xref></sup> However, other studies have not found elevated baseline cortisol levels in first episode psychosis and first episode SZ.<sup><xref ref-type="bibr" rid="R219">219</xref>, <xref ref-type="bibr" rid="R237">237</xref></sup> Interestingly, antipsychotics (risperidone, haloperidol, olanzapine or flupenthixol) have been shown to significantly reduce cortisol levels.<sup><xref ref-type="bibr" rid="R168">168</xref>, <xref ref-type="bibr" rid="R238">238</xref></sup> Consistent with some peripheral measures of ACTH, a postmortem analysis of pituitary glands found that the level of proACTH was elevated in pituitaries from subjects with SZ compared to controls.<sup><xref ref-type="bibr" rid="R239">239</xref></sup> Postmortem studies have also suggested a reduction in glucocorticoid receptors: glucocorticoid receptor mRNA expression was reduced in the basolateral/lateral nuclei of the amygdala, the frontal and temporal cortex and hippocampus.<sup><xref ref-type="bibr" rid="R240">240</xref>, <xref ref-type="bibr" rid="R241">241</xref></sup> Overall, the data are promising, however, additional studies assessing the relation of ACTH and cortisol with other biomarkers will improve our understanding of the role of the HPA axis in SZ.</p>
<p id="P38">Psychosis can occur as a result of elevated endogenous steroid levels (e.g., Cushing syndrome) or with exposure to exogenous steroids.<sup><xref ref-type="bibr" rid="R242">242</xref></sup> Steroid psychosis, a potential side effect of exogenous glucocorticoids, can present with sensory flooding, delusions, depression, and auditory and visual hallucinations.<sup><xref ref-type="bibr" rid="R243">243</xref></sup> Delusions and hallucinations, primarily auditory, can also occur in subjects with psychotic depression; some studies have shown that glucocorticoid antagonists, such as mifepristone, can have therapeutic effects on psychotic depression.<sup><xref ref-type="bibr" rid="R244">244</xref>, <xref ref-type="bibr" rid="R245">245</xref></sup> Given that the effects of glucocorticoids on the brain include synaptic regulation and epigenetic control of key molecules for dopamine neurons (e.g., tyrosine hydroxylase),<sup><xref ref-type="bibr" rid="R246">246</xref>, <xref ref-type="bibr" rid="R247">247</xref></sup> involvement of the HPA axis in SZ and psychosis is an important subject that should be studied to a greater extent. However, it may be important to sub-classify these conditions to increase the homogeneity of the study subjects.</p>
<p id="P39">SZ typically manifests later in life in females than men. This difference in age at onset might be partially attributed to the protective effect of estrogen. Estradiol has been found to be lower in subjects with SZ, males and females, compared to controls.<sup><xref ref-type="bibr" rid="R248">248</xref>, <xref ref-type="bibr" rid="R249">249</xref></sup> Furthermore, an association study found that a polymorphism in an intron of the estrogen receptor alpha gene occurred more frequently in subjects with SZ and was related to lower mRNA levels in the prefrontal cortex.<sup><xref ref-type="bibr" rid="R250">250</xref></sup> The molecular targets of estrogen are diverse, but animal studies have shown that it can modulate the dopaminergic, serotonergic and glutamatergic pathways: for example, estrogen has been shown to alter D2R density, decrease monoamine oxidase activity, increase tryptophan hydroxylase activity, downregulate 5HT<sub>1A</sub> receptors, upregulate 5HT<sub>2A</sub> receptors, and alter NMDA receptor density.<sup><xref ref-type="bibr" rid="R251">251</xref>-<xref ref-type="bibr" rid="R253">253</xref></sup></p>
<p id="P40">Taken together, hormonal measurements and studies with patient tissue suggest that the endocrine system is altered in SZ.</p>
</sec>
<sec id="S16">
<title>Metabolic cascades</title>
<p id="P41">Metabolic disturbances are highly prevalent in SZ patients. Obesity and diabetes are twice as common in SZ compared to the general population.<sup><xref ref-type="bibr" rid="R254">254</xref>, <xref ref-type="bibr" rid="R255">255</xref></sup> These disturbances create an increased metabolic load, eventually leading to cardiovascular issues and other physical conditions that possibly account for the higher mortality rate and shorter life span in SZ.<sup><xref ref-type="bibr" rid="R256">256</xref></sup> It has also been shown that diabetic SZ patients have worse overall cognitive performance compared to SZ patients without diabetes mellitus. Furthermore, patients with untreated diabetes mellitus showed poorer overall cognitive performance compared to SZ patients without diabetes mellitus.<sup><xref ref-type="bibr" rid="R257">257</xref></sup> Major metabolic disturbance in SZ patients is likely elicited by neuroleptic medication,<sup><xref ref-type="bibr" rid="R258">258</xref>-<xref ref-type="bibr" rid="R260">260</xref></sup> however, first onset SZ patients, including unmedicated patients, also show higher fasting blood insulin levels, insulin resistance, and impaired glucose tolerance.<sup><xref ref-type="bibr" rid="R261">261</xref>-<xref ref-type="bibr" rid="R264">264</xref></sup> While lifestyle and dietary habits may contribute to this difference, it is also likely that an inherent metabolic dysregulation underlies the pathology of SZ. Although this concept may not have a scientific consensus yet, we discuss observed changes in several peripheral factors and their effects on the brain in SZ.</p>
<p id="P42">Studies using blood samples indicate functional deficits in insulin signaling in SZ,<sup><xref ref-type="bibr" rid="R261">261</xref>-<xref ref-type="bibr" rid="R264">264</xref></sup> while a separate study reported elevated glucose levels in the CSF, but not in serum, of first onset drug naïve SZ subjects.<sup><xref ref-type="bibr" rid="R265">265</xref></sup> In unmedicated SZ subjects, PET studies have shown that glucose metabolism is reduced in several brain areas, in particular the frontal cortex.<sup><xref ref-type="bibr" rid="R266">266</xref>, <xref ref-type="bibr" rid="R267">267</xref></sup> A recent review has summarized microarray studies and found that several genes associated with metabolic cascades are differentially expressed in postmortem brains from SZ patients.<sup><xref ref-type="bibr" rid="R268">268</xref></sup> Postmortem studies have also found disturbances in the insulin-Akt pathway, a signaling pathway linked with several types of cognitive deficits.<sup><xref ref-type="bibr" rid="R269">269</xref>-<xref ref-type="bibr" rid="R272">272</xref></sup> Although data derived from postmortem brain tissue may be confounded by medication-induced metabolic changes, further analysis is warranted.<sup><xref ref-type="bibr" rid="R273">273</xref></sup> Some genetic studies have provided suggestive support for the involvement of glucose metabolism cascades in the genetic risk of SZ.<sup><xref ref-type="bibr" rid="R274">274</xref>, <xref ref-type="bibr" rid="R275">275</xref></sup> The gene coding for Akt is also a putative risk factor for SZ, at least in part disturbing the signaling cascade involving the insulin-Akt pathway.<sup><xref ref-type="bibr" rid="R276">276</xref></sup></p>
<p id="P43">In addition to glucose and insulin, other metabolic mediators (e.g., leptin and ghrelin) may play key roles in SZ pathology. Weight gain is associated with increased leptin and leptin resistance.<sup><xref ref-type="bibr" rid="R277">277</xref>, <xref ref-type="bibr" rid="R278">278</xref></sup> Leptin inhibits the effects of cortisol signaling in the hypothalamus and predisposes to mental manifestations, in particular depression.<sup><xref ref-type="bibr" rid="R279">279</xref>, <xref ref-type="bibr" rid="R280">280</xref></sup> The ghrelin receptor GHS-R1a forms functional heterodimers with the D2R.<sup><xref ref-type="bibr" rid="R281">281</xref></sup> Antipsychotics have differential effects on these two molecules: fasting morning leptin levels are increased by atypical antipsychotics (e.g., olanzapine and clozapine) but are unaffected by conventional antipsychotics (e.g., haloperidol).<sup><xref ref-type="bibr" rid="R282">282</xref></sup> On the other hand, fasting morning ghrelin levels are decreased in the first 2 weeks after atypical antipsychotic treatment but increase in the long-term.<sup><xref ref-type="bibr" rid="R282">282</xref></sup> Neurochemical studies suggest lipid metabolism may also be altered in SZ. Both chronic and unmedicated first onset SZ have significantly decreased apolipoprotein A1 (apoA1) in the brain, liver, red blood cells, sera, and CSF.<sup><xref ref-type="bibr" rid="R283">283</xref>, <xref ref-type="bibr" rid="R284">284</xref></sup> However, another group found that apoA1 was increased in the CSF of medicated first onset SZ.<sup><xref ref-type="bibr" rid="R285">285</xref></sup> Vitamin D deficiency is commonly observed in SZ patients and is associated with clinical features of the disease.<sup><xref ref-type="bibr" rid="R286">286</xref></sup> Vitamin D deficiency is also observed in first-episode psychosis patients and developmental vitamin D deficiency has been shown to contribute to the risk of SZ, suggesting that neurodevelopment may be affected by vitamin D deficiency.<sup><xref ref-type="bibr" rid="R287">287</xref>, <xref ref-type="bibr" rid="R288">288</xref></sup></p>
<p id="P44">Pharmacogenetic studies, primarily focusing on olanzapine and clozapine, have identified SNP in several genes associated with antipsychotic-induced weight gain in SZ patients.<sup><xref ref-type="bibr" rid="R289">289</xref></sup> SNP within the genes encoding the serotonin 2C receptor (5-HT2CR), melanocortin 4 receptor (MC4R), and leptin are those with the most consistently strong evidence, implicating serotonergic and feeding-regulation systems in antipsychotic-induced weight gain.<sup><xref ref-type="bibr" rid="R290">290</xref>-<xref ref-type="bibr" rid="R293">293</xref></sup> Although these molecules have been identified as genetic modifiers of adverse metabolic effects in SZ patients, elicited by medication, the question remains whether the cascades involving these factors play roles in the intrinsic abnormalities of both metabolic and mental dysfunction found in SZ patients.</p>
<p id="P45">In summary, metabolic cascades are altered in SZ patients, which include changes in the levels of glucose, insulin, leptin, ghrelin, and apoA1. Antipsychotics affect these metabolic cascades, yet there is also evidence that some metabolic disturbances precede antipsychotic exposure. Genetic factors are known to modulate these changes, but it remains elusive whether and how a genetic predisposition to metabolic disturbance plays a primary role in SZ pathology.</p>
</sec>
<sec id="S17">
<title>Modeling and future perspectives: towards understanding integrative systems</title>
<p id="P46">For this review article we chose to organize the molecular targets of SZ by biological system. However, there is obviously tremendous crosstalk among these biological systems (<bold><xref ref-type="fig" rid="F2">Figure 2</xref></bold>). Oxidative stress, inflammation, the HPA axis, and metabolic signaling are tightly interconnected as homeostatic and stress cascades.<sup><xref ref-type="bibr" rid="R294">294</xref>-<xref ref-type="bibr" rid="R296">296</xref></sup> Neural networks, the foundation of brain function and dysfunction, are finely regulated by neurotransmitters and white matter-associated connectivity (<bold><xref ref-type="fig" rid="F3">Figure 3</xref></bold>): recently, the significance of neuron-glia interactions in these fine regulations has been particularly recognized.<sup><xref ref-type="bibr" rid="R297">297</xref></sup> As described above, deviations in homeostatic and stress cascades affect key elements of neuronal circuitry, such as synaptic maintenance, interneuron functions, and myelination. Thus, the molecular changes described in the neurotransmission and white matter-associated connectivity subsections may be outcomes of the molecular disturbances in stress signaling described in the second half of this article. Alternately, disturbances in neural connectivity may also activate stress signaling, which in turn further alters the connectivity. While integration of evidence across biological systems remains elusive, this promising working hypothesis suggests a potential framework through which they could be linked.</p>
<p id="P47">Although human studies with patients and matched controls are essential to identify molecular substrates of SZ, there are many barriers to extending an in-depth understanding of the disease mechanisms exclusively through human studies. For example, the current spatial resolution of human brain imaging at both structural and functional levels cannot depict direct entities such as synapses and NoR where we can directly observe the functional outcome of the molecular substrates described above. In addition, while it is very important to grasp the overall molecular changes in the disease trajectory over 20 years, longitudinal human studies on this time scale are challenging and time-consuming.</p>
<p id="P48">Given the limitations of human studies, many people have supported the use of animal models. One of the major historical debates in regard to SZ animal models is whether we can reconstruct models for ‘human’ disease. It is impossible to recapitulate the human condition <italic>per se</italic> in animals. However, by targeting a particular system(s) and/or clinical endophenotype(s) in SZ, animal models can become very useful for understanding biological mechanisms. In addition to analyzing cross-sectional phenotypes in adult animals, it is even more crucial to analyze the disease trajectory from early development to disease onset in preclinical studies.<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Given the diversity of SZ molecular substrates, ranging from homeostatic and stress cascades to neural circuitry components, a major working question in the field of animal models is whether and how stress cascades may affect neural connectivity along a neurodevelopmental trajectory leading to SZ.</p>
<p id="P49">The selection of animal models and their validity in SZ research is very important to consider. After the recent introduction of new genetic manipulation technologies,<sup><xref ref-type="bibr" rid="R298">298</xref>-<xref ref-type="bibr" rid="R300">300</xref></sup> simultaneous modulation of multiple genes is now technically feasible, but only a few studies have been successful thus far. Thus, instead of reconstructing genetic validity from multiple common variants with mild biological impact on the pathology, we propose that models stemming from the modulation of rare genetic variants with a stronger biological impact (e.g., chromosomal micro-deletion or duplication, and genetic modulation identified from cytogenetic approaches) may be more widely used in SZ research.<sup><xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R18">18</xref>, <xref ref-type="bibr" rid="R301">301</xref></sup> To test the functional outcome of multiple common variants for SZ, human stem cell biology can be used as a complementary approach to animal models.<sup><xref ref-type="bibr" rid="R302">302</xref></sup> For example, CRISPR/Cas9 genetic manipulation of induced pluripotent stem cells (iPSCs) originally derived from patients carrying multiple disease-associated common genetic variants and subsequently differentiated into neurons and glia can be used to assess the contribution of each individual genetic variant.</p>
<p id="P50">Gene environment interaction plays a key role in the etiology of SZ;<sup><xref ref-type="bibr" rid="R165">165</xref>, <xref ref-type="bibr" rid="R200">200</xref>-<xref ref-type="bibr" rid="R202">202</xref></sup> therefore, consideration of proper environmental stressors, possibly in combination with a genetic factor(s), is crucial when building animal models. Some successful examples include combining adolescent social isolation or prenatal immune activation with a genetic risk factor.<sup><xref ref-type="bibr" rid="R202">202</xref>, <xref ref-type="bibr" rid="R247">247</xref>, <xref ref-type="bibr" rid="R303">303</xref>-<xref ref-type="bibr" rid="R305">305</xref></sup> Although an advantage of animal models includes their potential to trace the possible developmental trajectory to full onset of disease,<sup><xref ref-type="bibr" rid="R306">306</xref>-<xref ref-type="bibr" rid="R308">308</xref></sup> it is also useful to build models by administering relevant drugs to recapitulate specific pathophysiologies and phenotypes associated with SZ.</p>
<p id="P51">Taken together, several animal models have been proposed to understand the biology relevant to SZ. Regardless of whether these animal models are genetic or non-genetic, many of them are generated by perturbing biological processes of neurotransmission, white matter-associated connectivity, inflammatory and oxidative stress, or endocrinology/metabolisms (see in <bold><xref ref-type="table" rid="T4">Table 4</xref></bold> where representative models are introduced).<sup><xref ref-type="bibr" rid="R304">304</xref>, <xref ref-type="bibr" rid="R309">309</xref>-<xref ref-type="bibr" rid="R370">370</xref></sup> Most of the models were studied from the viewpoints of neurotransmission, neuropsychopharmacology, and behavioral neuroscience.<sup><xref ref-type="bibr" rid="R371">371</xref>, <xref ref-type="bibr" rid="R372">372</xref></sup> However, recent studies have revisited these models beyond these classic paradigms and also elucidated deficits in white matter and stress-associated cascades, such as inflammation, oxidative stress, and the HPA axis.<sup><xref ref-type="bibr" rid="R323">323</xref>, <xref ref-type="bibr" rid="R324">324</xref>, <xref ref-type="bibr" rid="R328">328</xref>, <xref ref-type="bibr" rid="R333">333</xref>, <xref ref-type="bibr" rid="R359">359</xref>, <xref ref-type="bibr" rid="R366">366</xref>, <xref ref-type="bibr" rid="R373">373</xref></sup> Furthermore, models in which stress-associated cascades are primarily perturbed have also displayed abnormalities in neurotransmission and behavior: for example, mice with glutathione deficiency show impairments in parvalbumin-positive interneurons, myelination, and behavior.<sup><xref ref-type="bibr" rid="R340">340</xref>, <xref ref-type="bibr" rid="R341">341</xref>, <xref ref-type="bibr" rid="R343">343</xref>, <xref ref-type="bibr" rid="R344">344</xref>, <xref ref-type="bibr" rid="R374">374</xref>, <xref ref-type="bibr" rid="R375">375</xref></sup> Several animal models have been designed to test the effect of stress cascades on neurodevelopment, including both prenatal and juvenile models of stress and immune activation.<sup><xref ref-type="bibr" rid="R322">322</xref>, <xref ref-type="bibr" rid="R376">376</xref>, <xref ref-type="bibr" rid="R377">377</xref></sup> These developmental stressors have been shown to affect neurotransmission, myelination, and even metabolism. The integrative biological concept of “disturbed homeostatic signaling to connectivity deficits” can be tested, at least in part, with such animal models.</p>
<p id="P52">In summary, this review highlights the molecular substrates discovered through studies with SZ patients that are implicated in SZ pathophysiology. We sub-classify the substrates by system, focusing on neurotransmission, targets in white matter-associated connectivity, immune/inflammatory and oxidative stress-related substrates, and molecules in endocrine and metabolic cascades, taking special note where there is convergence with genetic data. Crosstalk among these systems may be important in understanding disease progression and animal models should prove important in charting the developmental progression and interaction of these substrates. As a working hypothesis, we propose the molecular changes in neurotransmission and white matter-associated connectivity may be outcomes of molecular disturbances in stress signaling. Alternately, disturbances in neural connectivity may also activate stress signaling, in turn further altering the connectivity. We optimistically propose that the identified molecular markers, together with further continuous efforts, will aid in discovering biomarkers that may help in the diagnosis, treatment, or early intervention of SZ.</p>
</sec>
</body>
<back>
<ack id="S18">
<title>Acknowledgements</title>
<p>We thank Alan Anticevic, Anissa Abi-Dargham, Jennifer Coughlin and Anouk Marsman for scientific discussion. We thank Yukiko Lema for organizing the figures, in particular for contributing to the formatting process. MRI images were kindly provided by Susumu Mori and Michael Jacobs. This work was supported by USPHS grants MH-084018 (A.S.), MH-094268 Silvo O. Conte center (A.S.), MH-069853 (A.S.), MH-085226 (A.S.), MH-088753 (A.S.), MH-092443 (A.S.), Stanley (A.S.), RUSK (A.S.), S-R foundations (A.S.), NARSAD (A.S.) and the Maryland Stem Cell Research Fund (A.S.).</p>
</ack>
<fn-group>
<fn id="FN1">
<p id="P53">Conflict of Interest</p>
<p id="P54">A.S. currently receives research funding from Johnson and Johnson, Astellas, Takeda, Tanabe-Mitsubishi, Dainippon-Sumitomo, and Sucampo; has served as an advisory board and consultant for Amgen, Asubio, Eli Lilly, Pfizer, Sucampo, Taisho, and Takeda, and collaborated with Afraxis, Astrazeneca, and Sanofi-Aventis. However, none of these relationships affected the contents and statements of this review article. In addition, M.A.L-S and T.E.F. declare no potential conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perala</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suvisaari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Saarni</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Kuoppasalmi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Isometsa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pirkola</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lifetime prevalence of psychotic and bipolar I disorders in a general population.</article-title>
<source/>Archives of general psychiatry
          <year>2007</year>
<volume>64</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>28</lpage>
<comment>Epub 2007/01/03</comment>
<pub-id pub-id-type="pmid">17199051</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Os</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Linscott</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Myin-Germeys</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Delespaul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krabbendam</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder.</article-title>
<source/>Psychological medicine
          <year>2009</year>
<volume>39</volume>
<issue>2</issue>
<fpage>179</fpage>
<lpage>95</lpage>
<comment>Epub 2008/07/09</comment>
<pub-id pub-id-type="pmid">18606047</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Os</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Schizophrenia.</article-title>
<source/>Lancet
          <year>2009</year>
<volume>374</volume>
<issue>9690</issue>
<fpage>635</fpage>
<lpage>45</lpage>
<comment>Epub 2009/08/25</comment>
<pub-id pub-id-type="pmid">19700006</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaaro-Peled</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hayashi-Takagi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kamiya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brandon</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1.</article-title>
<source/>Trends in neurosciences
          <year>2009</year>
<volume>32</volume>
<issue>9</issue>
<fpage>485</fpage>
<lpage>95</lpage>
<comment>Epub 2009/08/29</comment>
<pub-id pub-id-type="pmid">19712980</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seeman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.</article-title>
<source/>Science (New York, NY)
          <year>1975</year>
<volume>188</volume>
<issue>4194</issue>
<fpage>1217</fpage>
<lpage>9</lpage>
<comment>Epub 1975/06/20</comment>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Creese</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Burt</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.</article-title>
<source/>Science (New York, NY)
          <year>1976</year>
<volume>192</volume>
<issue>4238</issue>
<fpage>481</fpage>
<lpage>3</lpage>
<comment>Epub 1976/04/30</comment>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.</article-title>
<source/>The American journal of psychiatry
          <year>1976</year>
<volume>133</volume>
<issue>2</issue>
<fpage>197</fpage>
<lpage>202</lpage>
<comment>Epub 1976/02/01</comment>
<pub-id pub-id-type="pmid">1251927</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merritt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Egerton</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis.</article-title>
<source/>Frontiers in psychiatry
          <year>2013</year>
<volume>4</volume>
<fpage>151</fpage>
<comment>Epub 2013/12/11</comment>
<pub-id pub-id-type="pmid">24324444</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Zukin</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>Recent advances in the phencyclidine model of schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>1991</year>
<volume>148</volume>
<issue>10</issue>
<fpage>1301</fpage>
<lpage>8</lpage>
<comment>Epub 1991/10/01</comment>
<pub-id pub-id-type="pmid">1654746</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wray</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Visscher</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>O'Donovan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.</article-title>
<source/>Nature
          <year>2009</year>
<volume>460</volume>
<issue>7256</issue>
<fpage>748</fpage>
<lpage>52</lpage>
<comment>Epub 2009/07/03</comment>
<pub-id pub-id-type="pmid">19571811</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ripke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>O'Dushlaine</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chambert</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Kahler</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Akterin</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide association analysis identifies 13 new risk loci for schizophrenia.</article-title>
<source/>Nature genetics
          <year>2013</year>
<volume>45</volume>
<issue>10</issue>
<fpage>1150</fpage>
<lpage>9</lpage>
<comment>Epub 2013/08/27</comment>
<pub-id pub-id-type="pmid">23974872</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruderfer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Solovieff</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Roussos</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A polygenic burden of rare disruptive mutations in schizophrenia.</article-title>
<source/>Nature
          <year>2014</year>
<volume>506</volume>
<issue>7487</issue>
<fpage>185</fpage>
<lpage>90</lpage>
<comment>Epub 2014/01/28</comment>
<pub-id pub-id-type="pmid">24463508</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doherty</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>O'Donovan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Recent genomic advances in schizophrenia.</article-title>
<source/>Clinical genetics
          <year>2012</year>
<volume>81</volume>
<issue>2</issue>
<fpage>103</fpage>
<lpage>9</lpage>
<comment>Epub 2011/09/08</comment>
<pub-id pub-id-type="pmid">21895634</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pocklington</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Dwyer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gormley</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in schizophrenia implicate synaptic networks.</article-title>
<source/>Nature
          <year>2014</year>
<volume>506</volume>
<issue>7487</issue>
<fpage>179</fpage>
<lpage>84</lpage>
<comment>Epub 2014/01/28</comment>
<pub-id pub-id-type="pmid">24463507</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Genetic overlap between autism, schizophrenia and bipolar disorder.</article-title>
<source/>Genome medicine
          <year>2009</year>
<volume>1</volume>
<issue>10</issue>
<fpage>102</fpage>
<comment>Epub 2009/11/06</comment>
<pub-id pub-id-type="pmid">19886976</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Ripke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Perlis</surname>
<given-names>RH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs.</article-title>
<source/>Nature genetics
          <year>2013</year>
<volume>45</volume>
<issue>9</issue>
<fpage>984</fpage>
<lpage>94</lpage>
<comment>Epub 2013/08/13</comment>
<pub-id pub-id-type="pmid">23933821</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<article-title>Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<issue>9875</issue>
<fpage>1371</fpage>
<lpage>9</lpage>
<comment>Epub 2013/03/05</comment>
<pub-id pub-id-type="pmid">23453885</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandon</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Linking neurodevelopmental and synaptic theories of mental illness through DISC1.</article-title>
<source/>Nature reviews Neuroscience
          <year>2011</year>
<volume>12</volume>
<issue>12</issue>
<fpage>707</fpage>
<lpage>22</lpage>
<comment>Epub 2011/11/19</comment>
<pub-id pub-id-type="pmid">22095064</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cuthbert</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heinssen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pine</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.</article-title>
<source/>The American journal of psychiatry
          <year>2010</year>
<volume>167</volume>
<issue>7</issue>
<fpage>748</fpage>
<lpage>51</lpage>
<comment>Epub 2010/07/03</comment>
<pub-id pub-id-type="pmid">20595427</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sebat</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>CNVs: harbingers of a rare variant revolution in psychiatric genetics.</article-title>
<source/>Cell
          <year>2012</year>
<volume>148</volume>
<issue>6</issue>
<fpage>1223</fpage>
<lpage>41</lpage>
<comment>Epub 2012/03/20</comment>
<pub-id pub-id-type="pmid">22424231</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>O'Donovan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetic architectures of psychiatric disorders: the emerging picture and its implications.</article-title>
<source/>Nature reviews Genetics
          <year>2012</year>
<volume>13</volume>
<issue>8</issue>
<fpage>537</fpage>
<lpage>51</lpage>
<comment>Epub 2012/07/11</comment>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Winchester</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.</article-title>
<source/>Nature reviews Drug discovery
          <year>2012</year>
<volume>11</volume>
<issue>7</issue>
<fpage>560</fpage>
<lpage>79</lpage>
<comment>Epub 2012/06/23</comment>
<pub-id pub-id-type="pmid">22722532</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaaro-Peled</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ayhan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pletnikov</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models.</article-title>
<source/>Schizophrenia bulletin
          <year>2010</year>
<volume>36</volume>
<issue>2</issue>
<fpage>301</fpage>
<lpage>13</lpage>
<comment>Epub 2009/11/12</comment>
<pub-id pub-id-type="pmid">19903746</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kvajo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McKellar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gogos</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models.</article-title>
<source/>Neuroscience
          <year>2012</year>
<volume>211</volume>
<fpage>136</fpage>
<lpage>64</lpage>
<comment>Epub 2011/08/09</comment>
<pub-id pub-id-type="pmid">21821099</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartwell</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mankoff</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Paulovich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ramsey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Swisher</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Cancer biomarkers: a systems approach.</article-title>
<source/>Nature biotechnology
          <year>2006</year>
<volume>24</volume>
<issue>8</issue>
<fpage>905</fpage>
<lpage>8</lpage>
<comment>Epub 2006/08/11</comment>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lusis</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Attie</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Reue</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Metabolic syndrome: from epidemiology to systems biology.</article-title>
<source/>Nature reviews Genetics
          <year>2008</year>
<volume>9</volume>
<issue>11</issue>
<fpage>819</fpage>
<lpage>30</lpage>
<comment>Epub 2008/10/15</comment>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="book">
<person-group person-group-type="editor">
<name>
<surname>Oresic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vidal-Puig</surname>
<given-names>A</given-names>
</name>
</person-group>
<source/>A Systems Biology Approach to Study Metabolic Syndrome
          <year>2014</year>
<fpage>384</fpage>
<publisher-name>Springer International Publishing</publisher-name>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gaiteri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bodea</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>McElwee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Podtelezhnikov</surname>
<given-names>AA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease.</article-title>
<source/>Cell
          <year>2013</year>
<volume>153</volume>
<issue>3</issue>
<fpage>707</fpage>
<lpage>20</lpage>
<comment>Epub 2013/04/30</comment>
<pub-id pub-id-type="pmid">23622250</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKhann</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Chertkow</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Kawas</surname>
<given-names>CH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</article-title>
<source/>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
          <year>2011</year>
<volume>7</volume>
<issue>3</issue>
<fpage>263</fpage>
<lpage>9</lpage>
<comment>Epub 2011/04/26</comment>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGowan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Sales</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Quested</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Grasby</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.</article-title>
<source/>Archives of general psychiatry
          <year>2004</year>
<volume>61</volume>
<issue>2</issue>
<fpage>134</fpage>
<lpage>42</lpage>
<comment>Epub 2004/02/06</comment>
<pub-id pub-id-type="pmid">14757589</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howes</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Asselin</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Valli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tabraham</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated striatal dopamine function linked to prodromal signs of schizophrenia.</article-title>
<source/>Archives of general psychiatry
          <year>2009</year>
<volume>66</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>20</lpage>
<comment>Epub 2009/01/07</comment>
<pub-id pub-id-type="pmid">19124684</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miletich</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Kohn</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Quarantelli</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.</article-title>
<source/>Nature neuroscience
          <year>2002</year>
<volume>5</volume>
<issue>3</issue>
<fpage>267</fpage>
<lpage>71</lpage>
<comment>Epub 2002/02/28</comment>
<pub-id pub-id-type="pmid">11865311</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nozaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arakawa</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET.</article-title>
<source/>Schizophrenia research
          <year>2009</year>
<volume>108</volume>
<issue>1-3</issue>
<fpage>78</fpage>
<lpage>84</lpage>
<comment>Epub 2008/12/06</comment>
<pub-id pub-id-type="pmid">19056247</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egerton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chaddock</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Winton-Brown</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Bloomfield</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bhattacharyya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort.</article-title>
<source/>Biological psychiatry
          <year>2013</year>
<volume>74</volume>
<issue>2</issue>
<fpage>106</fpage>
<lpage>12</lpage>
<comment>Epub 2013/01/15</comment>
<pub-id pub-id-type="pmid">23312565</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Kolachana</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>de Bartolomeis</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>1997</year>
<volume>94</volume>
<issue>6</issue>
<fpage>2569</fpage>
<lpage>74</lpage>
<comment>Epub 1997/03/18</comment>
<pub-id pub-id-type="pmid">9122236</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laruelle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Dyck</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>D'Souza</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Erdos</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>1996</year>
<volume>93</volume>
<issue>17</issue>
<fpage>9235</fpage>
<lpage>40</lpage>
<comment>Epub 1996/08/20</comment>
<pub-id pub-id-type="pmid">8799184</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baldwin</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Seibyl</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.</article-title>
<source/>The American journal of psychiatry
          <year>1998</year>
<volume>155</volume>
<issue>6</issue>
<fpage>761</fpage>
<lpage>7</lpage>
<comment>Epub 1998/06/10</comment>
<pub-id pub-id-type="pmid">9619147</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howes</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The dopamine hypothesis of schizophrenia: version III--the final common pathway.</article-title>
<source/>Schizophrenia bulletin
          <year>2009</year>
<volume>35</volume>
<issue>3</issue>
<fpage>549</fpage>
<lpage>62</lpage>
<comment>Epub 2009/03/28</comment>
<pub-id pub-id-type="pmid">19325164</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kegeles</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frankle</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Slifstein</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.</article-title>
<source/>Archives of general psychiatry
          <year>2010</year>
<volume>67</volume>
<issue>3</issue>
<fpage>231</fpage>
<lpage>9</lpage>
<comment>Epub 2010/03/03</comment>
<pub-id pub-id-type="pmid">20194823</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laruelle</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Imaging dopamine transmission in schizophrenia. A review and meta-analysis.</article-title>
<source/>The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
          <year>1998</year>
<volume>42</volume>
<issue>3</issue>
<fpage>211</fpage>
<lpage>21</lpage>
<comment>Epub 1998/10/31</comment>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuepper</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Skinbjerg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.</article-title>
<source/>Handbook of experimental pharmacology
          <year>2012</year>
<issue>212</issue>
<fpage>1</fpage>
<lpage>26</lpage>
<comment>Epub 2012/11/07</comment>
<pub-id pub-id-type="pmid">23129326</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<article-title>Biological insights from 108 schizophrenia-associated genetic loci.</article-title>
<source/>Nature
          <year>2014</year>
<volume>511</volume>
<issue>7510</issue>
<fpage>421</fpage>
<lpage>7</lpage>
<comment>Epub 2014/07/25</comment>
<pub-id pub-id-type="pmid">25056061</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okubo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Suhara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Terasaki</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.</article-title>
<source/>Nature
          <year>1997</year>
<volume>385</volume>
<issue>6617</issue>
<fpage>634</fpage>
<lpage>6</lpage>
<comment>Epub 1997/02/13</comment>
<pub-id pub-id-type="pmid">9024661</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karlsson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Farde</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Halldin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sedvall</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>2002</year>
<volume>159</volume>
<issue>5</issue>
<fpage>761</fpage>
<lpage>7</lpage>
<comment>Epub 2002/05/03</comment>
<pub-id pub-id-type="pmid">11986129</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kegeles</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Urban</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112.</article-title>
<source/>Journal of psychopharmacology (Oxford, England)
          <year>2012</year>
<volume>26</volume>
<issue>6</issue>
<fpage>794</fpage>
<lpage>805</lpage>
<comment>Epub 2011/07/20</comment>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kestler</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vega</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings.</article-title>
<source/>Behavioural pharmacology
          <year>2001</year>
<volume>12</volume>
<issue>5</issue>
<fpage>355</fpage>
<lpage>71</lpage>
<comment>Epub 2001/11/17</comment>
<pub-id pub-id-type="pmid">11710751</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beuger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Kammen</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>1996</year>
<volume>15</volume>
<issue>1</issue>
<fpage>75</fpage>
<lpage>86</lpage>
<comment>Epub 1996/07/01</comment>
<pub-id pub-id-type="pmid">8797194</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieselgren</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Lindstrom</surname>
<given-names>LH</given-names>
</name>
</person-group>
<article-title>CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia.</article-title>
<source/>Psychiatry research
          <year>1998</year>
<volume>81</volume>
<issue>2</issue>
<fpage>101</fpage>
<lpage>10</lpage>
<comment>Epub 1998/12/19</comment>
<pub-id pub-id-type="pmid">9858027</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Dopamine in schizophrenia: a review and reconceptualization.</article-title>
<source/>The American journal of psychiatry
          <year>1991</year>
<volume>148</volume>
<issue>11</issue>
<fpage>1474</fpage>
<lpage>86</lpage>
<comment>Epub 1991/11/01</comment>
<pub-id pub-id-type="pmid">1681750</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meador-Woodruff</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Powchik</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia.</article-title>
<source/>Archives of general psychiatry
          <year>1997</year>
<volume>54</volume>
<issue>12</issue>
<fpage>1089</fpage>
<lpage>95</lpage>
<comment>Epub 1997/12/24</comment>
<pub-id pub-id-type="pmid">9400344</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pantazopoulos</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Benes</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics.</article-title>
<source/>Synapse (New York, NY)
          <year>2004</year>
<volume>54</volume>
<issue>3</issue>
<fpage>147</fpage>
<lpage>55</lpage>
<comment>Epub 2004/09/29</comment>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akil</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Mohila</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects.</article-title>
<source/>The American journal of psychiatry
          <year>1999</year>
<volume>156</volume>
<issue>10</issue>
<fpage>1580</fpage>
<lpage>9</lpage>
<comment>Epub 1999/10/13</comment>
<pub-id pub-id-type="pmid">10518170</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akil</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Casali</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects.</article-title>
<source/>Biological psychiatry
          <year>2000</year>
<volume>47</volume>
<issue>5</issue>
<fpage>361</fpage>
<lpage>70</lpage>
<comment>Epub 2000/03/08</comment>
<pub-id pub-id-type="pmid">10704948</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rodenhiser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Printz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zea-Ponce</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kegeles</surname>
<given-names>LS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2000</year>
<volume>97</volume>
<issue>14</issue>
<fpage>8104</fpage>
<lpage>9</lpage>
<comment>Epub 2000/07/08</comment>
<pub-id pub-id-type="pmid">10884434</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinberger</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Mesoprefrontal cortical dopaminergic activity and prefrontal hypofunction in schizophrenia.</article-title>
<source/>Clinical neuropharmacology
          <year>1992</year>
<volume>15</volume>
<issue>Suppl 1 Pt A</issue>
<fpage>568A</fpage>
<lpage>9A</lpage>
<comment>Epub 1992/01/01</comment>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meltzer</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.</article-title>
<source/>The Journal of pharmacology and experimental therapeutics
          <year>1989</year>
<volume>251</volume>
<issue>1</issue>
<fpage>238</fpage>
<lpage>46</lpage>
<comment>Epub 1989/10/01</comment>
<pub-id pub-id-type="pmid">2571717</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vollenweider</surname>
<given-names>FX</given-names>
</name>
<name>
<surname>Vollenweider-Scherpenhuyzen</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Babler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hell</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.</article-title>
<source/>Neuroreport
          <year>1998</year>
<volume>9</volume>
<issue>17</issue>
<fpage>3897</fpage>
<lpage>902</lpage>
<comment>Epub 1999/01/06</comment>
<pub-id pub-id-type="pmid">9875725</pub-id>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burnet</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Eastwood</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>1996</year>
<volume>15</volume>
<issue>5</issue>
<fpage>442</fpage>
<lpage>55</lpage>
<comment>Epub 1996/11/01</comment>
<pub-id pub-id-type="pmid">8914117</pub-id>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anticevic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gancsos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Repovs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Driesen</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Ennis</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2012</year>
<volume>109</volume>
<issue>41</issue>
<fpage>16720</fpage>
<lpage>5</lpage>
<comment>Epub 2012/09/27</comment>
<pub-id pub-id-type="pmid">23012427</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krystal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Karper</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Seibyl</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bremner</surname>
<given-names>JD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.</article-title>
<source/>Archives of general psychiatry
          <year>1994</year>
<volume>51</volume>
<issue>3</issue>
<fpage>199</fpage>
<lpage>214</lpage>
<comment>Epub 1994/03/01</comment>
<pub-id pub-id-type="pmid">8122957</pub-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glantz</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia.</article-title>
<source/>Archives of general psychiatry
          <year>2000</year>
<volume>57</volume>
<issue>1</issue>
<fpage>65</fpage>
<lpage>73</lpage>
<comment>Epub 2000/01/13</comment>
<pub-id pub-id-type="pmid">10632234</pub-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garey</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Kanani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mortimer</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia.</article-title>
<source/>Journal of neurology, neurosurgery, and psychiatry
          <year>1998</year>
<volume>65</volume>
<issue>4</issue>
<fpage>446</fpage>
<lpage>53</lpage>
<comment>Epub 1998/10/15</comment>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayalew</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Le-Niculescu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Levey</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Changala</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>SD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.</article-title>
<source/>Molecular psychiatry
          <year>2012</year>
<volume>17</volume>
<issue>9</issue>
<fpage>887</fpage>
<lpage>905</lpage>
<comment>Epub 2012/05/16</comment>
<pub-id pub-id-type="pmid">22584867</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poels</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Kegeles</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Kantrowitz</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Slifstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.</article-title>
<source/>Molecular psychiatry
          <year>2014</year>
<volume>19</volume>
<issue>1</issue>
<fpage>20</fpage>
<lpage>9</lpage>
<comment>Epub 2013/10/30</comment>
<pub-id pub-id-type="pmid">24166406</pub-id>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van den Heuvel</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Klomp</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Luijten</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Hulshoff Pol</surname>
<given-names>HE</given-names>
</name>
</person-group>
<article-title>Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies.</article-title>
<source/>Schizophrenia bulletin
          <year>2013</year>
<volume>39</volume>
<issue>1</issue>
<fpage>120</fpage>
<lpage>9</lpage>
<comment>Epub 2011/07/13</comment>
<pub-id pub-id-type="pmid">21746807</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kegeles</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stanford</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Girgis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ojeil</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.</article-title>
<source/>Archives of general psychiatry
          <year>2012</year>
<volume>69</volume>
<issue>5</issue>
<fpage>449</fpage>
<lpage>59</lpage>
<comment>Epub 2012/01/04</comment>
<pub-id pub-id-type="pmid">22213769</pub-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egerton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brugger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Raffin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Lythgoe</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>PK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2012</year>
<volume>37</volume>
<issue>11</issue>
<fpage>2515</fpage>
<lpage>21</lpage>
<comment>Epub 2012/07/06</comment>
<pub-id pub-id-type="pmid">22763619</pub-id>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demjaha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Egerton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Howes</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.</article-title>
<source/>Biological psychiatry
          <year>2014</year>
<volume>75</volume>
<issue>5</issue>
<fpage>e11</fpage>
<lpage>3</lpage>
<comment>Epub 2013/07/31</comment>
<pub-id pub-id-type="pmid">23890739</pub-id>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stan</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Ghose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hulsey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mihalakos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yanagi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2014</year>
<comment>Epub 2014/06/11</comment>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>G</given-names>
</name>
<name>
<surname>van Kammen</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Grier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>1998</year>
<volume>44</volume>
<issue>8</issue>
<fpage>667</fpage>
<lpage>74</lpage>
<comment>Epub 1998/11/03</comment>
<pub-id pub-id-type="pmid">9798069</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Engberg</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nordin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lindstrom</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients.</article-title>
<source/>BMC psychiatry
          <year>2005</year>
<volume>5</volume>
<fpage>6</fpage>
<comment>Epub 2005/02/03</comment>
<pub-id pub-id-type="pmid">15683541</pub-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
<name>
<surname>Lauer</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zollinger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gutteck-Amsler</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders.</article-title>
<source/>Journal of neurochemistry
          <year>1995</year>
<volume>65</volume>
<issue>6</issue>
<fpage>2652</fpage>
<lpage>62</lpage>
<comment>Epub 1995/12/01</comment>
<pub-id pub-id-type="pmid">7595563</pub-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schobel</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Lewandowski</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Corcoran</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Malaspina</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders.</article-title>
<source/>Archives of general psychiatry
          <year>2009</year>
<volume>66</volume>
<issue>9</issue>
<fpage>938</fpage>
<lpage>46</lpage>
<comment>Epub 2009/09/09</comment>
<pub-id pub-id-type="pmid">19736350</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schobel</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Chaudhury</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>UA</given-names>
</name>
<name>
<surname>Paniagua</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Styner</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Asllani</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.</article-title>
<source/>Neuron
          <year>2013</year>
<volume>78</volume>
<issue>1</issue>
<fpage>81</fpage>
<lpage>93</lpage>
<comment>Epub 2013/04/16</comment>
<pub-id pub-id-type="pmid">23583108</pub-id>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wandinger</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Saschenbrecker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stoecker</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis.</article-title>
<source/>Journal of neuroimmunology
          <year>2011</year>
<volume>231</volume>
<issue>1-2</issue>
<fpage>86</fpage>
<lpage>91</lpage>
<comment>Epub 2010/10/19</comment>
<pub-id pub-id-type="pmid">20951441</pub-id>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gleichman</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.</article-title>
<source/>Lancet neurology
          <year>2008</year>
<volume>7</volume>
<issue>12</issue>
<fpage>1091</fpage>
<lpage>8</lpage>
<comment>Epub 2008/10/15</comment>
<pub-id pub-id-type="pmid">18851928</pub-id>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lancaster</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martinez-Hernandez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Balice-Gordon</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.</article-title>
<source/>Lancet neurology
          <year>2011</year>
<volume>10</volume>
<issue>1</issue>
<fpage>63</fpage>
<lpage>74</lpage>
<comment>Epub 2010/12/18</comment>
<pub-id pub-id-type="pmid">21163445</pub-id>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bien</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Irani</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Autoantibodies associated with diseases of the CNS: new developments and future challenges.</article-title>
<source/>Lancet neurology
          <year>2011</year>
<volume>10</volume>
<issue>8</issue>
<fpage>759</fpage>
<lpage>72</lpage>
<comment>Epub 2011/07/23</comment>
<pub-id pub-id-type="pmid">21777830</pub-id>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesher</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Tecklenburg</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Streck</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Anti-N-methyl-D-aspartate receptor encephalitis associated with an ovarian teratoma in an adolescent female.</article-title>
<source/>Journal of pediatric surgery
          <year>2010</year>
<volume>45</volume>
<issue>7</issue>
<fpage>1550</fpage>
<lpage>3</lpage>
<comment>Epub 2010/07/20</comment>
<pub-id pub-id-type="pmid">20638543</pub-id>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iizuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nihei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis.</article-title>
<source/>Journal of neurology, neurosurgery, and psychiatry
          <year>2008</year>
<volume>79</volume>
<issue>3</issue>
<fpage>324</fpage>
<lpage>6</lpage>
<comment>Epub 2007/11/23</comment>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moriya</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kakeda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ikenouchi-Sugita</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study.</article-title>
<source/>Schizophrenia research
          <year>2009</year>
<volume>112</volume>
<issue>1-3</issue>
<fpage>192</fpage>
<lpage>3</lpage>
<comment>Epub 2009/05/26</comment>
<pub-id pub-id-type="pmid">19464152</pub-id>
</element-citation>
</ref>
<ref id="R82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayoshi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakataki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sumitani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shibuya-Tayoshi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Numata</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study.</article-title>
<source/>Schizophrenia research
          <year>2010</year>
<volume>117</volume>
<issue>1</issue>
<fpage>83</fpage>
<lpage>91</lpage>
<comment>Epub 2009/12/22</comment>
<pub-id pub-id-type="pmid">20022731</pub-id>
</element-citation>
</ref>
<ref id="R83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Maddock</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Rokem</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Minzenberg</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ragland</surname>
<given-names>JD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2010</year>
<volume>30</volume>
<issue>10</issue>
<fpage>3777</fpage>
<lpage>81</lpage>
<comment>Epub 2010/03/12</comment>
<pub-id pub-id-type="pmid">20220012</pub-id>
</element-citation>
</ref>
<ref id="R84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ongur</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Prescot</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Renshaw</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Elevated gamma-aminobutyric acid levels in chronic schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>2010</year>
<volume>68</volume>
<issue>7</issue>
<fpage>667</fpage>
<lpage>70</lpage>
<comment>Epub 2010/07/06</comment>
<pub-id pub-id-type="pmid">20598290</pub-id>
</element-citation>
</ref>
<ref id="R85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowland</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Kontson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>West</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Edden</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wijtenburg</surname>
<given-names>SA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo measurements of glutamate, GABA, and NAAG in schizophrenia.</article-title>
<source/>Schizophrenia bulletin
          <year>2013</year>
<volume>39</volume>
<issue>5</issue>
<fpage>1096</fpage>
<lpage>104</lpage>
<comment>Epub 2012/10/20</comment>
<pub-id pub-id-type="pmid">23081992</pub-id>
</element-citation>
</ref>
<ref id="R86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cousijn</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Haegens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wallis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Near</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stokes</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resting GABA and glutamate concentrations do not predict visual gamma frequency or amplitude.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2014</year>
<volume>111</volume>
<issue>25</issue>
<fpage>9301</fpage>
<lpage>6</lpage>
<comment>Epub 2014/06/14</comment>
<pub-id pub-id-type="pmid">24927588</pub-id>
</element-citation>
</ref>
<ref id="R87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerner</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>TA</given-names>
</name>
</person-group>
<article-title>CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa.</article-title>
<source/>The American journal of psychiatry
          <year>1981</year>
<volume>138</volume>
<issue>8</issue>
<fpage>1098</fpage>
<lpage>101</lpage>
<comment>Epub 1981/08/01</comment>
<pub-id pub-id-type="pmid">7258390</pub-id>
</element-citation>
</ref>
<ref id="R88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lichtshtein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dobkin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ebstein</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Biederman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rimon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Belmaker</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment.</article-title>
<source/>The British journal of psychiatry : the journal of mental science
          <year>1978</year>
<volume>132</volume>
<fpage>145</fpage>
<lpage>8</lpage>
<comment>Epub 1978/02/01</comment>
<pub-id pub-id-type="pmid">623945</pub-id>
</element-citation>
</ref>
<ref id="R89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petty</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Plasma GABA levels in psychiatric illness.</article-title>
<source/>Journal of affective disorders
          <year>1984</year>
<volume>6</volume>
<issue>2</issue>
<fpage>131</fpage>
<lpage>8</lpage>
<comment>Epub 1984/04/01</comment>
<pub-id pub-id-type="pmid">6233345</pub-id>
</element-citation>
</ref>
<ref id="R90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Kammen</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Bunney</surname>
<given-names>WE</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients.</article-title>
<source/>Archives of general psychiatry
          <year>1982</year>
<volume>39</volume>
<issue>1</issue>
<fpage>91</fpage>
<lpage>7</lpage>
<comment>Epub 1982/01/01</comment>
<pub-id pub-id-type="pmid">7055411</pub-id>
</element-citation>
</ref>
<ref id="R91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarthy</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>UR</given-names>
</name>
<name>
<surname>Neethling</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Shanley</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Taljaard</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Potgieter</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>gamma-Aminobutyric acid concentration in cerebrospinal fluid in schizophrenia.</article-title>
<source/>Journal of neurochemistry
          <year>1981</year>
<volume>36</volume>
<issue>4</issue>
<fpage>1406</fpage>
<lpage>8</lpage>
<comment>Epub 1981/04/01</comment>
<pub-id pub-id-type="pmid">7264636</pub-id>
</element-citation>
</ref>
<ref id="R92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benes</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Berretta</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2001</year>
<volume>25</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>27</lpage>
<comment>Epub 2001/05/30</comment>
<pub-id pub-id-type="pmid">11377916</pub-id>
</element-citation>
</ref>
<ref id="R93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Early developmental disturbances of cortical inhibitory neurons: contribution to cognitive deficits in schizophrenia.</article-title>
<source/>Schizophrenia bulletin
          <year>2014</year>
<volume>40</volume>
<issue>5</issue>
<fpage>952</fpage>
<lpage>7</lpage>
<comment>Epub 2014/07/24</comment>
<pub-id pub-id-type="pmid">25053651</pub-id>
</element-citation>
</ref>
<ref id="R94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Eggan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Mirnics</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2003</year>
<volume>23</volume>
<issue>15</issue>
<fpage>6315</fpage>
<lpage>26</lpage>
<comment>Epub 2003/07/18</comment>
<pub-id pub-id-type="pmid">12867516</pub-id>
</element-citation>
</ref>
<ref id="R95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sengupta</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Georgiev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Minabe</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>2012</year>
<volume>169</volume>
<issue>10</issue>
<fpage>1082</fpage>
<lpage>91</lpage>
<comment>Epub 2012/09/18</comment>
<pub-id pub-id-type="pmid">22983435</pub-id>
</element-citation>
</ref>
<ref id="R96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbarian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Hagman</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Tafazzoli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bunney</surname>
<given-names>WE</given-names>
<suffix>Jr.</suffix>
</name>
<etal></etal>
</person-group>
<article-title>Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.</article-title>
<source/>Archives of general psychiatry
          <year>1995</year>
<volume>52</volume>
<issue>4</issue>
<fpage>258</fpage>
<lpage>66</lpage>
<comment>Epub 1995/04/01</comment>
<pub-id pub-id-type="pmid">7702443</pub-id>
</element-citation>
</ref>
<ref id="R97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guidotti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Auta</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Di-Giorgi-Gerevini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dwivedi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Grayson</surname>
<given-names>DR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study.</article-title>
<source/>Archives of general psychiatry
          <year>2000</year>
<volume>57</volume>
<issue>11</issue>
<fpage>1061</fpage>
<lpage>9</lpage>
<comment>Epub 2000/11/14</comment>
<pub-id pub-id-type="pmid">11074872</pub-id>
</element-citation>
</ref>
<ref id="R98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curley</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Arion</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Asafu-Adjei</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Fish</surname>
<given-names>KN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features.</article-title>
<source/>The American journal of psychiatry
          <year>2011</year>
<volume>168</volume>
<issue>9</issue>
<fpage>921</fpage>
<lpage>9</lpage>
<comment>Epub 2011/06/03</comment>
<pub-id pub-id-type="pmid">21632647</pub-id>
</element-citation>
</ref>
<ref id="R99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanagi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Joho</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Southcott</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Ghose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tamminga</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs.</article-title>
<source/>Molecular psychiatry
          <year>2014</year>
<volume>19</volume>
<issue>5</issue>
<fpage>573</fpage>
<lpage>9</lpage>
<comment>Epub 2013/05/01</comment>
<pub-id pub-id-type="pmid">23628987</pub-id>
</element-citation>
</ref>
<ref id="R100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Georgiev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Arion</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Enwright</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Minabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Corradi</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lower gene expression for KCNS3 potassium channel subunit in parvalbumin-containing neurons in the prefrontal cortex in schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>2014</year>
<volume>171</volume>
<issue>1</issue>
<fpage>62</fpage>
<lpage>71</lpage>
<comment>Epub 2013/10/31</comment>
<pub-id pub-id-type="pmid">24170294</pub-id>
</element-citation>
</ref>
<ref id="R101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Cortical inhibitory neurons and schizophrenia.</article-title>
<source/>Nature reviews Neuroscience
          <year>2005</year>
<volume>6</volume>
<issue>4</issue>
<fpage>312</fpage>
<lpage>24</lpage>
<comment>Epub 2005/04/02</comment>
<pub-id pub-id-type="pmid">15803162</pub-id>
</element-citation>
</ref>
<ref id="R102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Arion</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maldonado-Aviles</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2008</year>
<volume>13</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>61</lpage>
<comment>Epub 2007/05/02</comment>
<pub-id pub-id-type="pmid">17471287</pub-id>
</element-citation>
</ref>
<ref id="R103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adler</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Hoffer</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Wiser</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Normalization of auditory physiology by cigarette smoking in schizophrenic patients.</article-title>
<source/>The American journal of psychiatry
          <year>1993</year>
<volume>150</volume>
<issue>12</issue>
<fpage>1856</fpage>
<lpage>61</lpage>
<comment>Epub 1993/12/01</comment>
<pub-id pub-id-type="pmid">8238642</pub-id>
</element-citation>
</ref>
<ref id="R104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>XS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>ZP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients.</article-title>
<source/>Psychiatry research
          <year>2011</year>
<volume>188</volume>
<issue>3</issue>
<fpage>327</fpage>
<lpage>33</lpage>
<comment>Epub 2011/01/11</comment>
<pub-id pub-id-type="pmid">21216472</pub-id>
</element-citation>
</ref>
<ref id="R105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumari</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Soni</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia.</article-title>
<source/>Human psychopharmacology
          <year>2001</year>
<volume>16</volume>
<issue>4</issue>
<fpage>321</fpage>
<lpage>6</lpage>
<comment>Epub 2002/10/31</comment>
<pub-id pub-id-type="pmid">12404567</pub-id>
</element-citation>
</ref>
<ref id="R106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Coon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Myles-Worsley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Orr-Urtreger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>1997</year>
<volume>94</volume>
<issue>2</issue>
<fpage>587</fpage>
<lpage>92</lpage>
<comment>Epub 1997/01/21</comment>
<pub-id pub-id-type="pmid">9012828</pub-id>
</element-citation>
</ref>
<ref id="R107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufmann</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Suarez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Malaspina</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pepple</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Svrakic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Markel</surname>
<given-names>PD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees.</article-title>
<source/>American journal of medical genetics
          <year>1998</year>
<volume>81</volume>
<issue>4</issue>
<fpage>282</fpage>
<lpage>9</lpage>
<comment>Epub 1998/07/23</comment>
<pub-id pub-id-type="pmid">9674972</pub-id>
</element-citation>
</ref>
<ref id="R108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riley</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Makoff</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mogudi-Carter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families.</article-title>
<source/>American journal of medical genetics
          <year>2000</year>
<volume>96</volume>
<issue>2</issue>
<fpage>196</fpage>
<lpage>201</lpage>
<comment>Epub 2000/07/14</comment>
<pub-id pub-id-type="pmid">10893497</pub-id>
</element-citation>
</ref>
<ref id="R109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>1995</year>
<volume>38</volume>
<issue>1</issue>
<fpage>22</fpage>
<lpage>33</lpage>
<comment>Epub 1995/07/01</comment>
<pub-id pub-id-type="pmid">7548469</pub-id>
</element-citation>
</ref>
<ref id="R110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Court</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spurden</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McKeith</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus.</article-title>
<source/>Journal of neurochemistry
          <year>1999</year>
<volume>73</volume>
<issue>4</issue>
<fpage>1590</fpage>
<lpage>7</lpage>
<comment>Epub 1999/09/29</comment>
<pub-id pub-id-type="pmid">10501205</pub-id>
</element-citation>
</ref>
<ref id="R111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marutle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Court</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Piggott</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia.</article-title>
<source/>Journal of chemical neuroanatomy
          <year>2001</year>
<volume>22</volume>
<issue>1-2</issue>
<fpage>115</fpage>
<lpage>26</lpage>
<comment>Epub 2001/07/27</comment>
<pub-id pub-id-type="pmid">11470559</pub-id>
</element-citation>
</ref>
<ref id="R112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Souza</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Esterlis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Carbuto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krasenics</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seibyl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bois</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lower ss2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>2012</year>
<volume>169</volume>
<issue>3</issue>
<fpage>326</fpage>
<lpage>34</lpage>
<comment>Epub 2011/12/24</comment>
<pub-id pub-id-type="pmid">22193533</pub-id>
</element-citation>
</ref>
<ref id="R113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brasic</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Cascella</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Raymont</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Positron emission tomography experience with 2-[(1)(8)F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[(1)(8)F]FA) in the living human brain of smokers with paranoid schizophrenia.</article-title>
<source/>Synapse (New York, NY)
          <year>2012</year>
<volume>66</volume>
<issue>4</issue>
<fpage>352</fpage>
<lpage>68</lpage>
<comment>Epub 2011/12/16</comment>
</element-citation>
</ref>
<ref id="R114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zeledon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Synapse-specific contributions in the cortical pathology of schizophrenia.</article-title>
<source/>Neurobiology of disease
          <year>2013</year>
<volume>53</volume>
<fpage>26</fpage>
<lpage>35</lpage>
<comment>Epub 2013/01/23</comment>
<pub-id pub-id-type="pmid">23336981</pub-id>
</element-citation>
</ref>
<ref id="R115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi-Takagi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Graziane</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Murdoch</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1.</article-title>
<source/>Nature neuroscience
          <year>2010</year>
<volume>13</volume>
<issue>3</issue>
<fpage>327</fpage>
<lpage>32</lpage>
<comment>Epub 2010/02/09</comment>
<pub-id pub-id-type="pmid">20139976</pub-id>
</element-citation>
</ref>
<ref id="R116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi-Takagi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vollrath</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Duron</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2014</year>
<volume>111</volume>
<issue>17</issue>
<fpage>6461</fpage>
<lpage>6</lpage>
<comment>Epub 2014/04/08</comment>
<pub-id pub-id-type="pmid">24706880</pub-id>
</element-citation>
</ref>
<ref id="R117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Cormican</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>O'Dushlaine</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Perreault</surname>
<given-names>LP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An inherited duplication at the gene p21 Protein-Activated Kinase 7 (PAK7) is a risk factor for psychosis.</article-title>
<source/>Human molecular genetics
          <year>2014</year>
<volume>23</volume>
<issue>12</issue>
<fpage>3316</fpage>
<lpage>26</lpage>
<comment>Epub 2014/01/30</comment>
<pub-id pub-id-type="pmid">24474471</pub-id>
</element-citation>
</ref>
<ref id="R118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirnics</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Marquez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex.</article-title>
<source/>Neuron
          <year>2000</year>
<volume>28</volume>
<issue>1</issue>
<fpage>53</fpage>
<lpage>67</lpage>
<comment>Epub 2000/11/22</comment>
<pub-id pub-id-type="pmid">11086983</pub-id>
</element-citation>
</ref>
<ref id="R119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arancibia-Carcamo</surname>
<given-names>IL</given-names>
</name>
<name>
<surname>Attwell</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The node of Ranvier in CNS pathology.</article-title>
<source/>Acta neuropathologica
          <year>2014</year>
<comment>Epub 2014/06/11</comment>
</element-citation>
</ref>
<ref id="R120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjartmar</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Trapp</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Axonal pathology in myelin disorders.</article-title>
<source/>Journal of neurocytology
          <year>1999</year>
<volume>28</volume>
<issue>4-5</issue>
<fpage>383</fpage>
<lpage>95</lpage>
<comment>Epub 2000/03/30</comment>
<pub-id pub-id-type="pmid">10739578</pub-id>
</element-citation>
</ref>
<ref id="R121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shenton</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Whitford</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Kubicki</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Structural neuroimaging in schizophrenia: from methods to insights to treatments.</article-title>
<source/>Dialogues in clinical neuroscience
          <year>2010</year>
<volume>12</volume>
<issue>3</issue>
<fpage>317</fpage>
<lpage>32</lpage>
<comment>Epub 2010/10/20</comment>
<pub-id pub-id-type="pmid">20954428</pub-id>
</element-citation>
</ref>
<ref id="R122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanaan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brammer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giampietro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Shergill</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Woolley</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>White matter microstructure in schizophrenia: effects of disorder, duration and medication.</article-title>
<source/>The British journal of psychiatry : the journal of mental science
          <year>2009</year>
<volume>194</volume>
<issue>3</issue>
<fpage>236</fpage>
<lpage>42</lpage>
<comment>Epub 2009/03/03</comment>
<pub-id pub-id-type="pmid">19252154</pub-id>
</element-citation>
</ref>
<ref id="R123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>KO</given-names>
</name>
</person-group>
<article-title>Diffusion tensor imaging in psychiatric disorders.</article-title>
<source/>Topics in magnetic resonance imaging : TMRI
          <year>2008</year>
<volume>19</volume>
<issue>2</issue>
<fpage>97</fpage>
<lpage>109</lpage>
<comment>Epub 2009/04/14</comment>
<pub-id pub-id-type="pmid">19363432</pub-id>
</element-citation>
</ref>
<ref id="R124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellison-Wright</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bullmore</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Meta-analysis of diffusion tensor imaging studies in schizophrenia.</article-title>
<source/>Schizophrenia research
          <year>2009</year>
<volume>108</volume>
<issue>1-3</issue>
<fpage>3</fpage>
<lpage>10</lpage>
<comment>Epub 2009/01/09</comment>
<pub-id pub-id-type="pmid">19128945</pub-id>
</element-citation>
</ref>
<ref id="R125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witthaus</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Brune</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bohner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ozgurdal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gudlowski</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients.</article-title>
<source/>Schizophrenia research
          <year>2008</year>
<volume>102</volume>
<issue>1-3</issue>
<fpage>141</fpage>
<lpage>9</lpage>
<comment>Epub 2008/06/03</comment>
<pub-id pub-id-type="pmid">18515047</pub-id>
</element-citation>
</ref>
<ref id="R126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Epstein</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kumra</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>White matter abnormalities and cognitive impairment in early-onset schizophrenia-spectrum disorders.</article-title>
<source/>Journal of the American Academy of Child and Adolescent Psychiatry
          <year>2014</year>
<volume>53</volume>
<issue>3</issue>
<fpage>362</fpage>
<lpage>72</lpage>
<fpage>e1</fpage>
<lpage>2</lpage>
<comment>Epub 2014/02/26</comment>
<pub-id pub-id-type="pmid">24565363</pub-id>
</element-citation>
</ref>
<ref id="R127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreasen</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Nopoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Magnotta</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pierson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ziebell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>BC</given-names>
</name>
</person-group>
<article-title>Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>2011</year>
<volume>70</volume>
<issue>7</issue>
<fpage>672</fpage>
<lpage>9</lpage>
<comment>Epub 2011/07/26</comment>
<pub-id pub-id-type="pmid">21784414</pub-id>
</element-citation>
</ref>
<ref id="R128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Repovs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Savic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Glasser</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered global brain signal in schizophrenia.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2014</year>
<volume>111</volume>
<issue>20</issue>
<fpage>7438</fpage>
<lpage>43</lpage>
<comment>Epub 2014/05/07</comment>
<pub-id pub-id-type="pmid">24799682</pub-id>
</element-citation>
</ref>
<ref id="R129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynall</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Bassett</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Kerwin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Kitzbichler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>U</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional connectivity and brain networks in schizophrenia.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2010</year>
<volume>30</volume>
<issue>28</issue>
<fpage>9477</fpage>
<lpage>87</lpage>
<comment>Epub 2010/07/16</comment>
<pub-id pub-id-type="pmid">20631176</pub-id>
</element-citation>
</ref>
<ref id="R130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cole</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Anticevic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Repovs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Barch</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Variable global dysconnectivity and individual differences in schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>2011</year>
<volume>70</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>50</lpage>
<comment>Epub 2011/04/19</comment>
<pub-id pub-id-type="pmid">21496789</pub-id>
</element-citation>
</ref>
<ref id="R131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Masters</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Yeo</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Krienen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Buckner</surname>
<given-names>RL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder.</article-title>
<source/>JAMA psychiatry
          <year>2014</year>
<volume>71</volume>
<issue>2</issue>
<fpage>109</fpage>
<lpage>18</lpage>
<comment>Epub 2013/12/07</comment>
<pub-id pub-id-type="pmid">24306091</pub-id>
</element-citation>
</ref>
<ref id="R132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodward</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Karbasforoushan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heckers</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Thalamocortical dysconnectivity in schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>2012</year>
<volume>169</volume>
<issue>10</issue>
<fpage>1092</fpage>
<lpage>9</lpage>
<comment>Epub 2012/10/04</comment>
<pub-id pub-id-type="pmid">23032387</pub-id>
</element-citation>
</ref>
<ref id="R133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anticevic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Repovs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Brumbaugh</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterizing Thalamo-Cortical Disturbances in Schizophrenia and Bipolar Illness.</article-title>
<source/>Cerebral cortex (New York, NY : 1991)
          <year>2013</year>
<comment>Epub 2013/07/05</comment>
</element-citation>
</ref>
<ref id="R134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kubicki</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Reduced task-related suppression during semantic repetition priming in schizophrenia.</article-title>
<source/>Psychiatry research
          <year>2010</year>
<volume>181</volume>
<issue>2</issue>
<fpage>114</fpage>
<lpage>20</lpage>
<comment>Epub 2010/01/20</comment>
<pub-id pub-id-type="pmid">20083395</pub-id>
</element-citation>
</ref>
<ref id="R135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Whitfield-Gabrieli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shinn</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Gabrieli</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Nieto Castanon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2011</year>
<volume>36</volume>
<issue>10</issue>
<fpage>2009</fpage>
<lpage>17</lpage>
<comment>Epub 2011/06/10</comment>
<pub-id pub-id-type="pmid">21654735</pub-id>
</element-citation>
</ref>
<ref id="R136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anticevic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Corlett</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>The role of default network deactivation in cognition and disease.</article-title>
<source/>Trends in cognitive sciences
          <year>2012</year>
<volume>16</volume>
<issue>12</issue>
<fpage>584</fpage>
<lpage>92</lpage>
<comment>Epub 2012/11/13</comment>
<pub-id pub-id-type="pmid">23142417</pub-id>
</element-citation>
</ref>
<ref id="R137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzsimmons</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kubicki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shenton</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Review of functional and anatomical brain connectivity findings in schizophrenia.</article-title>
<source/>Current opinion in psychiatry
          <year>2013</year>
<volume>26</volume>
<issue>2</issue>
<fpage>172</fpage>
<lpage>87</lpage>
<comment>Epub 2013/01/18</comment>
<pub-id pub-id-type="pmid">23324948</pub-id>
</element-citation>
</ref>
<ref id="R138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fornito</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zalesky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pantelis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bullmore</surname>
<given-names>ET</given-names>
</name>
</person-group>
<article-title>Schizophrenia, neuroimaging and connectomics.</article-title>
<source/>NeuroImage
          <year>2012</year>
<volume>62</volume>
<issue>4</issue>
<fpage>2296</fpage>
<lpage>314</lpage>
<comment>Epub 2012/03/06</comment>
<pub-id pub-id-type="pmid">22387165</pub-id>
</element-citation>
</ref>
<ref id="R139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anticevic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Repovs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Savic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Driesen</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia.</article-title>
<source/>Frontiers in psychiatry
          <year>2013</year>
<volume>4</volume>
<fpage>169</fpage>
<comment>Epub 2014/01/09</comment>
<pub-id pub-id-type="pmid">24399974</pub-id>
</element-citation>
</ref>
<ref id="R140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sequeira</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Vawter</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>The first decade and beyond of transcriptional profiling in schizophrenia.</article-title>
<source/>Neurobiology of disease
          <year>2012</year>
<volume>45</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>36</lpage>
<comment>Epub 2011/03/15</comment>
<pub-id pub-id-type="pmid">21396449</pub-id>
</element-citation>
</ref>
<ref id="R141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hof</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Friedrich</surname>
<given-names>VL</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Byne</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Buitron</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Perl</surname>
<given-names>DP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>2003</year>
<volume>53</volume>
<issue>12</issue>
<fpage>1075</fpage>
<lpage>85</lpage>
<comment>Epub 2003/06/20</comment>
<pub-id pub-id-type="pmid">12814859</pub-id>
</element-citation>
</ref>
<ref id="R142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hakak</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>JD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2001</year>
<volume>98</volume>
<issue>8</issue>
<fpage>4746</fpage>
<lpage>51</lpage>
<comment>Epub 2001/04/11</comment>
<pub-id pub-id-type="pmid">11296301</pub-id>
</element-citation>
</ref>
<ref id="R143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tkachev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mimmack</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wayland</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>PB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oligodendrocyte dysfunction in schizophrenia and bipolar disorder.</article-title>
<source/>Lancet
          <year>2003</year>
<volume>362</volume>
<issue>9386</issue>
<fpage>798</fpage>
<lpage>805</lpage>
<comment>Epub 2003/09/19</comment>
<pub-id pub-id-type="pmid">13678875</pub-id>
</element-citation>
</ref>
<ref id="R144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aston</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sokolov</surname>
<given-names>BP</given-names>
</name>
</person-group>
<article-title>Microarray analysis of postmortem temporal cortex from patients with schizophrenia.</article-title>
<source/>Journal of neuroscience research
          <year>2004</year>
<volume>77</volume>
<issue>6</issue>
<fpage>858</fpage>
<lpage>66</lpage>
<comment>Epub 2004/08/31</comment>
<pub-id pub-id-type="pmid">15334603</pub-id>
</element-citation>
</ref>
<ref id="R145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katsel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study.</article-title>
<source/>Schizophrenia research
          <year>2005</year>
<volume>79</volume>
<issue>2-3</issue>
<fpage>157</fpage>
<lpage>73</lpage>
<comment>Epub 2005/09/06</comment>
<pub-id pub-id-type="pmid">16139990</pub-id>
</element-citation>
</ref>
<ref id="R146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Katsel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dracheva</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
</person-group>
<article-title>Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia.</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2007</year>
<volume>10</volume>
<issue>4</issue>
<fpage>565</fpage>
<lpage>73</lpage>
<comment>Epub 2007/02/13</comment>
<pub-id pub-id-type="pmid">17291370</pub-id>
</element-citation>
</ref>
<ref id="R147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia.</article-title>
<source/>Progress in neurobiology
          <year>2011</year>
<volume>93</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>24</lpage>
<comment>Epub 2010/10/19</comment>
<pub-id pub-id-type="pmid">20950668</pub-id>
</element-citation>
</ref>
<ref id="R148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sigurdsson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Steinthorsdottir</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bjornsdottir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sigmundsson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuregulin 1 and susceptibility to schizophrenia.</article-title>
<source/>American journal of human genetics
          <year>2002</year>
<volume>71</volume>
<issue>4</issue>
<fpage>877</fpage>
<lpage>92</lpage>
<comment>Epub 2002/07/30</comment>
<pub-id pub-id-type="pmid">12145742</pub-id>
</element-citation>
</ref>
<ref id="R149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Preece</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spurlock</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Zammit</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2003</year>
<volume>8</volume>
<issue>5</issue>
<fpage>485</fpage>
<lpage>7</lpage>
<comment>Epub 2003/06/17</comment>
<pub-id pub-id-type="pmid">12808428</pub-id>
</element-citation>
</ref>
<ref id="R150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corfas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia.</article-title>
<source/>Nature neuroscience
          <year>2004</year>
<volume>7</volume>
<issue>6</issue>
<fpage>575</fpage>
<lpage>80</lpage>
<comment>Epub 2004/05/27</comment>
<pub-id pub-id-type="pmid">15162166</pub-id>
</element-citation>
</ref>
<ref id="R151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novak</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Seeman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tallerico</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert.</article-title>
<source/>Brain research Molecular brain research
          <year>2002</year>
<volume>107</volume>
<issue>2</issue>
<fpage>183</fpage>
<lpage>9</lpage>
<comment>Epub 2002/11/12</comment>
<pub-id pub-id-type="pmid">12425946</pub-id>
</element-citation>
</ref>
<ref id="R152">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chew-Ping Lim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>YY</given-names>
</name>
</person-group>
<article-title>Gender-specific association of insertion/deletion polymorphisms in the nogo gene and chronic schizophrenia.</article-title>
<source/>Brain research Molecular brain research
          <year>2005</year>
<volume>139</volume>
<issue>2</issue>
<fpage>212</fpage>
<lpage>6</lpage>
<comment>Epub 2005/06/15</comment>
<pub-id pub-id-type="pmid">15953657</pub-id>
</element-citation>
</ref>
<ref id="R153">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinibaldi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bellacchio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pasini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paloscia</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia.</article-title>
<source/>Human mutation
          <year>2004</year>
<volume>24</volume>
<issue>6</issue>
<fpage>534</fpage>
<lpage>5</lpage>
<comment>Epub 2004/11/09</comment>
<pub-id pub-id-type="pmid">15532024</pub-id>
</element-citation>
</ref>
<ref id="R154">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prata</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kanaan</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Shergill</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Woolley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Georgieva</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Risk variant of oligodendrocyte lineage transcription factor 2 is associated with reduced white matter integrity.</article-title>
<source/>Human brain mapping
          <year>2013</year>
<volume>34</volume>
<issue>9</issue>
<fpage>2025</fpage>
<lpage>31</lpage>
<comment>Epub 2012/04/17</comment>
<pub-id pub-id-type="pmid">22505278</pub-id>
</element-citation>
</ref>
<ref id="R155">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felsky</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Voineskos</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Lerch</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Nazeri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Rajji</surname>
<given-names>TK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Myelin-associated glycoprotein gene and brain morphometry in schizophrenia.</article-title>
<source/>Frontiers in psychiatry
          <year>2012</year>
<volume>3</volume>
<fpage>40</fpage>
<comment>Epub 2012/05/09</comment>
<pub-id pub-id-type="pmid">22563322</pub-id>
</element-citation>
</ref>
<ref id="R156">
<label>156</label>
<element-citation publication-type="journal">
<article-title>Genome-wide association study identifies five new schizophrenia loci.</article-title>
<source/>Nature genetics
          <year>2011</year>
<volume>43</volume>
<issue>10</issue>
<fpage>969</fpage>
<lpage>76</lpage>
<comment>Epub 2011/09/20</comment>
<pub-id pub-id-type="pmid">21926974</pub-id>
</element-citation>
</ref>
<ref id="R157">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A hypothesis-driven pathway analysis reveals myelin-related pathways that contribute to the risk of schizophrenia and bipolar disorder.</article-title>
<source/>Progress in neuro-psychopharmacology &amp; biological psychiatry
          <year>2014</year>
<comment>Epub 2014/01/23</comment>
</element-citation>
</ref>
<ref id="R158">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goudriaan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Leeuw</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ripke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hultman</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Sklar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Specific Glial Functions Contribute to Schizophrenia Susceptibility.</article-title>
<source/>Schizophrenia bulletin
          <year>2013</year>
<comment>Epub 2013/08/21</comment>
</element-citation>
</ref>
<ref id="R159">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McIntosh</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Moorhead</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Job</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lymer</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Munoz Maniega</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McKirdy</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The effects of a neuregulin 1 variant on white matter density and integrity.</article-title>
<source/>Molecular psychiatry
          <year>2008</year>
<volume>13</volume>
<issue>11</issue>
<fpage>1054</fpage>
<lpage>9</lpage>
<comment>Epub 2007/10/11</comment>
<pub-id pub-id-type="pmid">17925794</pub-id>
</element-citation>
</ref>
<ref id="R160">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roussos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Katsel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Bitsios</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Giakoumaki</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Jogia</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia.</article-title>
<source/>Archives of general psychiatry
          <year>2012</year>
<volume>69</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>15</lpage>
<comment>Epub 2011/09/07</comment>
<pub-id pub-id-type="pmid">21893642</pub-id>
</element-citation>
</ref>
<ref id="R161">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roussos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities.</article-title>
<source/>Frontiers in cellular neuroscience
          <year>2014</year>
<volume>8</volume>
<fpage>5</fpage>
<comment>Epub 2014/01/31</comment>
<pub-id pub-id-type="pmid">24478629</pub-id>
</element-citation>
</ref>
<ref id="R162">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voineskos</surname>
<given-names>AN</given-names>
</name>
</person-group>
<article-title>Genetic underpinnings of white matter ‘connectivity’: Heritability, risk, and heterogeneity in schizophrenia.</article-title>
<source/>Schizophrenia research
          <year>2014</year>
<comment>Epub 2014/06/05</comment>
</element-citation>
</ref>
<ref id="R163">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartzokis</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.</article-title>
<source/>Neuropharmacology
          <year>2012</year>
<volume>62</volume>
<issue>7</issue>
<fpage>2137</fpage>
<lpage>53</lpage>
<comment>Epub 2012/02/07</comment>
<pub-id pub-id-type="pmid">22306524</pub-id>
</element-citation>
</ref>
<ref id="R164">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reis Marques</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chaddock</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dell'acqua</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Handley</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Reinders</surname>
<given-names>AA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>White matter integrity as a predictor of response to treatment in first episode psychosis.</article-title>
<source/>Brain : a journal of neurology
          <year>2014</year>
<volume>137</volume>
<issue>Pt 1</issue>
<fpage>172</fpage>
<lpage>82</lpage>
<comment>Epub 2013/11/21</comment>
<pub-id pub-id-type="pmid">24253201</pub-id>
</element-citation>
</ref>
<ref id="R165">
<label>165</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>The environment and susceptibility to schizophrenia.</article-title>
<source/>Progress in neurobiology
          <year>2011</year>
<volume>93</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>58</lpage>
<comment>Epub 2010/10/20</comment>
<pub-id pub-id-type="pmid">20955757</pub-id>
</element-citation>
</ref>
<ref id="R166">
<label>166</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insel</surname>
<given-names>TR</given-names>
</name>
</person-group>
<article-title>Rethinking schizophrenia.</article-title>
<source/>Nature
          <year>2010</year>
<volume>468</volume>
<issue>7321</issue>
<fpage>187</fpage>
<lpage>93</lpage>
<comment>Epub 2010/11/12</comment>
<pub-id pub-id-type="pmid">21068826</pub-id>
</element-citation>
</ref>
<ref id="R167">
<label>167</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drexhage</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Weigelt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van Beveren</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Versnel</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immune and neuroimmune alterations in mood disorders and schizophrenia.</article-title>
<source/>International review of neurobiology
          <year>2011</year>
<volume>101</volume>
<fpage>169</fpage>
<lpage>201</lpage>
<comment>Epub 2011/11/05</comment>
<pub-id pub-id-type="pmid">22050852</pub-id>
</element-citation>
</ref>
<ref id="R168">
<label>168</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>YC</given-names>
</name>
</person-group>
<article-title>Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2005</year>
<volume>30</volume>
<issue>8</issue>
<fpage>1532</fpage>
<lpage>8</lpage>
<comment>Epub 2005/05/12</comment>
<pub-id pub-id-type="pmid">15886721</pub-id>
</element-citation>
</ref>
<ref id="R169">
<label>169</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebrinc</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Top</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oncul</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Basoglu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cavuslu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cetin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia.</article-title>
<source/>The Journal of international medical research
          <year>2002</year>
<volume>30</volume>
<issue>3</issue>
<fpage>314</fpage>
<lpage>7</lpage>
<comment>Epub 2002/08/09</comment>
<pub-id pub-id-type="pmid">12166349</pub-id>
</element-citation>
</ref>
<ref id="R170">
<label>170</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteleone</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fabrazzo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tortorella</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maj</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.</article-title>
<source/>Psychiatry research
          <year>1997</year>
<volume>71</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>7</lpage>
<comment>Epub 1997/06/16</comment>
<pub-id pub-id-type="pmid">9247977</pub-id>
</element-citation>
</ref>
<ref id="R171">
<label>171</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>LX</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>WQ</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>2009</year>
<volume>65</volume>
<issue>6</issue>
<fpage>481</fpage>
<lpage>8</lpage>
<comment>Epub 2008/12/09</comment>
<pub-id pub-id-type="pmid">19058794</pub-id>
</element-citation>
</ref>
<ref id="R172">
<label>172</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erbagci</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Herken</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Koyluoglu</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tarakcioglu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.</article-title>
<source/>Mediators of inflammation
          <year>2001</year>
<volume>10</volume>
<issue>3</issue>
<fpage>109</fpage>
<lpage>15</lpage>
<comment>Epub 2001/09/08</comment>
<pub-id pub-id-type="pmid">11545247</pub-id>
</element-citation>
</ref>
<ref id="R173">
<label>173</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Theodoropoulou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spanakos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baxevanis</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Economou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gritzapis</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Papamichail</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients.</article-title>
<source/>Schizophrenia research
          <year>2001</year>
<volume>47</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>25</lpage>
<comment>Epub 2001/02/13</comment>
<pub-id pub-id-type="pmid">11163541</pub-id>
</element-citation>
</ref>
<ref id="R174">
<label>174</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upthegrove</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Manzanares-Teson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>NM</given-names>
</name>
</person-group>
<article-title>Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis.</article-title>
<source/>Schizophrenia research
          <year>2014</year>
<volume>155</volume>
<issue>1-3</issue>
<fpage>101</fpage>
<lpage>8</lpage>
<comment>Epub 2014/04/08</comment>
<pub-id pub-id-type="pmid">24704219</pub-id>
</element-citation>
</ref>
<ref id="R175">
<label>175</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tourjman</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kouassi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Koue</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Rocchetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fortin-Fournier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fusar-Poli</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis.</article-title>
<source/>Schizophrenia research
          <year>2013</year>
<volume>151</volume>
<issue>1-3</issue>
<fpage>43</fpage>
<lpage>7</lpage>
<comment>Epub 2013/11/10</comment>
<pub-id pub-id-type="pmid">24200418</pub-id>
</element-citation>
</ref>
<ref id="R176">
<label>176</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Hooton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Petkova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Babulas</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring.</article-title>
<source/>The American journal of psychiatry
          <year>2004</year>
<volume>161</volume>
<issue>5</issue>
<fpage>889</fpage>
<lpage>95</lpage>
<comment>Epub 2004/05/04</comment>
<pub-id pub-id-type="pmid">15121655</pub-id>
</element-citation>
</ref>
<ref id="R177">
<label>177</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buka</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Torrey</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Klebanoff</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Yolken</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Maternal cytokine levels during pregnancy and adult psychosis.</article-title>
<source/>Brain, behavior, and immunity
          <year>2001</year>
<volume>15</volume>
<issue>4</issue>
<fpage>411</fpage>
<lpage>20</lpage>
<comment>Epub 2002/01/10</comment>
</element-citation>
</ref>
<ref id="R178">
<label>178</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayes</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Severance</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Leek</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Gressitt</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Rohleder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Coughlin</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inflammatory Molecular Signature Associated With Infectious Agents in Psychosis.</article-title>
<source/>Schizophrenia bulletin
          <year>2014</year>
<comment>Epub 2014/04/20</comment>
</element-citation>
</ref>
<ref id="R179">
<label>179</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beumer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gibney</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Drexhage</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Pont-Lezica</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Doorduin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>HC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes.</article-title>
<source/>Journal of leukocyte biology
          <year>2012</year>
<volume>92</volume>
<issue>5</issue>
<fpage>959</fpage>
<lpage>75</lpage>
<comment>Epub 2012/08/10</comment>
<pub-id pub-id-type="pmid">22875882</pub-id>
</element-citation>
</ref>
<ref id="R180">
<label>180</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikkila</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ahokas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miettinen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rimon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes.</article-title>
<source/>The American journal of psychiatry
          <year>1999</year>
<volume>156</volume>
<issue>11</issue>
<fpage>1725</fpage>
<lpage>9</lpage>
<comment>Epub 1999/11/30</comment>
<pub-id pub-id-type="pmid">10553735</pub-id>
</element-citation>
</ref>
<ref id="R181">
<label>181</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schafer</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Lehrman</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Kautzman</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Koyama</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mardinly</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner.</article-title>
<source/>Neuron
          <year>2012</year>
<volume>74</volume>
<issue>4</issue>
<fpage>691</fpage>
<lpage>705</lpage>
<comment>Epub 2012/05/29</comment>
<pub-id pub-id-type="pmid">22632727</pub-id>
</element-citation>
</ref>
<ref id="R182">
<label>182</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paolicelli</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Bolasco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Maggi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Scianni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Panzanelli</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synaptic pruning by microglia is necessary for normal brain development.</article-title>
<source/>Science (New York, NY)
          <year>2011</year>
<volume>333</volume>
<issue>6048</issue>
<fpage>1456</fpage>
<lpage>8</lpage>
<comment>Epub 2011/07/23</comment>
</element-citation>
</ref>
<ref id="R183">
<label>183</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyauchi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tsirka</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Microglia: an active player in the regulation of synaptic activity.</article-title>
<source/>Neural plasticity
          <year>2013</year>
<volume>2013</volume>
<fpage>627325</fpage>
<comment>Epub 2013/12/05</comment>
<pub-id pub-id-type="pmid">24303218</pub-id>
</element-citation>
</ref>
<ref id="R184">
<label>184</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feinberg</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?</article-title>
<source/>Journal of psychiatric research
          <year>1982</year>
<volume>17</volume>
<issue>4</issue>
<fpage>319</fpage>
<lpage>34</lpage>
<comment>Epub 1982/01/01</comment>
<pub-id pub-id-type="pmid">7187776</pub-id>
</element-citation>
</ref>
<ref id="R185">
<label>185</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wierzba-Bobrowicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lewandowska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lechowicz</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Stepien</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pasennik</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics.</article-title>
<source/>Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences
          <year>2005</year>
<volume>43</volume>
<issue>2</issue>
<fpage>81</fpage>
<lpage>9</lpage>
<comment>Epub 2005/07/14</comment>
</element-citation>
</ref>
<ref id="R186">
<label>186</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radewicz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Garey</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Gentleman</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics.</article-title>
<source/>Journal of neuropathology and experimental neurology
          <year>2000</year>
<volume>59</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>50</lpage>
<comment>Epub 2000/04/05</comment>
<pub-id pub-id-type="pmid">10749103</pub-id>
</element-citation>
</ref>
<ref id="R187">
<label>187</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnold</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Gur</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia.</article-title>
<source/>Archives of general psychiatry
          <year>1998</year>
<volume>55</volume>
<issue>3</issue>
<fpage>225</fpage>
<lpage>32</lpage>
<comment>Epub 1998/03/24</comment>
<pub-id pub-id-type="pmid">9510216</pub-id>
</element-citation>
</ref>
<ref id="R188">
<label>188</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falke</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia.</article-title>
<source/>Psychiatry research
          <year>2000</year>
<volume>93</volume>
<issue>2</issue>
<fpage>103</fpage>
<lpage>10</lpage>
<comment>Epub 2000/03/22</comment>
<pub-id pub-id-type="pmid">10725527</pub-id>
</element-citation>
</ref>
<ref id="R189">
<label>189</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Sommer</surname>
<given-names>IE</given-names>
</name>
</person-group>
<article-title>The neurobiology and treatment of first-episode schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2014</year>
<comment>Epub 2014/07/23</comment>
</element-citation>
</ref>
<ref id="R190">
<label>190</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fillman</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Cloonan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Catts</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McCrossin</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>2</issue>
<fpage>206</fpage>
<lpage>14</lpage>
<comment>Epub 2012/08/08</comment>
<pub-id pub-id-type="pmid">22869038</pub-id>
</element-citation>
</ref>
<ref id="R191">
<label>191</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fillman</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Cloonan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Weickert</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Markers of inflammation in the prefrontal cortex of individuals with schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>2</issue>
<fpage>133</fpage>
<comment>Epub 2013/01/25</comment>
<pub-id pub-id-type="pmid">23344565</pub-id>
</element-citation>
</ref>
<ref id="R192">
<label>192</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rupprecht</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rammes</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baghai</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Akula</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.</article-title>
<source/>Nature reviews Drug discovery
          <year>2010</year>
<volume>9</volume>
<issue>12</issue>
<fpage>971</fpage>
<lpage>88</lpage>
<comment>Epub 2010/12/02</comment>
<pub-id pub-id-type="pmid">21119734</pub-id>
</element-citation>
</ref>
<ref id="R193">
<label>193</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banati</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Newcombe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gunn</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Cagnin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turkheimer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Heppner</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.</article-title>
<source/>Brain : a journal of neurology
          <year>2000</year>
<volume>123</volume>
<issue>Pt 11</issue>
<fpage>2321</fpage>
<lpage>37</lpage>
<comment>Epub 2000/10/26</comment>
<pub-id pub-id-type="pmid">11050032</pub-id>
</element-citation>
</ref>
<ref id="R194">
<label>194</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banati</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Egensperger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maassen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hager</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kreutzberg</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Graeber</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>Mitochondria in activated microglia in vitro.</article-title>
<source/>Journal of neurocytology
          <year>2004</year>
<volume>33</volume>
<issue>5</issue>
<fpage>535</fpage>
<lpage>41</lpage>
<comment>Epub 2005/05/21</comment>
<pub-id pub-id-type="pmid">15906160</pub-id>
</element-citation>
</ref>
<ref id="R195">
<label>195</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doorduin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in schizophrenia-related psychosis: a PET study.</article-title>
<source/>Journal of nuclear medicine : official publication, Society of Nuclear Medicine
          <year>2009</year>
<volume>50</volume>
<issue>11</issue>
<fpage>1801</fpage>
<lpage>7</lpage>
<comment>Epub 2009/10/20</comment>
</element-citation>
</ref>
<ref id="R196">
<label>196</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Berckel</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Bossong</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Boellaard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kloet</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schuitemaker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Caspers</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study.</article-title>
<source/>Biological psychiatry
          <year>2008</year>
<volume>64</volume>
<issue>9</issue>
<fpage>820</fpage>
<lpage>2</lpage>
<comment>Epub 2008/06/07</comment>
<pub-id pub-id-type="pmid">18534557</pub-id>
</element-citation>
</ref>
<ref id="R197">
<label>197</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doorduin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders.</article-title>
<source/>Current pharmaceutical design
          <year>2008</year>
<volume>14</volume>
<issue>31</issue>
<fpage>3297</fpage>
<lpage>315</lpage>
<comment>Epub 2008/12/17</comment>
<pub-id pub-id-type="pmid">19075709</pub-id>
</element-citation>
</ref>
<ref id="R198">
<label>198</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Yeo</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Gunn</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wadsworth</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28.</article-title>
<source/>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
          <year>2012</year>
<volume>32</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>5</lpage>
<comment>Epub 2011/10/20</comment>
</element-citation>
</ref>
<ref id="R199">
<label>199</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manji</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Di Prospero</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Ness</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Krams</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired mitochondrial function in psychiatric disorders.</article-title>
<source/>Nature reviews Neuroscience
          <year>2012</year>
<volume>13</volume>
<issue>5</issue>
<fpage>293</fpage>
<lpage>307</lpage>
<comment>Epub 2012/04/19</comment>
<pub-id pub-id-type="pmid">22510887</pub-id>
</element-citation>
</ref>
<ref id="R200">
<label>200</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGrath</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Visscher</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Wray</surname>
<given-names>NR</given-names>
</name>
</person-group>
<article-title>Where GWAS and epidemiology meet: opportunities for the simultaneous study of genetic and environmental risk factors in schizophrenia.</article-title>
<source/>Schizophrenia bulletin
          <year>2013</year>
<volume>39</volume>
<issue>5</issue>
<fpage>955</fpage>
<lpage>9</lpage>
<comment>Epub 2013/08/03</comment>
<pub-id pub-id-type="pmid">23907349</pub-id>
</element-citation>
</ref>
<ref id="R201">
<label>201</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayhan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Pletnikov</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Animal models of gene-environment interactions in schizophrenia.</article-title>
<source/>Behavioural brain research
          <year>2009</year>
<volume>204</volume>
<issue>2</issue>
<fpage>274</fpage>
<lpage>81</lpage>
<comment>Epub 2009/04/22</comment>
<pub-id pub-id-type="pmid">19379776</pub-id>
</element-citation>
</ref>
<ref id="R202">
<label>202</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kannan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pletnikov</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Mouse models of gene-environment interactions in schizophrenia.</article-title>
<source/>Neurobiology of disease
          <year>2013</year>
<volume>57</volume>
<fpage>5</fpage>
<lpage>11</lpage>
<comment>Epub 2013/06/12</comment>
<pub-id pub-id-type="pmid">23748077</pub-id>
</element-citation>
</ref>
<ref id="R203">
<label>203</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benros</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis.</article-title>
<source/>Biological psychiatry
          <year>2013</year>
<comment>Epub 2013/11/10</comment>
</element-citation>
</ref>
<ref id="R204">
<label>204</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eaton</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ewald</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mors</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Agerbo</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of schizophrenia and autoimmune diseases: linkage of Danish national registers.</article-title>
<source/>The American journal of psychiatry
          <year>2006</year>
<volume>163</volume>
<issue>3</issue>
<fpage>521</fpage>
<lpage>8</lpage>
<comment>Epub 2006/03/04</comment>
<pub-id pub-id-type="pmid">16513876</pub-id>
</element-citation>
</ref>
<ref id="R205">
<label>205</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ophoff</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Andreassen</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Cichon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common variants conferring risk of schizophrenia.</article-title>
<source/>Nature
          <year>2009</year>
<volume>460</volume>
<issue>7256</issue>
<fpage>744</fpage>
<lpage>7</lpage>
<comment>Epub 2009/07/03</comment>
<pub-id pub-id-type="pmid">19571808</pub-id>
</element-citation>
</ref>
<ref id="R206">
<label>206</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fanous</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Kendler</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>A bias-reducing pathway enrichment analysis of genome-wide association data confirmed association of the MHC region with schizophrenia.</article-title>
<source/>Journal of medical genetics
          <year>2012</year>
<volume>49</volume>
<issue>2</issue>
<fpage>96</fpage>
<lpage>103</lpage>
<comment>Epub 2011/12/22</comment>
<pub-id pub-id-type="pmid">22187495</pub-id>
</element-citation>
</ref>
<ref id="R207">
<label>207</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bitanihirwe</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>TU</given-names>
</name>
</person-group>
<article-title>Oxidative stress in schizophrenia: an integrated approach.</article-title>
<source/>Neuroscience and biobehavioral reviews
          <year>2011</year>
<volume>35</volume>
<issue>3</issue>
<fpage>878</fpage>
<lpage>93</lpage>
<comment>Epub 2010/10/27</comment>
<pub-id pub-id-type="pmid">20974172</pub-id>
</element-citation>
</ref>
<ref id="R208">
<label>208</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emiliani</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Sedlak</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Oxidative stress and schizophrenia: recent breakthroughs from an old story.</article-title>
<source/>Current opinion in psychiatry
          <year>2014</year>
<volume>27</volume>
<issue>3</issue>
<fpage>185</fpage>
<lpage>90</lpage>
<comment>Epub 2014/03/13</comment>
<pub-id pub-id-type="pmid">24613987</pub-id>
</element-citation>
</ref>
<ref id="R209">
<label>209</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flatow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Meta-analysis of oxidative stress in schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>2013</year>
<volume>74</volume>
<issue>6</issue>
<fpage>400</fpage>
<lpage>9</lpage>
<comment>Epub 2013/05/21</comment>
<pub-id pub-id-type="pmid">23683390</pub-id>
</element-citation>
</ref>
<ref id="R210">
<label>210</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gawryluk</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Andreazza</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LT</given-names>
</name>
</person-group>
<article-title>Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders.</article-title>
<source/>The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
          <year>2011</year>
<volume>14</volume>
<issue>1</issue>
<fpage>123</fpage>
<lpage>30</lpage>
<comment>Epub 2010/07/17</comment>
<pub-id pub-id-type="pmid">20633320</pub-id>
</element-citation>
</ref>
<ref id="R211">
<label>211</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Parikh</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Coussons</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Mahadik</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title>Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment.</article-title>
<source/>Prostaglandins, leukotrienes, and essential fatty acids
          <year>2003</year>
<volume>69</volume>
<issue>6</issue>
<fpage>393</fpage>
<lpage>9</lpage>
<comment>Epub 2003/11/19</comment>
</element-citation>
</ref>
<ref id="R212">
<label>212</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coughlin</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ishizuka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kano</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Seifuddin</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Shimano</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>1</issue>
<fpage>10</fpage>
<lpage>1</lpage>
<comment>Epub 2012/02/22</comment>
<pub-id pub-id-type="pmid">22349781</pub-id>
</element-citation>
</ref>
<ref id="R213">
<label>213</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raffa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Atig</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mhalla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kerkeni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mechri</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients.</article-title>
<source/>BMC psychiatry
          <year>2011</year>
<volume>11</volume>
<fpage>124</fpage>
<comment>Epub 2011/08/04</comment>
<pub-id pub-id-type="pmid">21810251</pub-id>
</element-citation>
</ref>
<ref id="R214">
<label>214</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Colantuoni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>7</issue>
<fpage>740</fpage>
<lpage>2</lpage>
<comment>Epub 2012/08/29</comment>
<pub-id pub-id-type="pmid">22925834</pub-id>
</element-citation>
</ref>
<ref id="R215">
<label>215</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
<name>
<surname>Trabesinger</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Kirsten-Kruger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lauer</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Dydak</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hell</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.</article-title>
<source/>The European journal of neuroscience
          <year>2000</year>
<volume>12</volume>
<issue>10</issue>
<fpage>3721</fpage>
<lpage>8</lpage>
<comment>Epub 2000/10/13</comment>
<pub-id pub-id-type="pmid">11029642</pub-id>
</element-citation>
</ref>
<ref id="R216">
<label>216</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terpstra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vaughan</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Ugurbil</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>KO</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia.</article-title>
<source/>Magma (New York, NY)
          <year>2005</year>
<volume>18</volume>
<issue>5</issue>
<fpage>276</fpage>
<lpage>82</lpage>
<comment>Epub 2005/12/02</comment>
</element-citation>
</ref>
<ref id="R217">
<label>217</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuzawa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Obata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shirayama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nonaka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kanazawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoshitome</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study.</article-title>
<source/>PloS one
          <year>2008</year>
<volume>3</volume>
<issue>4</issue>
<fpage>e1944</fpage>
<comment>Epub 2008/04/10</comment>
<pub-id pub-id-type="pmid">18398470</pub-id>
</element-citation>
</ref>
<ref id="R218">
<label>218</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Wellard</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Proffitt</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>McConchie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation.</article-title>
<source/>Neurobiology of disease
          <year>2009</year>
<volume>33</volume>
<issue>3</issue>
<fpage>354</fpage>
<lpage>7</lpage>
<comment>Epub 2009/01/03</comment>
<pub-id pub-id-type="pmid">19118629</pub-id>
</element-citation>
</ref>
<ref id="R219">
<label>219</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borges</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gayer-Anderson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mondelli</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis.</article-title>
<source/>Psychoneuroendocrinology
          <year>2013</year>
<volume>38</volume>
<issue>5</issue>
<fpage>603</fpage>
<lpage>11</lpage>
<comment>Epub 2013/02/02</comment>
<pub-id pub-id-type="pmid">23369532</pub-id>
</element-citation>
</ref>
<ref id="R220">
<label>220</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pariante</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Vassilopoulou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Velakoulis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Soulsby</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pituitary volume in psychosis.</article-title>
<source/>The British journal of psychiatry : the journal of mental science
          <year>2004</year>
<volume>185</volume>
<fpage>5</fpage>
<lpage>10</lpage>
<comment>Epub 2004/07/03</comment>
<pub-id pub-id-type="pmid">15231549</pub-id>
</element-citation>
</ref>
<ref id="R221">
<label>221</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Furuichi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kido</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased pituitary volume in subjects at risk for psychosis and patients with first-episode schizophrenia.</article-title>
<source/>Psychiatry and clinical neurosciences
          <year>2013</year>
<volume>67</volume>
<issue>7</issue>
<fpage>540</fpage>
<lpage>8</lpage>
<comment>Epub 2013/10/10</comment>
<pub-id pub-id-type="pmid">24102999</pub-id>
</element-citation>
</ref>
<ref id="R222">
<label>222</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buschlen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Borgwardt</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Aston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gschwandtner</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Pflueger</surname>
<given-names>MO</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pituitary volume increase during emerging psychosis.</article-title>
<source/>Schizophrenia research
          <year>2011</year>
<volume>125</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>8</lpage>
<comment>Epub 2010/11/16</comment>
<pub-id pub-id-type="pmid">21074369</pub-id>
</element-citation>
</ref>
<ref id="R223">
<label>223</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romo-Nava</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hoogenboom</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Pelavin</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Alvarado</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Bobrow</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Macmaster</surname>
<given-names>FP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pituitary volume in schizophrenia spectrum disorders.</article-title>
<source/>Schizophrenia research
          <year>2013</year>
<volume>146</volume>
<issue>1-3</issue>
<fpage>301</fpage>
<lpage>7</lpage>
<comment>Epub 2013/03/26</comment>
<pub-id pub-id-type="pmid">23522905</pub-id>
</element-citation>
</ref>
<ref id="R224">
<label>224</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Sevy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gunduz-Bruce</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pituitary volume in first-episode schizophrenia.</article-title>
<source/>Psychiatry research
          <year>2012</year>
<volume>203</volume>
<issue>1</issue>
<fpage>100</fpage>
<lpage>2</lpage>
<comment>Epub 2012/08/04</comment>
<pub-id pub-id-type="pmid">22858406</pub-id>
</element-citation>
</ref>
<ref id="R225">
<label>225</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tournikioti</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tansella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perlini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rambaldelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cerini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Versace</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Normal pituitary volumes in chronic schizophrenia.</article-title>
<source/>Psychiatry research
          <year>2007</year>
<volume>154</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>8</lpage>
<comment>Epub 2006/12/23</comment>
<pub-id pub-id-type="pmid">17184977</pub-id>
</element-citation>
</ref>
<ref id="R226">
<label>226</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhyaya</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>El-Sheikh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>MacMaster</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Diwadkar</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Keshavan</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Pituitary volume in neuroleptic-naive schizophrenia: a structural MRI study.</article-title>
<source/>Schizophrenia research
          <year>2007</year>
<volume>90</volume>
<issue>1-3</issue>
<fpage>266</fpage>
<lpage>73</lpage>
<comment>Epub 2006/12/26</comment>
<pub-id pub-id-type="pmid">17187962</pub-id>
</element-citation>
</ref>
<ref id="R227">
<label>227</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tognin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rambaldelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Perlini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bellani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marinelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zoccatelli</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enlarged hypothalamic volumes in schizophrenia.</article-title>
<source/>Psychiatry research
          <year>2012</year>
<volume>204</volume>
<issue>2-3</issue>
<fpage>75</fpage>
<lpage>81</lpage>
<comment>Epub 2012/12/12</comment>
<pub-id pub-id-type="pmid">23217575</pub-id>
</element-citation>
</ref>
<ref id="R228">
<label>228</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Makris</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ahern</surname>
<given-names>T</given-names>
</name>
<name>
<surname>O'Brien</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Caviness</surname>
<given-names>VS</given-names>
<suffix>Jr.</suffix>
</name>
<etal></etal>
</person-group>
<article-title>Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability.</article-title>
<source/>Biological psychiatry
          <year>2007</year>
<volume>61</volume>
<issue>8</issue>
<fpage>935</fpage>
<lpage>45</lpage>
<comment>Epub 2006/10/19</comment>
<pub-id pub-id-type="pmid">17046727</pub-id>
</element-citation>
</ref>
<ref id="R229">
<label>229</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koolschijn</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>van Haren</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Hulshoff Pol</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Hypothalamus volume in twin pairs discordant for schizophrenia.</article-title>
<source/>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
          <year>2008</year>
<volume>18</volume>
<issue>4</issue>
<fpage>312</fpage>
<lpage>5</lpage>
<comment>Epub 2008/01/29</comment>
<pub-id pub-id-type="pmid">18222652</pub-id>
</element-citation>
</ref>
<ref id="R230">
<label>230</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klomp</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koolschijn</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Hulshoff Pol</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Haren</surname>
<given-names>NE</given-names>
</name>
</person-group>
<article-title>Hypothalamus and pituitary volume in schizophrenia: a structural MRI study.</article-title>
<source/>The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
          <year>2012</year>
<volume>15</volume>
<issue>2</issue>
<fpage>281</fpage>
<lpage>8</lpage>
<comment>Epub 2011/07/08</comment>
<pub-id pub-id-type="pmid">21733239</pub-id>
</element-citation>
</ref>
<ref id="R231">
<label>231</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Spelman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sharifi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thakore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release.</article-title>
<source/>Psychoneuroendocrinology
          <year>2005</year>
<volume>30</volume>
<issue>5</issue>
<fpage>431</fpage>
<lpage>7</lpage>
<comment>Epub 2005/02/22</comment>
<pub-id pub-id-type="pmid">15721055</pub-id>
</element-citation>
</ref>
<ref id="R232">
<label>232</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritsner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gibel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maayan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ram</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Modai</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients.</article-title>
<source/>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
          <year>2007</year>
<volume>17</volume>
<issue>4</issue>
<fpage>257</fpage>
<lpage>64</lpage>
<comment>Epub 2006/11/17</comment>
<pub-id pub-id-type="pmid">17107774</pub-id>
</element-citation>
</ref>
<ref id="R233">
<label>233</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallagher</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Ferrier</surname>
<given-names>IN</given-names>
</name>
</person-group>
<article-title>Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder.</article-title>
<source/>Schizophrenia research
          <year>2007</year>
<volume>90</volume>
<issue>1-3</issue>
<fpage>258</fpage>
<lpage>65</lpage>
<comment>Epub 2007/01/16</comment>
<pub-id pub-id-type="pmid">17222537</pub-id>
</element-citation>
</ref>
<ref id="R234">
<label>234</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Herken</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cicek</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Celik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yurekli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akyol</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia.</article-title>
<source/>Medical principles and practice : international journal of the Kuwait University, Health Science Centre
          <year>2007</year>
<volume>16</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>41</lpage>
<comment>Epub 2007/02/17</comment>
</element-citation>
</ref>
<ref id="R235">
<label>235</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Sharifi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Condren</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Thakore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia.</article-title>
<source/>Psychoneuroendocrinology
          <year>2004</year>
<volume>29</volume>
<issue>8</issue>
<fpage>1065</fpage>
<lpage>70</lpage>
<comment>Epub 2004/06/29</comment>
<pub-id pub-id-type="pmid">15219658</pub-id>
</element-citation>
</ref>
<ref id="R236">
<label>236</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Trotman</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Addington</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cadenhead</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Cornblatt</surname>
<given-names>BA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study.</article-title>
<source/>Biological psychiatry
          <year>2013</year>
<volume>74</volume>
<issue>6</issue>
<fpage>410</fpage>
<lpage>7</lpage>
<comment>Epub 2013/04/09</comment>
<pub-id pub-id-type="pmid">23562006</pub-id>
</element-citation>
</ref>
<ref id="R237">
<label>237</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strous</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Maayan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lapidus</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Goredetsky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zeldich</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kotler</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology.</article-title>
<source/>Schizophrenia research
          <year>2004</year>
<volume>71</volume>
<issue>2-3</issue>
<fpage>427</fpage>
<lpage>34</lpage>
<comment>Epub 2004/10/12</comment>
<pub-id pub-id-type="pmid">15474914</pub-id>
</element-citation>
</ref>
<ref id="R238">
<label>238</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkatasubramanian</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chittiprol</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neelakantachar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shetty</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gangadhar</surname>
<given-names>BN</given-names>
</name>
</person-group>
<article-title>Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study.</article-title>
<source/>Schizophrenia research
          <year>2010</year>
<volume>119</volume>
<issue>1-3</issue>
<fpage>131</fpage>
<lpage>7</lpage>
<comment>Epub 2010/03/17</comment>
<pub-id pub-id-type="pmid">20226630</pub-id>
</element-citation>
</ref>
<ref id="R239">
<label>239</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnamurthy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Koutroukides</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Rahmoune</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pietsch</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects.</article-title>
<source/>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
          <year>2013</year>
<volume>14</volume>
<issue>7</issue>
<fpage>478</fpage>
<lpage>89</lpage>
<comment>Epub 2012/01/18</comment>
</element-citation>
</ref>
<ref id="R240">
<label>240</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlman</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kleinman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Weickert</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness.</article-title>
<source/>Biological psychiatry
          <year>2004</year>
<volume>56</volume>
<issue>11</issue>
<fpage>844</fpage>
<lpage>52</lpage>
<comment>Epub 2004/12/04</comment>
<pub-id pub-id-type="pmid">15576061</pub-id>
</element-citation>
</ref>
<ref id="R241">
<label>241</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webster</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Knable</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>O'Grady</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Orthmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weickert</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders.</article-title>
<source/>Molecular psychiatry
          <year>2002</year>
<volume>7</volume>
<issue>9</issue>
<fpage>985</fpage>
<lpage>94, 24</lpage>
<comment>Epub 2002/10/26</comment>
<pub-id pub-id-type="pmid">12399952</pub-id>
</element-citation>
</ref>
<ref id="R242">
<label>242</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Orr</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kantarovich</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hermesh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Cushing's syndrome presenting as a schizophrenia-like psychotic state.</article-title>
<source/>The Israel journal of psychiatry and related sciences
          <year>2000</year>
<volume>37</volume>
<issue>1</issue>
<fpage>46</fpage>
<lpage>50</lpage>
<comment>Epub 2000/06/17</comment>
<pub-id pub-id-type="pmid">10857272</pub-id>
</element-citation>
</ref>
<ref id="R243">
<label>243</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Popkin</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Stickney</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>ER</given-names>
</name>
</person-group>
<article-title>Presentation of the steroid psychoses.</article-title>
<source/>The Journal of nervous and mental disease
          <year>1979</year>
<volume>167</volume>
<issue>4</issue>
<fpage>229</fpage>
<lpage>36</lpage>
<comment>Epub 1979/04/01</comment>
<pub-id pub-id-type="pmid">438794</pub-id>
</element-citation>
</ref>
<ref id="R244">
<label>244</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flores</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Kenna</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Solvason</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Schatzberg</surname>
<given-names>AF</given-names>
</name>
</person-group>
<article-title>Clinical and biological effects of mifepristone treatment for psychotic depression.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2006</year>
<volume>31</volume>
<issue>3</issue>
<fpage>628</fpage>
<lpage>36</lpage>
<comment>Epub 2005/09/15</comment>
<pub-id pub-id-type="pmid">16160710</pub-id>
</element-citation>
</ref>
<ref id="R245">
<label>245</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schatzberg</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Lindley</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.</article-title>
<source/>European journal of pharmacology
          <year>2008</year>
<volume>583</volume>
<issue>2-3</issue>
<fpage>358</fpage>
<lpage>64</lpage>
<comment>Epub 2008/03/15</comment>
<pub-id pub-id-type="pmid">18339372</pub-id>
</element-citation>
</ref>
<ref id="R246">
<label>246</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myers</surname>
<given-names>B</given-names>
</name>
<name>
<surname>McKlveen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Glucocorticoid actions on synapses, circuits, and behavior: implications for the energetics of stress.</article-title>
<source/>Frontiers in neuroendocrinology
          <year>2014</year>
<volume>35</volume>
<issue>2</issue>
<fpage>180</fpage>
<lpage>96</lpage>
<comment>Epub 2013/12/24</comment>
<pub-id pub-id-type="pmid">24361584</pub-id>
</element-citation>
</ref>
<ref id="R247">
<label>247</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niwa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jaaro-Peled</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tankou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hikida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids.</article-title>
<source/>Science (New York, NY)
          <year>2013</year>
<volume>339</volume>
<issue>6117</issue>
<fpage>335</fpage>
<lpage>9</lpage>
<comment>Epub 2013/01/19</comment>
</element-citation>
</ref>
<ref id="R248">
<label>248</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Tettenborn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leifke</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Emrich</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Sex hormones in psychotic men.</article-title>
<source/>Psychoneuroendocrinology
          <year>2005</year>
<volume>30</volume>
<issue>1</issue>
<fpage>111</fpage>
<lpage>4</lpage>
<comment>Epub 2004/09/11</comment>
<pub-id pub-id-type="pmid">15358449</pub-id>
</element-citation>
</ref>
<ref id="R249">
<label>249</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergemann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mundt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Parzer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jannakos</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nagl</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Salbach</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics.</article-title>
<source/>Schizophrenia research
          <year>2005</year>
<volume>73</volume>
<issue>2-3</issue>
<fpage>357</fpage>
<lpage>66</lpage>
<comment>Epub 2005/01/18</comment>
<pub-id pub-id-type="pmid">15653282</pub-id>
</element-citation>
</ref>
<ref id="R250">
<label>250</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weickert</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Miranda-Angulo</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Radhakrishna</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia.</article-title>
<source/>Human molecular genetics
          <year>2008</year>
<volume>17</volume>
<issue>15</issue>
<fpage>2293</fpage>
<lpage>309</lpage>
<comment>Epub 2008/04/22</comment>
<pub-id pub-id-type="pmid">18424448</pub-id>
</element-citation>
</ref>
<ref id="R251">
<label>251</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulkarni</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gavrilidis</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Hormones and schizophrenia.</article-title>
<source/>Current opinion in psychiatry
          <year>2012</year>
<volume>25</volume>
<issue>2</issue>
<fpage>89</fpage>
<lpage>95</lpage>
<comment>Epub 2012/01/18</comment>
<pub-id pub-id-type="pmid">22249082</pub-id>
</element-citation>
</ref>
<ref id="R252">
<label>252</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lokuge</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The rapid effects of estrogen: a mini-review.</article-title>
<source/>Behavioural pharmacology
          <year>2010</year>
<volume>21</volume>
<issue>5-6</issue>
<fpage>465</fpage>
<lpage>72</lpage>
<comment>Epub 2010/07/28</comment>
<pub-id pub-id-type="pmid">20661136</pub-id>
</element-citation>
</ref>
<ref id="R253">
<label>253</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cyr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ghribi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Di Paolo</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Regional and selective effects of oestradiol and progesterone on NMDA and AMPA receptors in the rat brain.</article-title>
<source/>Journal of neuroendocrinology
          <year>2000</year>
<volume>12</volume>
<issue>5</issue>
<fpage>445</fpage>
<lpage>52</lpage>
<comment>Epub 2000/05/03</comment>
<pub-id pub-id-type="pmid">10792584</pub-id>
</element-citation>
</ref>
<ref id="R254">
<label>254</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allison</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Fontaine</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Heo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mentore</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Cappelleri</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Chandler</surname>
<given-names>LP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The distribution of body mass index among individuals with and without schizophrenia.</article-title>
<source/>The Journal of clinical psychiatry
          <year>1999</year>
<volume>60</volume>
<issue>4</issue>
<fpage>215</fpage>
<lpage>20</lpage>
<comment>Epub 1999/04/30</comment>
<pub-id pub-id-type="pmid">10221280</pub-id>
</element-citation>
</ref>
<ref id="R255">
<label>255</label>
<element-citation publication-type="journal">
<article-title>Consensus development conference on antipsychotic drugs and obesity and diabetes.</article-title>
<source/>The Journal of clinical psychiatry
          <year>2004</year>
<volume>65</volume>
<issue>2</issue>
<fpage>267</fpage>
<lpage>72</lpage>
<comment>Epub 2004/03/09</comment>
<pub-id pub-id-type="pmid">15003083</pub-id>
</element-citation>
</ref>
<ref id="R256">
<label>256</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boke</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Aker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sarisoy</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Saricicek</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Prevalence of metabolic syndrome among inpatients with schizophrenia.</article-title>
<source/>International journal of psychiatry in medicine
          <year>2008</year>
<volume>38</volume>
<issue>1</issue>
<fpage>103</fpage>
<lpage>12</lpage>
<comment>Epub 2008/07/16</comment>
<pub-id pub-id-type="pmid">18624022</pub-id>
</element-citation>
</ref>
<ref id="R257">
<label>257</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takayanagi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cascella</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>WW</given-names>
</name>
</person-group>
<article-title>Diabetes is associated with lower global cognitive function in schizophrenia.</article-title>
<source/>Schizophrenia research
          <year>2012</year>
<volume>142</volume>
<issue>1-3</issue>
<fpage>183</fpage>
<lpage>7</lpage>
<comment>Epub 2012/10/04</comment>
<pub-id pub-id-type="pmid">23031192</pub-id>
</element-citation>
</ref>
<ref id="R258">
<label>258</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popovic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Doknic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maric</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pekic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Damjanovic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miljic</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.</article-title>
<source/>Neuroendocrinology
          <year>2007</year>
<volume>85</volume>
<issue>4</issue>
<fpage>249</fpage>
<lpage>56</lpage>
<comment>Epub 2007/06/16</comment>
<pub-id pub-id-type="pmid">17570902</pub-id>
</element-citation>
</ref>
<ref id="R259">
<label>259</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doknic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maric</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Britvic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pekic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Damjanovic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miljic</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.</article-title>
<source/>Neuroendocrinology
          <year>2011</year>
<volume>94</volume>
<issue>3</issue>
<fpage>246</fpage>
<lpage>54</lpage>
<comment>Epub 2011/10/12</comment>
<pub-id pub-id-type="pmid">21986470</pub-id>
</element-citation>
</ref>
<ref id="R260">
<label>260</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Hert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peuskens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Winkel</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Mortality in patients with schizophrenia.</article-title>
<source/>Lancet
          <year>2009</year>
<volume>374</volume>
<issue>9701</issue>
<fpage>1591</fpage>
<comment>author reply 2-3. Epub 2009/11/10</comment>
<pub-id pub-id-type="pmid">19897118</pub-id>
</element-citation>
</ref>
<ref id="R261">
<label>261</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spelman</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Sharifi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thakore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia.</article-title>
<source/>Diabetic medicine : a journal of the British Diabetic Association
          <year>2007</year>
<volume>24</volume>
<issue>5</issue>
<fpage>481</fpage>
<lpage>5</lpage>
<comment>Epub 2007/03/27</comment>
<pub-id pub-id-type="pmid">17381506</pub-id>
</element-citation>
</ref>
<ref id="R262">
<label>262</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thakore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>2003</year>
<volume>160</volume>
<issue>2</issue>
<fpage>284</fpage>
<lpage>9</lpage>
<comment>Epub 2003/02/04</comment>
<pub-id pub-id-type="pmid">12562574</pub-id>
</element-citation>
</ref>
<ref id="R263">
<label>263</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirkpatrick</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Schizophrenia as a systemic disease.</article-title>
<source/>Schizophrenia bulletin
          <year>2009</year>
<volume>35</volume>
<issue>2</issue>
<fpage>381</fpage>
<lpage>2</lpage>
<comment>Epub 2009/02/06</comment>
<pub-id pub-id-type="pmid">19193741</pub-id>
</element-citation>
</ref>
<ref id="R264">
<label>264</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guest</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Martins-de-Souza</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vanattou-Saifoudine</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Bahn</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Abnormalities in metabolism and hypothalamic-pituitary-adrenal axis function in schizophrenia.</article-title>
<source/>International review of neurobiology
          <year>2011</year>
<volume>101</volume>
<fpage>145</fpage>
<lpage>68</lpage>
<comment>Epub 2011/11/05</comment>
<pub-id pub-id-type="pmid">22050851</pub-id>
</element-citation>
</ref>
<ref id="R265">
<label>265</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Leweke</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Koethe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gerth</surname>
<given-names>CW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia.</article-title>
<source/>PLoS medicine
          <year>2006</year>
<volume>3</volume>
<issue>8</issue>
<fpage>e327</fpage>
<comment>Epub 2006/08/29</comment>
<pub-id pub-id-type="pmid">16933966</pub-id>
</element-citation>
</ref>
<ref id="R266">
<label>266</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamminga</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Thaker</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alphs</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Chase</surname>
<given-names>TN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.</article-title>
<source/>Archives of general psychiatry
          <year>1992</year>
<volume>49</volume>
<issue>7</issue>
<fpage>522</fpage>
<lpage>30</lpage>
<comment>Epub 1992/07/01</comment>
<pub-id pub-id-type="pmid">1627043</pub-id>
</element-citation>
</ref>
<ref id="R267">
<label>267</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchsbaum</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Buchsbaum</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Hazlett</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Haznedar</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Newmark</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>CY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relative glucose metabolic rate higher in white matter in patients with schizophrenia.</article-title>
<source/>The American journal of psychiatry
          <year>2007</year>
<volume>164</volume>
<issue>7</issue>
<fpage>1072</fpage>
<lpage>81</lpage>
<comment>Epub 2007/07/04</comment>
<pub-id pub-id-type="pmid">17606659</pub-id>
</element-citation>
</ref>
<ref id="R268">
<label>268</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jaaro-Peled</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models.</article-title>
<source/>Neurobiology of disease
          <year>2012</year>
<volume>45</volume>
<issue>1</issue>
<fpage>48</fpage>
<lpage>56</lpage>
<comment>Epub 2011/09/15</comment>
<pub-id pub-id-type="pmid">21914480</pub-id>
</element-citation>
</ref>
<ref id="R269">
<label>269</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ksiezak-Reding</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Riggio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pasinetti</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction.</article-title>
<source/>Schizophrenia research
          <year>2006</year>
<volume>84</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>14</lpage>
<comment>Epub 2006/04/04</comment>
<pub-id pub-id-type="pmid">16581231</pub-id>
</element-citation>
</ref>
<ref id="R270">
<label>270</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lendeckel</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Bukowska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ansorge</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stauch</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia.</article-title>
<source/>Journal of psychiatric research
          <year>2009</year>
<volume>43</volume>
<issue>13</issue>
<fpage>1095</fpage>
<lpage>105</lpage>
<comment>Epub 2009/04/28</comment>
<pub-id pub-id-type="pmid">19394958</pub-id>
</element-citation>
</ref>
<ref id="R271">
<label>271</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Neill</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kiely</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Coakley</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Manning</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Long-Smith</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease.</article-title>
<source/>Biochemical Society transactions
          <year>2012</year>
<volume>40</volume>
<issue>4</issue>
<fpage>721</fpage>
<lpage>7</lpage>
<comment>Epub 2012/07/24</comment>
<pub-id pub-id-type="pmid">22817723</pub-id>
</element-citation>
</ref>
<ref id="R272">
<label>272</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>C</surname>
<given-names>ON</given-names>
</name>
</person-group>
<article-title>PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.</article-title>
<source/>Experimental gerontology
          <year>2013</year>
<volume>48</volume>
<issue>7</issue>
<fpage>647</fpage>
<lpage>53</lpage>
<comment>Epub 2013/03/09</comment>
<pub-id pub-id-type="pmid">23470275</pub-id>
</element-citation>
</ref>
<ref id="R273">
<label>273</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McEvoy</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Goff</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Nasrallah</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.</article-title>
<source/>Schizophrenia research
          <year>2005</year>
<volume>80</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>32</lpage>
<comment>Epub 2005/09/03</comment>
<pub-id pub-id-type="pmid">16137860</pub-id>
</element-citation>
</ref>
<ref id="R274">
<label>274</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tarbox</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Van Eerdewegh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample.</article-title>
<source/>American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
          <year>2004</year>
<volume>127B</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>10</lpage>
<comment>Epub 2004/04/27</comment>
</element-citation>
</ref>
<ref id="R275">
<label>275</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olsen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jakobsen</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Djurovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Melle</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Agartz</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples.</article-title>
<source/>BMC medical genetics
          <year>2008</year>
<volume>9</volume>
<fpage>39</fpage>
<comment>Epub 2008/05/08</comment>
<pub-id pub-id-type="pmid">18460190</pub-id>
</element-citation>
</ref>
<ref id="R276">
<label>276</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freyberg</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ferrando</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Javitch</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.</article-title>
<source/>The American journal of psychiatry
          <year>2010</year>
<volume>167</volume>
<issue>4</issue>
<fpage>388</fpage>
<lpage>96</lpage>
<comment>Epub 2009/11/18</comment>
<pub-id pub-id-type="pmid">19917593</pub-id>
</element-citation>
</ref>
<ref id="R277">
<label>277</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinha</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Opentanova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ohannesian</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Kolaczynski</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Heiman</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Hale</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting.</article-title>
<source/>The Journal of clinical investigation
          <year>1996</year>
<volume>98</volume>
<issue>6</issue>
<fpage>1277</fpage>
<lpage>82</lpage>
<comment>Epub 1996/09/15</comment>
<pub-id pub-id-type="pmid">8823291</pub-id>
</element-citation>
</ref>
<ref id="R278">
<label>278</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Considine</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Heiman</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Kriauciunas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Nyce</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum immunoreactive-leptin concentrations in normal-weight and obese humans.</article-title>
<source/>The New England journal of medicine
          <year>1996</year>
<volume>334</volume>
<issue>5</issue>
<fpage>292</fpage>
<lpage>5</lpage>
<comment>Epub 1996/02/01</comment>
<pub-id pub-id-type="pmid">8532024</pub-id>
</element-citation>
</ref>
<ref id="R279">
<label>279</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Jacka</surname>
<given-names>FN</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Kotowicz</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study.</article-title>
<source/>Journal of affective disorders
          <year>2008</year>
<volume>107</volume>
<issue>1-3</issue>
<fpage>221</fpage>
<lpage>5</lpage>
<comment>Epub 2007/08/31</comment>
<pub-id pub-id-type="pmid">17727958</pub-id>
</element-citation>
</ref>
<ref id="R280">
<label>280</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malcher-Lopes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marcheselli</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Stuart</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Bazan</surname>
<given-names>NG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2006</year>
<volume>26</volume>
<issue>24</issue>
<fpage>6643</fpage>
<lpage>50</lpage>
<comment>Epub 2006/06/16</comment>
<pub-id pub-id-type="pmid">16775153</pub-id>
</element-citation>
</ref>
<ref id="R281">
<label>281</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kern</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albarran-Zeckler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>RG</given-names>
</name>
</person-group>
<article-title>Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism.</article-title>
<source/>Neuron
          <year>2012</year>
<volume>73</volume>
<issue>2</issue>
<fpage>317</fpage>
<lpage>32</lpage>
<comment>Epub 2012/01/31</comment>
<pub-id pub-id-type="pmid">22284186</pub-id>
</element-citation>
</ref>
<ref id="R282">
<label>282</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sentissi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Epelbaum</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Olie</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review.</article-title>
<source/>Schizophrenia bulletin
          <year>2008</year>
<volume>34</volume>
<issue>6</issue>
<fpage>1189</fpage>
<lpage>99</lpage>
<comment>Epub 2008/01/01</comment>
<pub-id pub-id-type="pmid">18165262</pub-id>
</element-citation>
</ref>
<ref id="R283">
<label>283</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Prabakaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wengenroth</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lockstone</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Koethe</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues.</article-title>
<source/>Molecular psychiatry
          <year>2008</year>
<volume>13</volume>
<issue>12</issue>
<fpage>1118</fpage>
<lpage>28</lpage>
<comment>Epub 2007/10/17</comment>
<pub-id pub-id-type="pmid">17938634</pub-id>
</element-citation>
</ref>
<ref id="R284">
<label>284</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls.</article-title>
<source/>Schizophrenia research
          <year>2013</year>
<volume>150</volume>
<issue>1</issue>
<fpage>157</fpage>
<lpage>62</lpage>
<comment>Epub 2013/09/04</comment>
<pub-id pub-id-type="pmid">23998954</pub-id>
</element-citation>
</ref>
<ref id="R285">
<label>285</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins-De-Souza</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wobrock</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zerr</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gawinecka</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schneider-Axmann</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls.</article-title>
<source/>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
          <year>2010</year>
<volume>11</volume>
<issue>5</issue>
<fpage>719</fpage>
<lpage>28</lpage>
<comment>Epub 2010/05/08</comment>
</element-citation>
</ref>
<ref id="R286">
<label>286</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cieslak</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Feingold</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Antonius</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walsh-Messinger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dracxler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rosedale</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Low Vitamin D levels predict clinical features of schizophrenia.</article-title>
<source/>Schizophrenia research
          <year>2014</year>
<volume>159</volume>
<issue>2-3</issue>
<fpage>543</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">25311777</pub-id>
</element-citation>
</ref>
<ref id="R287">
<label>287</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crews</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lally</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gardner-Sood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Howes</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bonaccorso</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vitamin D deficiency in first episode psychosis: a case-control study.</article-title>
<source/>Schizophrenia research
          <year>2013</year>
<volume>150</volume>
<issue>2-3</issue>
<fpage>533</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">24060571</pub-id>
</element-citation>
</ref>
<ref id="R288">
<label>288</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGrath</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Burne</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Feron</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eyles</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update.</article-title>
<source/>Schizophrenia bulletin
          <year>2010</year>
<volume>36</volume>
<issue>6</issue>
<fpage>1073</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">20833696</pub-id>
</element-citation>
</ref>
<ref id="R289">
<label>289</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kao</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Genetics of antipsychotic-induced weight gain: update and current perspectives.</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<issue>16</issue>
<fpage>2067</fpage>
<lpage>83</lpage>
<comment>Epub 2013/11/28</comment>
<pub-id pub-id-type="pmid">24279860</pub-id>
</element-citation>
</ref>
<ref id="R290">
<label>290</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallace</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Brandl</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain.</article-title>
<source/>Pharmacogenomics and personalized medicine
          <year>2011</year>
<volume>4</volume>
<fpage>83</fpage>
<lpage>93</lpage>
<comment>Epub 2011/01/01</comment>
<pub-id pub-id-type="pmid">23226055</pub-id>
</element-citation>
</ref>
<ref id="R291">
<label>291</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sicard</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis.</article-title>
<source/>Pharmacogenomics
          <year>2010</year>
<volume>11</volume>
<issue>11</issue>
<fpage>1561</fpage>
<lpage>71</lpage>
<comment>Epub 2010/12/03</comment>
<pub-id pub-id-type="pmid">21121776</pub-id>
</element-citation>
</ref>
<ref id="R292">
<label>292</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Correll</surname>
<given-names>CU</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Gregersen</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.</article-title>
<source/>Archives of general psychiatry
          <year>2012</year>
<volume>69</volume>
<issue>9</issue>
<fpage>904</fpage>
<lpage>12</lpage>
<comment>Epub 2012/05/09</comment>
<pub-id pub-id-type="pmid">22566560</pub-id>
</element-citation>
</ref>
<ref id="R293">
<label>293</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandl</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Frydrychowicz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Lett</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Kitzrow</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Buttner</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain.</article-title>
<source/>Progress in neuro-psychopharmacology &amp; biological psychiatry
          <year>2012</year>
<volume>38</volume>
<issue>2</issue>
<fpage>134</fpage>
<lpage>41</lpage>
<comment>Epub 2012/03/20</comment>
<pub-id pub-id-type="pmid">22426215</pub-id>
</element-citation>
</ref>
<ref id="R294">
<label>294</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellavance</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rivest</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The HPA - Immune Axis and the Immunomodulatory Actions of Glucocorticoids in the Brain.</article-title>
<source/>Frontiers in immunology
          <year>2014</year>
<volume>5</volume>
<fpage>136</fpage>
<comment>Epub 2014/04/20</comment>
<pub-id pub-id-type="pmid">24744759</pub-id>
</element-citation>
</ref>
<ref id="R295">
<label>295</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valleau</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>EL</given-names>
</name>
</person-group>
<article-title>The impact of leptin on perinatal development and psychopathology.</article-title>
<source/>Journal of chemical neuroanatomy
          <year>2014</year>
<comment>Epub 2014/05/28</comment>
</element-citation>
</ref>
<ref id="R296">
<label>296</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB.</article-title>
<source/>Aging
          <year>2012</year>
<volume>4</volume>
<issue>2</issue>
<fpage>98</fpage>
<lpage>115</lpage>
<comment>Epub 2012/02/14</comment>
<pub-id pub-id-type="pmid">22328600</pub-id>
</element-citation>
</ref>
<ref id="R297">
<label>297</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guest</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Dobrowolny</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bogerts</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy.</article-title>
<source/>Schizophrenia research
          <year>2014</year>
<comment>Epub 2014/06/21</comment>
</element-citation>
</ref>
<ref id="R298">
<label>298</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyado</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tamano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rapid generation of mouse models with defined point mutations by the CRISPR/Cas9 system.</article-title>
<source/>Scientific reports
          <year>2014</year>
<volume>4</volume>
<fpage>5396</fpage>
<comment>Epub 2014/06/24</comment>
<pub-id pub-id-type="pmid">24953798</pub-id>
</element-citation>
</ref>
<ref id="R299">
<label>299</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects.</article-title>
<source/>Nature methods
          <year>2014</year>
<volume>11</volume>
<issue>4</issue>
<fpage>399</fpage>
<lpage>402</lpage>
<comment>Epub 2014/03/04</comment>
<pub-id pub-id-type="pmid">24584192</pub-id>
</element-citation>
</ref>
<ref id="R300">
<label>300</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijshake</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>van de Sluis</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Endonucleases: new tools to edit the mouse genome.</article-title>
<source/>Biochimica et biophysica acta
          <year>2014</year>
<comment>Epub 2014/05/06</comment>
</element-citation>
</ref>
<ref id="R301">
<label>301</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiroi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hishimoto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Boku</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hiramoto</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders.</article-title>
<source/>Molecular psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>11</issue>
<fpage>1153</fpage>
<lpage>65</lpage>
<comment>Epub 2013/08/07</comment>
<pub-id pub-id-type="pmid">23917946</pub-id>
</element-citation>
</ref>
<ref id="R302">
<label>302</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brennand</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Savas</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Simone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hashimoto-Torii</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia.</article-title>
<source/>Molecular psychiatry
          <year>2014</year>
<comment>Epub 2014/04/02</comment>
</element-citation>
</ref>
<ref id="R303">
<label>303</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abazyan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kannan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ishizuka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tamashiro</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Nucifora</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology.</article-title>
<source/>Biological psychiatry
          <year>2010</year>
<volume>68</volume>
<issue>12</issue>
<fpage>1172</fpage>
<lpage>81</lpage>
<comment>Epub 2010/12/07</comment>
<pub-id pub-id-type="pmid">21130225</pub-id>
</element-citation>
</ref>
<ref id="R304">
<label>304</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desbonnet</surname>
<given-names>L</given-names>
</name>
<name>
<surname>O'Tuathaigh</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>O'Leary</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Petit</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene x environment interaction.</article-title>
<source/>Brain, behavior, and immunity
          <year>2012</year>
<volume>26</volume>
<issue>4</issue>
<fpage>660</fpage>
<lpage>71</lpage>
<comment>Epub 2012/03/20</comment>
</element-citation>
</ref>
<ref id="R305">
<label>305</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vuillermot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Joodmardi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Perlmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ogren</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Feldon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2012</year>
<volume>32</volume>
<issue>2</issue>
<fpage>436</fpage>
<lpage>51</lpage>
<comment>Epub 2012/01/13</comment>
<pub-id pub-id-type="pmid">22238080</pub-id>
</element-citation>
</ref>
<ref id="R306">
<label>306</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niwa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kamiya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits.</article-title>
<source/>Neuron
          <year>2010</year>
<volume>65</volume>
<issue>4</issue>
<fpage>480</fpage>
<lpage>9</lpage>
<comment>Epub 2010/03/02</comment>
<pub-id pub-id-type="pmid">20188653</pub-id>
</element-citation>
</ref>
<ref id="R307">
<label>307</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>O'Donnell</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Delayed mesolimbic system alteration in a developmental animal model of schizophrenia.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2002</year>
<volume>22</volume>
<issue>20</issue>
<fpage>9070</fpage>
<lpage>7</lpage>
<comment>Epub 2002/10/22</comment>
<pub-id pub-id-type="pmid">12388614</pub-id>
</element-citation>
</ref>
<ref id="R308">
<label>308</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feleder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Calhoon</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>O'Donnell</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Neonatal intrahippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats.</article-title>
<source/>Biological psychiatry
          <year>2010</year>
<volume>67</volume>
<issue>4</issue>
<fpage>386</fpage>
<lpage>92</lpage>
<comment>Epub 2009/11/17</comment>
<pub-id pub-id-type="pmid">19914600</pub-id>
</element-citation>
</ref>
<ref id="R309">
<label>309</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kluge</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Alsaif</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guest</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bahn</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders.</article-title>
<source/>Expert review of molecular diagnostics
          <year>2011</year>
<volume>11</volume>
<issue>7</issue>
<fpage>721</fpage>
<lpage>33</lpage>
<comment>Epub 2011/09/10</comment>
<pub-id pub-id-type="pmid">21902534</pub-id>
</element-citation>
</ref>
<ref id="R310">
<label>310</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pechnick</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>George</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Poland</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hiramatsu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Characterization of the effects of the acute and chronic administration of phencyclidine on the release of adrenocorticotropin, corticosterone and prolactin in the rat: evidence for the differential development of tolerance.</article-title>
<source/>The Journal of pharmacology and experimental therapeutics
          <year>1989</year>
<volume>250</volume>
<issue>2</issue>
<fpage>534</fpage>
<lpage>40</lpage>
<comment>Epub 1989/08/01</comment>
<pub-id pub-id-type="pmid">2547936</pub-id>
</element-citation>
</ref>
<ref id="R311">
<label>311</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fattorini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Melone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bragina</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Candiracci</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cozzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pellegrini Giampietro</surname>
<given-names>DE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GLT-1 expression and Glu uptake in rat cerebral cortex are increased by phencyclidine.</article-title>
<source/>Glia
          <year>2008</year>
<volume>56</volume>
<issue>12</issue>
<fpage>1320</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">18615569</pub-id>
</element-citation>
</ref>
<ref id="R312">
<label>312</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Matsui</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kamei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mouri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Matsuba</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling.</article-title>
<source/>Behavioural brain research
          <year>2007</year>
<volume>180</volume>
<issue>2</issue>
<fpage>152</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">17451820</pub-id>
</element-citation>
</ref>
<ref id="R313">
<label>313</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenkins</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Harte</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>McKibben</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>GP</given-names>
</name>
</person-group>
<article-title>Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat.</article-title>
<source/>Behavioural brain research
          <year>2008</year>
<volume>194</volume>
<issue>2</issue>
<fpage>230</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">18706451</pub-id>
</element-citation>
</ref>
<ref id="R314">
<label>314</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKibben</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Harte</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>GP</given-names>
</name>
</person-group>
<article-title>Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat.</article-title>
<source/>Behavioural brain research
          <year>2010</year>
<volume>208</volume>
<issue>1</issue>
<fpage>132</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">19914297</pub-id>
</element-citation>
</ref>
<ref id="R315">
<label>315</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braun</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Genius</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grunze</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moller</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.</article-title>
<source/>Schizophrenia research
          <year>2007</year>
<volume>97</volume>
<issue>1-3</issue>
<fpage>254</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">17601703</pub-id>
</element-citation>
</ref>
<ref id="R316">
<label>316</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bullock</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Bolognani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Botta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Valenzuela</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Perrone-Bizzozero</surname>
<given-names>NI</given-names>
</name>
</person-group>
<article-title>Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine.</article-title>
<source/>Neurochemistry international
          <year>2009</year>
<volume>55</volume>
<issue>8</issue>
<fpage>775</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">19651169</pub-id>
</element-citation>
</ref>
<ref id="R317">
<label>317</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Snigdha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shahid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Neill</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Tarazi</surname>
<given-names>FI</given-names>
</name>
</person-group>
<article-title>Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.</article-title>
<source/>Journal of molecular neuroscience : MN
          <year>2009</year>
<volume>38</volume>
<issue>3</issue>
<fpage>227</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">19455435</pub-id>
</element-citation>
</ref>
<ref id="R318">
<label>318</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beninger</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Beuk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Banasikowski</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>van Adel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boivin</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Subchronic phencyclidine in rats: alterations in locomotor activity, maze performance, and GABA(A) receptor binding.</article-title>
<source/>Behavioural pharmacology
          <year>2010</year>
<volume>21</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">19949321</pub-id>
</element-citation>
</ref>
<ref id="R319">
<label>319</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyde</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Effects of phencyclidine on 5-hydroxytryptophan- and suckling-induced prolactin release.</article-title>
<source/>Brain research
          <year>1992</year>
<volume>573</volume>
<issue>2</issue>
<fpage>204</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">1504760</pub-id>
</element-citation>
</ref>
<ref id="R320">
<label>320</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kakita</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Futamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sakimura</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment.</article-title>
<source/>Journal of neurochemistry
          <year>2006</year>
<volume>99</volume>
<issue>3</issue>
<fpage>770</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">16903871</pub-id>
</element-citation>
</ref>
<ref id="R321">
<label>321</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oskvig</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Elkahloun</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Herkenham</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response.</article-title>
<source/>Brain, behavior, and immunity
          <year>2012</year>
<volume>26</volume>
<issue>4</issue>
<fpage>623</fpage>
<lpage>34</lpage>
<comment>Epub 2012/02/09</comment>
</element-citation>
</ref>
<ref id="R322">
<label>322</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems.</article-title>
<source/>Biological psychiatry
          <year>2014</year>
<volume>75</volume>
<issue>4</issue>
<fpage>307</fpage>
<lpage>15</lpage>
<comment>Epub 2013/08/14</comment>
<pub-id pub-id-type="pmid">23938317</pub-id>
</element-citation>
</ref>
<ref id="R323">
<label>323</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>XR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>White matter injuries induced by MK-801 in a mouse model of schizophrenia based on NMDA antagonism.</article-title>
<source/>Anatomical record
          <year>2014</year>
<volume>297</volume>
<issue>8</issue>
<fpage>1498</fpage>
<lpage>507</lpage>
</element-citation>
</ref>
<ref id="R324">
<label>324</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic Phencyclidine Induces Inflammatory Responses and Activates GSK3beta in Mice.</article-title>
<source/>Neurochemical research
          <year>2014</year>
<volume>39</volume>
<issue>12</issue>
<fpage>2385</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">25270429</pub-id>
</element-citation>
</ref>
<ref id="R325">
<label>325</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venancio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Felix</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Coutinho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Antunes</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peixoto</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Acute Ketamine Impairs Mitochondrial Function and Promotes Superoxide Dismutase Activity in the Rat Brain.</article-title>
<source/>Anesthesia and analgesia
          <year>2014</year>
</element-citation>
</ref>
<ref id="R326">
<label>326</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dean</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Karl</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pavey</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duffy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Scarr</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice.</article-title>
<source/>Schizophrenia research
          <year>2008</year>
<volume>99</volume>
<issue>1-3</issue>
<fpage>341</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">18054201</pub-id>
</element-citation>
</ref>
<ref id="R327">
<label>327</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iltis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Koski</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Eberly</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Deelchand</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Valette</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study.</article-title>
<source/>NMR in biomedicine
          <year>2009</year>
<volume>22</volume>
<issue>7</issue>
<fpage>737</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">19338025</pub-id>
</element-citation>
</ref>
<ref id="R328">
<label>328</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ernst</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Garcia-Perez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kluge</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular validation of the acute phencyclidine rat model for schizophrenia: identification of translational changes in energy metabolism and neurotransmission.</article-title>
<source/>Journal of proteome research
          <year>2012</year>
<volume>11</volume>
<issue>7</issue>
<fpage>3704</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">22613019</pub-id>
</element-citation>
</ref>
<ref id="R329">
<label>329</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XM</given-names>
</name>
</person-group>
<article-title>Neuregulin 1/ErbB4 enhances synchronized oscillations of prefrontal cortex neurons via inhibitory synapses.</article-title>
<source/>Neuroscience
          <year>2014</year>
<volume>261</volume>
<fpage>107</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">24374327</pub-id>
</element-citation>
</ref>
<ref id="R330">
<label>330</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ginsberg</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lotan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Khatib</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Awad</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Errison</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maternal lipopolysaccharide alters the newborn oxidative stress and C-reactive protein levels in response to an inflammatory stress.</article-title>
<source/>Journal of developmental origins of health and disease
          <year>2012</year>
<volume>3</volume>
<issue>5</issue>
<fpage>358</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">25102265</pub-id>
</element-citation>
</ref>
<ref id="R331">
<label>331</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirsten</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Lippi</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Bevilacqua</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>LPS exposure increases maternal corticosterone levels, causes placental injury and increases IL-1Beta levels in adult rat offspring: relevance to autism.</article-title>
<source/>PloS one
          <year>2013</year>
<volume>8</volume>
<issue>12</issue>
<fpage>e82244</fpage>
<pub-id pub-id-type="pmid">24312647</pub-id>
</element-citation>
</ref>
<ref id="R332">
<label>332</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burt</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Boksa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>TP</given-names>
</name>
</person-group>
<article-title>Prenatal immune activation interacts with stress and corticosterone exposure later in life to modulate N-methyl-D-aspartate receptor synaptic function and plasticity.</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2013</year>
<volume>16</volume>
<issue>8</issue>
<fpage>1835</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">23552018</pub-id>
</element-citation>
</ref>
<ref id="R333">
<label>333</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacheco-Lopez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Giovanoli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Langhans</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia.</article-title>
<source/>Schizophrenia bulletin
          <year>2013</year>
<volume>39</volume>
<issue>2</issue>
<fpage>319</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">22186136</pub-id>
</element-citation>
</ref>
<ref id="R334">
<label>334</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cole</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Co</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Mohar</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>LG</given-names>
</name>
</person-group>
<article-title>Behavioral Characterization of GCLM-Knockout Mice, a Model for Enhanced Susceptibility to Oxidative Stress.</article-title>
<source/>Journal of toxicology
          <year>2011</year>
<volume>2011</volume>
<fpage>157687</fpage>
<pub-id pub-id-type="pmid">21559092</pub-id>
</element-citation>
</ref>
<ref id="R335">
<label>335</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flores</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Labelle-Dumais</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kolb</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Chronic phencyclidine treatment increases dendritic spine density in prefrontal cortex and nucleus accumbens neurons.</article-title>
<source/>Synapse (New York, NY)
          <year>2007</year>
<volume>61</volume>
<issue>12</issue>
<fpage>978</fpage>
<lpage>84</lpage>
</element-citation>
</ref>
<ref id="R336">
<label>336</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohn</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Gainetdinov</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Koller</surname>
<given-names>BH</given-names>
</name>
</person-group>
<article-title>Mice with reduced NMDA receptor expression display behaviors related to schizophrenia.</article-title>
<source/>Cell
          <year>1999</year>
<volume>98</volume>
<issue>4</issue>
<fpage>427</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">10481908</pub-id>
</element-citation>
</ref>
<ref id="R337">
<label>337</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fradley</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>O'Meara</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Andrieux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Job</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating.</article-title>
<source/>Behavioural brain research
          <year>2005</year>
<volume>163</volume>
<issue>2</issue>
<fpage>257</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">16046005</pub-id>
</element-citation>
</ref>
<ref id="R338">
<label>338</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holloway</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Umali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rayannavar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hodes</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2013</year>
<volume>33</volume>
<issue>3</issue>
<fpage>1088</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">23325246</pub-id>
</element-citation>
</ref>
<ref id="R339">
<label>339</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tezuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sakaue</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takemoto</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis.</article-title>
<source/>Neurobiology of disease
          <year>2013</year>
<volume>59</volume>
<fpage>63</fpage>
<lpage>8</lpage>
<comment>Epub 2013/07/23</comment>
<pub-id pub-id-type="pmid">23867234</pub-id>
</element-citation>
</ref>
<ref id="R340">
<label>340</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabungcal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morishita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kraftsik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hensch</surname>
<given-names>TK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Perineuronal nets protect fast-spiking interneurons against oxidative stress.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2013</year>
<volume>110</volume>
<issue>22</issue>
<fpage>9130</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">23671099</pub-id>
</element-citation>
</ref>
<ref id="R341">
<label>341</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Griffa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mekle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients.</article-title>
<source/>Molecular psychiatry
          <year>2014</year>
</element-citation>
</ref>
<ref id="R342">
<label>342</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kendig</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Krishan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Genter</surname>
<given-names>MB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lipid metabolism and body composition in Gclm(−/−) mice.</article-title>
<source/>Toxicology and applied pharmacology
          <year>2011</year>
<volume>257</volume>
<issue>3</issue>
<fpage>338</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">21967773</pub-id>
</element-citation>
</ref>
<ref id="R343">
<label>343</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder.</article-title>
<source/>Behavioural brain research
          <year>2012</year>
<volume>226</volume>
<issue>2</issue>
<fpage>563</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">22033334</pub-id>
</element-citation>
</ref>
<ref id="R344">
<label>344</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Curran</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Nebert</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Vorhees</surname>
<given-names>CV</given-names>
</name>
</person-group>
<article-title>Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm−/− knockout mice.</article-title>
<source/>Neurotoxicology and teratology
          <year>2012</year>
<volume>34</volume>
<issue>4</issue>
<fpage>450</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">22580179</pub-id>
</element-citation>
</ref>
<ref id="R345">
<label>345</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eyles</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Almeras</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Benech</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patatian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain.</article-title>
<source/>The Journal of steroid biochemistry and molecular biology
          <year>2007</year>
<volume>103</volume>
<issue>3-5</issue>
<fpage>538</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">17293106</pub-id>
</element-citation>
</ref>
<ref id="R346">
<label>346</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kesby</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Burne</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Eyles</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia.</article-title>
<source/>Biological psychiatry
          <year>2006</year>
<volume>60</volume>
<issue>6</issue>
<fpage>591</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">16697353</pub-id>
</element-citation>
</ref>
<ref id="R347">
<label>347</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eyles</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Burne</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease.</article-title>
<source/>Frontiers in neuroendocrinology
          <year>2013</year>
<volume>34</volume>
<issue>1</issue>
<fpage>47</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">22796576</pub-id>
</element-citation>
</ref>
<ref id="R348">
<label>348</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Paterlini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pavlidis</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2006</year>
<volume>103</volume>
<issue>45</issue>
<fpage>16906</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">17077150</pub-id>
</element-citation>
</ref>
<ref id="R349">
<label>349</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balu</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kazi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hill-Smith</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Easton</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function.</article-title>
<source/>Hippocampus
          <year>2012</year>
<volume>22</volume>
<issue>2</issue>
<fpage>230</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">21049487</pub-id>
</element-citation>
</ref>
<ref id="R350">
<label>350</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Thorvaldsen</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice.</article-title>
<source/>The Journal of biological chemistry
          <year>2001</year>
<volume>276</volume>
<issue>42</issue>
<fpage>38349</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">11533044</pub-id>
</element-citation>
</ref>
<ref id="R351">
<label>351</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dummler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hemmings</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Physiological roles of PKB/Akt isoforms in development and disease.</article-title>
<source/>Biochemical Society transactions
          <year>2007</year>
<volume>35</volume>
<issue>Pt 2</issue>
<fpage>231</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">17371246</pub-id>
</element-citation>
</ref>
<ref id="R352">
<label>352</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makinodan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corfas</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>A critical period for social experience-dependent oligodendrocyte maturation and myelination.</article-title>
<source/>Science (New York, NY)
          <year>2012</year>
<volume>337</volume>
<issue>6100</issue>
<fpage>1357</fpage>
<lpage>60</lpage>
</element-citation>
</ref>
<ref id="R353">
<label>353</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toua</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brand</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Moller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Emsley</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>BH</given-names>
</name>
</person-group>
<article-title>The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats.</article-title>
<source/>Neuroscience
          <year>2010</year>
<volume>165</volume>
<issue>2</issue>
<fpage>492</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">19854242</pub-id>
</element-citation>
</ref>
<ref id="R354">
<label>354</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malone</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Kearn</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Chongue</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mackie</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Effect of social isolation on CB1 and D2 receptor and fatty acid amide hydrolase expression in rats.</article-title>
<source/>Neuroscience
          <year>2008</year>
<volume>152</volume>
<issue>1</issue>
<fpage>265</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">18082330</pub-id>
</element-citation>
</ref>
<ref id="R355">
<label>355</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassidy</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Mulvany</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Pangalos</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Developmental emergence of reelin deficits in the prefrontal cortex of Wistar rats reared in social isolation.</article-title>
<source/>Neuroscience
          <year>2010</year>
<volume>166</volume>
<issue>2</issue>
<fpage>377</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">20035841</pub-id>
</element-citation>
</ref>
<ref id="R356">
<label>356</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipska</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Lerman</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Khaing</surname>
<given-names>ZZ</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain.</article-title>
<source/>The European journal of neuroscience
          <year>2003</year>
<volume>18</volume>
<issue>11</issue>
<fpage>3097</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">14656305</pub-id>
</element-citation>
</ref>
<ref id="R357">
<label>357</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname>
<given-names>RQ</given-names>
</name>
<name>
<surname>Giovanni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kafka</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and in vivo microdialysis studies.</article-title>
<source/>Behavioural brain research
          <year>1996</year>
<volume>78</volume>
<issue>2</issue>
<fpage>211</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">8864054</pub-id>
</element-citation>
</ref>
<ref id="R358">
<label>358</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>Neonatal lesions of the ventral hippocampal formation disrupt neuroendocrine responses to auditory stress in the adult rat.</article-title>
<source/>Psychoneuroendocrinology
          <year>2004</year>
<volume>29</volume>
<issue>10</issue>
<fpage>1317</fpage>
<lpage>25</lpage>
<comment>Epub 2004/08/04</comment>
<pub-id pub-id-type="pmid">15288711</pub-id>
</element-citation>
</ref>
<ref id="R359">
<label>359</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francois</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Koning</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ferrandon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sandner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nehlig</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Metabolic activity in the brain of juvenile and adult rats with a neonatal ventral hippocampal lesion.</article-title>
<source/>Hippocampus
          <year>2010</year>
<volume>20</volume>
<issue>7</issue>
<fpage>841</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">19650120</pub-id>
</element-citation>
</ref>
<ref id="R360">
<label>360</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bachevalier</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Alterations of hippocampal projections in adult macaques with neonatal hippocampal lesions: A Diffusion Tensor Imaging study.</article-title>
<source/>NeuroImage
          <year>2014</year>
<volume>102</volume>
<issue>Pt 2</issue>
<fpage>828</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">25204865</pub-id>
</element-citation>
</ref>
<ref id="R361">
<label>361</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murtie</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>El-Khodor</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sardi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Hooks</surname>
<given-names>BM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2007</year>
<volume>104</volume>
<issue>19</issue>
<fpage>8131</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">17483467</pub-id>
</element-citation>
</ref>
<ref id="R362">
<label>362</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brinkmann</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sereda</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Garratt</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wende</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system.</article-title>
<source/>Neuron
          <year>2008</year>
<volume>59</volume>
<issue>4</issue>
<fpage>581</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">18760695</pub-id>
</element-citation>
</ref>
<ref id="R363">
<label>363</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flagstad</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mork</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Glenthoj</surname>
<given-names>BY</given-names>
</name>
<name>
<surname>van Beek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Michael-Titus</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Didriksen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2004</year>
<volume>29</volume>
<issue>11</issue>
<fpage>2052</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">15199377</pub-id>
</element-citation>
</ref>
<ref id="R364">
<label>364</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penschuck</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Flagstad</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Didriksen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Michael-Titus</surname>
<given-names>AT</given-names>
</name>
</person-group>
<article-title>Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia.</article-title>
<source/>The European journal of neuroscience
          <year>2006</year>
<volume>23</volume>
<issue>1</issue>
<fpage>279</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">16420437</pub-id>
</element-citation>
</ref>
<ref id="R365">
<label>365</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsutani</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A neurochemical study of experimental microencephalic rat.</article-title>
<source/>The Journal of toxicological sciences
          <year>1984</year>
<volume>9</volume>
<issue>3</issue>
<fpage>205</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">6094841</pub-id>
</element-citation>
</ref>
<ref id="R366">
<label>366</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chin</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Curzon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>O'Connor</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Rueter</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>GB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia.</article-title>
<source/>Synapse (New York, NY)
          <year>2011</year>
<volume>65</volume>
<issue>5</issue>
<fpage>393</fpage>
<lpage>403</lpage>
</element-citation>
</ref>
<ref id="R367">
<label>367</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonnum</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lock</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>The contributions of excitotoxicity, glutathione depletion and DNA repair in chemically induced injury to neurones: exemplified with toxic effects on cerebellar granule cells.</article-title>
<source/>Journal of neurochemistry
          <year>2004</year>
<volume>88</volume>
<issue>3</issue>
<fpage>513</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">14720201</pub-id>
</element-citation>
</ref>
<ref id="R368">
<label>368</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmerman</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Bellaire</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ewing</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Grace</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<issue>11</issue>
<fpage>2131</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">23652286</pub-id>
</element-citation>
</ref>
<ref id="R369">
<label>369</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grace</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stampachiacchiere</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Aloe</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Impaired brain development in the rat following prenatal exposure to methylazoxymethanol acetate at gestational day 17 and neurotrophin distribution.</article-title>
<source/>Neuroreport
          <year>2004</year>
<volume>15</volume>
<issue>11</issue>
<fpage>1791</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15257149</pub-id>
</element-citation>
</ref>
<ref id="R370">
<label>370</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makinodan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tatsumi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Manabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Makinodan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Matsuyoshi</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring.</article-title>
<source/>Journal of neuroscience research
          <year>2008</year>
<volume>86</volume>
<issue>10</issue>
<fpage>2190</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">18438922</pub-id>
</element-citation>
</ref>
<ref id="R371">
<label>371</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcotte</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>LK</given-names>
</name>
</person-group>
<article-title>Animal models of schizophrenia: a critical review.</article-title>
<source/>Journal of psychiatry &amp; neuroscience : JPN
          <year>2001</year>
<volume>26</volume>
<issue>5</issue>
<fpage>395</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="pmid">11762207</pub-id>
</element-citation>
</ref>
<ref id="R372">
<label>372</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipska</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>To model a psychiatric disorder in animals: schizophrenia as a reality test.</article-title>
<source/>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          <year>2000</year>
<volume>23</volume>
<issue>3</issue>
<fpage>223</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">10942847</pub-id>
</element-citation>
</ref>
<ref id="R373">
<label>373</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Jaaro-Peled</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shahani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sedlak</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Zoubovsky</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Burruss</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness.</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>2013</year>
<volume>110</volume>
<issue>30</issue>
<fpage>12462</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">23840059</pub-id>
</element-citation>
</ref>
<ref id="R374">
<label>374</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dieter</surname>
<given-names>MZ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shertzer</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Nebert</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>TP</given-names>
</name>
</person-group>
<article-title>Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(−/−) knockout mouse. Novel model system for a severely compromised oxidative stress response.</article-title>
<source/>The Journal of biological chemistry
          <year>2002</year>
<volume>277</volume>
<issue>51</issue>
<fpage>49446</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">12384496</pub-id>
</element-citation>
</ref>
<ref id="R375">
<label>375</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cabungcal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kulak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kraftsik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>TP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors.</article-title>
<source/>The Journal of neuroscience : the official journal of the Society for Neuroscience
          <year>2010</year>
<volume>30</volume>
<issue>7</issue>
<fpage>2547</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">20164340</pub-id>
</element-citation>
</ref>
<ref id="R376">
<label>376</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matrisciano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tueting</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dalal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kadriu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grayson</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice.</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>68</volume>
<fpage>184</fpage>
<lpage>94</lpage>
<comment>Epub 2012/05/09</comment>
<pub-id pub-id-type="pmid">22564440</pub-id>
</element-citation>
</ref>
<ref id="R377">
<label>377</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferdman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Murmu</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Bock</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leshem</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Weaning age, social isolation, and gender, interact to determine adult explorative and social behavior, and dendritic and spine morphology in prefrontal cortex of rats.</article-title>
<source/>Behavioural brain research
          <year>2007</year>
<volume>180</volume>
<issue>2</issue>
<fpage>174</fpage>
<lpage>82</lpage>
<comment>Epub 2007/05/05</comment>
<pub-id pub-id-type="pmid">17477981</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>L-[β-<sup>11</sup>C]-DOPA and [<sup>18</sup>F]-DOPA positron emission tomography (PET) imaging. (A) Individual k<sub>i</sub> values in the left caudate nucleus. Horizontal lines represent mean values of the groups. In the schizophrenia group, closed circles indicate antipsychotic drug-naïve patients while open circles indicate drug-free patients. There was a significant group difference in k<sub>i</sub> values for the left caudate nucleus. (reproduced with permission from Nozaki <italic>et al</italic>.<sup><xref ref-type="bibr" rid="R33">33</xref></sup>) (B) Individual and group mean±SD [<sup>18</sup>F]-DOPA uptake (k<sub>i</sub><sup>cer</sup>) (min–1) values in the whole, associative, sensorimotor, and limbic striatum. Data in the healthy control group are represented by grey diamonds and data in the ultra-high risk group (UHR) by black triangles. k<sub>i</sub><sup>cer</sup> values were significantly higher in the UHR than control group in the whole and associative striatum (*p&lt;.05), indicating elevated dopamine synthesis capacity. (reproduced with permission from Egerton <italic>et al.</italic><sup><xref ref-type="bibr" rid="R34">34</xref></sup>)</p>
</caption>
<graphic xlink:href="nihms-703456-f0001"></graphic>
</fig>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Molecular crosstalk between the biological systems in schizophrenia. Mesolimbic dopaminergic projections (yellow) between the ventral tegmental area (VTA) and striatum (Str.) are significantly increased. The dopaminergic mesocortical pathway is also affected. Multiple glutamatergic (pink) pathways are affected. GABAergic (blue) pathways are also affected. Glucocorticoids released from the adrenal glands affect numerous brain targets including the cortex, hippocampus (Hip.), hypothalamus (Hyp) and pituitary gland. Molecular substrates of adipose tissue and the gut interact with the hypothalamic-pituitary-adrenal axis via the hypothalamus. Th, thalamus; WM, white matter; CRH, corticotropin releasing hormone; ACTH, adrenocorticotropic hormone.</p>
</caption>
<graphic xlink:href="nihms-703456-f0002"></graphic>
</fig>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Inter-cellular interactions of some important molecular substrates affected in schizophrenia. A glutamatergic synapse with contact from a nearby astrocyte represents changes in neuronal signaling. Changes in myelination and formation of nodes of Ranvier along the axon are represented by a single oligodendrocyte. Peripheral factors enter the brain through the blood-brain barrier formed between blood vessels and astrocyte end feet. Inflammatory factors are released by microglia and astrocytes. NRG1, neuregulin-1; MAG, myelin-associated glycoprotein; PLP1, proteolipid protein 1; ANK3, ankyrin-3; ARC, activity-regulated cytoskeleton-associated protein; PSD-95, postsynaptic density protein 95; DISC1, disrupted in schizophrenia 1; PAK6, p21 protein-activated kinase 6; PAK7, p21 protein-activated kinase 7.</p>
</caption>
<graphic xlink:href="nihms-703456-f0003"></graphic>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Molecular and Cellular<sup><xref ref-type="table-fn" rid="TFN1">1</xref></sup> Substrates of Schizophrenia, Organized by System</p>
</caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Neurotransmission</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dopamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">D2 Receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">D1 Receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Homovanillic acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tyrosine hydroxylase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5HT2A receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glutamate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NMDA Receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glutamate receptor, ionotropic, NMDAR 2A (GRIN2A)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glutamate receptor, ionotropic, AMPA 1 (GRIA1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Activity-regulated cytoskeleton-associated protein (ARC) signaling complex</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glutamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GABA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GAD67</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Parvalbumin (PV)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kv3.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">KCNS3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Somatostatin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cholecystokinin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nicotinic acetylcholine receptors (nAChRs)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Potassium channel tetramerization domain containing 13 (KCTD13)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Contactin 4 (CNTN4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">P21 protein-activated kinase 6 (PAK6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neuroligin 4, X-linked (NLGN4X)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Disrupted in schizophrenia 1 (DISCI)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">P21 protein-activated kinase 7 (PAK7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">N-thylmaleimide sensitive factor (NSF)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Synapsin II (SYN2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Dendritic Spines</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>White matter-associated connectivity</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Proteolipid protein 1 (PLP1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Myelin-associated glycoprotein (MAG)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Myelin oligodendrocyte glycoprotein (MOG)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">oligodendrocyte transcription factor 2 (OLIG2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neuregulin-1 (NRG1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Receptor tyrosine-protein kinase erbB4 (ERBB4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">reticulon 4 (RTN4/NOGO)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cyclic-nucleotide-3′-phosphodiesterase (CNP1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Akyrin-3 (ANK3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zinc finger binding protein 804A (ZNF804A)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">L-type voltage-dependent calcium channel CAV1.2 (CACNA1C)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">MicroRNA-137 (MIR137)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Disrupted in schizophrenia 1 (DISC1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Myelin</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Node of Ranvier</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Oligodendrocytes</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Immune/inflammatory response and oxidative stress</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IL-1β</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IL-2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IL-6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TNF-α</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">soluble IL-2 receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IL-12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IFN-γ</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IL-8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Translocator protein (TSPO)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Major histocompability complex (MHC)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glutathione (GSH)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Microsomal glutathione S -transferase 1 (MGST1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Superoxide dismutase (SOD)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Catalase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Inflammation</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Oxidative stress</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Microglia</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>T Cells</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Macrophages</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Endocrine system</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Adrenocorticotropic hormone (ACTH); proACTH</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Corticosterone; Cortisol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glucocorticoids; Glucocorticoid receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Estradiol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Hypothalamic-pituitary-adrenal (HPA) axis</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Metabolic cascades</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glucose</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin; proinsulin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Akt</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Leptin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ghrelin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Apolipoprotein1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Melanocortin 4 receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5HT2C receptor</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>1</label>
<p id="P55">Cellular substrates appear in italics</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" orientation="landscape" position="float">
<label>Table 2</label>
<caption>
<p>Summary of Clinical Evidence by System</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">System</th>
<th align="center" colspan="1" rowspan="1" valign="top">Brain Imaging</th>
<th align="center" colspan="1" rowspan="1" valign="top">Neurochemical</th>
<th align="center" colspan="1" rowspan="1" valign="top">Postmortem</th>
<th align="center" colspan="1" rowspan="1" valign="top">Genetic</th>
<th align="center" colspan="1" rowspan="1" valign="top">Clinicopharmacological</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neurotransmission</td>
<td align="center" colspan="1" rowspan="1" valign="top">+++</td>
<td align="center" colspan="1" rowspan="1" valign="top">+++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">+++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">White matter-associated connectivity</td>
<td align="center" colspan="1" rowspan="1" valign="top">+++</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Immune/Inflammatory response and oxidative stress</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Endocrine system</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">+++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">+/−</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Metabolic cascades</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
<td align="center" colspan="1" rowspan="1" valign="top">++</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>+++, strong evidence; ++ sufficient evidence; + additional evidence needed; +/− some evidence</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<p>Summary of glutamate and GABA <sup>1</sup>H MRS studies</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" valign="top">Glutamatergic level (subject vs control)</th>
<th align="center" colspan="1" rowspan="1" valign="top">Brain Region</th>
<th align="center" colspan="1" rowspan="1" valign="top">Disease stage</th>
<th align="center" colspan="1" rowspan="1" valign="top">Antipsychotic Status</th>
<th align="center" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↑
</td>
<td align="center" colspan="1" rowspan="1" valign="top">MPFC, ACC</td>
<td align="center" colspan="1" rowspan="1" valign="top">E, C</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Poels <italic>et al.</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↓
</td>
<td align="center" colspan="1" rowspan="1" valign="top">MPFC, ACC</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Marsman et al.<sup><xref ref-type="bibr" rid="R65">65</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">ARMS</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">E</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">E</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">NR, +</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">MPFC, ACC</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Poels <italic>et al.</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">DLPFC</td>
<td align="center" colspan="1" rowspan="1" valign="top">E, C</td>
<td align="center" colspan="1" rowspan="1" valign="top">-, +</td>
<td align="center" colspan="1" rowspan="1" valign="top">Poels <italic>et al.</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Hippocampus</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Poels <italic>et al.</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup>, Marsman et al.<sup><xref ref-type="bibr" rid="R65">65</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">ARMS</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">NR</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">E, C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↓
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Hippocampus</td>
<td align="center" colspan="1" rowspan="1" valign="top">NR</td>
<td align="center" colspan="1" rowspan="1" valign="top">-, +</td>
<td align="center" colspan="1" rowspan="1" valign="top">Stan <italic>et al.</italic><sup><xref ref-type="bibr" rid="R69">69</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↓
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Thalamus</td>
<td align="center" colspan="1" rowspan="1" valign="top">ARMS</td>
<td align="center" colspan="1" rowspan="1" valign="top">-, +</td>
<td align="center" colspan="1" rowspan="1" valign="top">Poels <italic>et al.</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↑
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Thalamus</td>
<td align="center" colspan="1" rowspan="1" valign="top">E</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Poels <italic>et al.</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Thalamus</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Poels <italic>et al.</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup>, Marsman et al.<sup><xref ref-type="bibr" rid="R65">65</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">ARMS</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">E</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
</tbody>
</table>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" valign="top">GABA level (subject vs control)</th>
<th align="center" colspan="1" rowspan="1" valign="top">Brain Region</th>
<th align="center" colspan="1" rowspan="1" valign="top">Disease stage</th>
<th align="center" colspan="1" rowspan="1" valign="top">Antipsychotic Status</th>
<th align="center" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Frontal Lobe</td>
<td align="center" colspan="1" rowspan="1" valign="top">E</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Goto <italic>et al.</italic><sup><xref ref-type="bibr" rid="R81">81</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↑
</td>
<td align="center" colspan="1" rowspan="1" valign="top">ACC</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Ongur <italic>et al.</italic><sup><xref ref-type="bibr" rid="R84">84</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">ACC</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Tayoshi <italic>et al.</italic><sup><xref ref-type="bibr" rid="R82">82</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↓
</td>
<td align="center" colspan="1" rowspan="1" valign="top">ACC</td>
<td align="center" colspan="1" rowspan="1" valign="top">C, older age</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rowland <italic>et al.</italic><sup><xref ref-type="bibr" rid="R85">85</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↑
</td>
<td align="center" colspan="1" rowspan="1" valign="top">MPFC</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Kegeles <italic>et al.</italic><sup><xref ref-type="bibr" rid="R66">66</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">MPFC</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Kegeles <italic>et al.</italic><sup><xref ref-type="bibr" rid="R66">66</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">DLPFC</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">-, +</td>
<td align="center" colspan="1" rowspan="1" valign="top">Kegeles <italic>et al.</italic><sup><xref ref-type="bibr" rid="R66">66</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↓
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Basal Ganglia</td>
<td align="center" colspan="1" rowspan="1" valign="top">E</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Goto <italic>et al.</italic><sup><xref ref-type="bibr" rid="R81">81</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Basal Ganglia</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Tayoshi <italic>et al.</italic><sup><xref ref-type="bibr" rid="R82">82</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↑
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Parieto-Occipital Cortex</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">+</td>
<td align="center" colspan="1" rowspan="1" valign="top">Ongur <italic>et al.</italic><sup><xref ref-type="bibr" rid="R84">84</xref></sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">
↓
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Visual Cortex</td>
<td align="center" colspan="1" rowspan="1" valign="top">E, C</td>
<td align="center" colspan="1" rowspan="1" valign="top">-, +</td>
<td align="center" colspan="1" rowspan="1" valign="top">Yoon <italic>et al.</italic><sup><xref ref-type="bibr" rid="R83">83</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Abbreviations: MPFC, medial prefrontal cortex; ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; E, first-episode or early; C, chronic; ARMS, at-risk mental state; -, unmedicated; +, medicated; NR, not reported</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T4" orientation="landscape" position="float">
<label>Table 4</label>
<caption>
<p>Animal models relevant to schizophrenia classified by molecular system</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="7" rowspan="1" valign="top">Molecular Substrates Affected<hr/></th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" valign="top">
<italic>Target System</italic>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<italic>Animal Model<sup><xref ref-type="table-fn" rid="TFN2">1</xref></sup></italic>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<italic>Neurotransmission<sup><xref ref-type="table-fn" rid="TFN3">2</xref></sup></italic>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<italic>White Matter<sup><xref ref-type="table-fn" rid="TFN4">3</xref></sup></italic>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<italic>Immune/Oxidative Stress<sup><xref ref-type="table-fn" rid="TFN5">4</xref></sup></italic>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<italic>Endocrine/Metabolic<sup><xref ref-type="table-fn" rid="TFN6">5</xref></sup></italic>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<italic>Misc.</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">NT</td>
<td align="center" colspan="1" rowspan="1" valign="top">NMDAR antagonists (PCP, MK-801, ketamine)</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA, 5HT, spines</td>
<td align="center" colspan="1" rowspan="1" valign="top">WM tracts</td>
<td align="center" colspan="1" rowspan="1" valign="top">cytokines, nitrosative/oxidative stress</td>
<td align="center" colspan="1" rowspan="1" valign="top">HPA, glucose/insulin</td>
<td align="center" colspan="1" rowspan="1" valign="top">BDNF</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">NT</td>
<td align="center" colspan="1" rowspan="1" valign="top">NR1 haplomorph</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, DA</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">White Matter</td>
<td align="center" colspan="1" rowspan="1" valign="top">NRG1 and ErbB4 knockout</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA, 5HT, spines,</td>
<td align="center" colspan="1" rowspan="1" valign="top">WM tracts, oligodendrocytes</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">HPA</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Immune/Oxidative Stress</td>
<td align="center" colspan="1" rowspan="1" valign="top">Maternal immune activation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA, 5HT, spines,</td>
<td align="center" colspan="1" rowspan="1" valign="top">WM tracts</td>
<td align="center" colspan="1" rowspan="1" valign="top">cytokines, oxidative stress</td>
<td align="center" colspan="1" rowspan="1" valign="top">HPA, glucose/insulin</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Immune/Oxidative Stress</td>
<td align="center" colspan="1" rowspan="1" valign="top">Short-term cuprizone</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, DA,</td>
<td align="center" colspan="1" rowspan="1" valign="top">WM tracts</td>
<td align="center" colspan="1" rowspan="1" valign="top">cytokines</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Immune/Oxidative Stress</td>
<td align="center" colspan="1" rowspan="1" valign="top">Genetic glutathione depletion (GCLM knockout)</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA</td>
<td align="center" colspan="1" rowspan="1" valign="top">WM tracts, oligodendrocytes</td>
<td align="center" colspan="1" rowspan="1" valign="top">GSH</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Endocrine/Metabolic</td>
<td align="center" colspan="1" rowspan="1" valign="top">Vitamin D deficiency</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA,</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">redox</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Endocrine/Metabolic</td>
<td align="center" colspan="1" rowspan="1" valign="top">AKT1 knockout</td>
<td align="center" colspan="1" rowspan="1" valign="top">Spines</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Misc.</td>
<td align="center" colspan="1" rowspan="1" valign="top">Social isolation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA, 5HT, CB1, spines</td>
<td align="center" colspan="1" rowspan="1" valign="top">oligodendrocytes</td>
<td align="center" colspan="1" rowspan="1" valign="top">cytokines</td>
<td align="center" colspan="1" rowspan="1" valign="top">HPA, metabolic</td>
<td align="center" colspan="1" rowspan="1" valign="top">BDNF</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Misc.</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neonatal ventral hippocampal lesion</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA, ACh, spines,</td>
<td align="center" colspan="1" rowspan="1" valign="top">WM tracts</td>
<td align="center" colspan="1" rowspan="1" valign="top">oxidative stress</td>
<td align="center" colspan="1" rowspan="1" valign="top">HPA, glucose/insulin</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Misc.</td>
<td align="center" colspan="1" rowspan="1" valign="top">MAM</td>
<td align="center" colspan="1" rowspan="1" valign="top">Glu, GABA, DA, spines</td>
<td align="center" colspan="1" rowspan="1" valign="top">WM tracts</td>
<td align="center" colspan="1" rowspan="1" valign="top">GSH</td>
<td align="center" colspan="1" rowspan="1" valign="top">HPA</td>
<td align="center" colspan="1" rowspan="1" valign="top">BDNF, NGF</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Abbreviations: NT, neurotransmission; PCP, phencyclidine; Glu, glutamate; GABA, γ-aminobutyric acid; DA, Dopamine; 5HT, serotonin; WM, white matter; HPA, hypothalamus-pituitary-adrenal axis; BDNF, brain-derived neurotrophic factor; NR1, NMDA receptor subunit NR1; NRG1, neuregulin-1; ErbB4, receptor tyrosine kinase erbB4; GCLM, glutamate-cysteine ligase modulatory subunit; GSH, glutathione; AKT1, RAC-alpha serine/threonine-protein kinase; CB1, cannabinoid receptor type 1; ACh, Acetylcholine; MAM, methylazoxymethanol; NGF, nerve</p>
<fn id="TFN2">
<label>1</label>
<p id="P56">A selection of representative genetic and non-genetic animal models targeting particular systems discussed in the text are listed. These animal models have already been validated from behavioral viewpoints.</p>
</fn>
<fn id="TFN3">
<label>2</label>
<p id="P57">Molecular substrates affecting neurotransmission are grouped into glutamate (Glu), GABA, dopamine (DA), serotonin (5HT), acetylcholine (Ach), and dendritic spine (spines) systems.</p>
</fn>
<fn id="TFN4">
<label>3</label>
<p id="P58">White matter is divided between tissue level analysis (WM tracts) and cellular-level studies (oligodendrocytes).</p>
</fn>
<fn id="TFN5">
<label>4</label>
<p id="P59">Molecular substrates affecting inflammation (cytokines) and oxidative stress cascades (oxidative stress) are grouped. We make special note of redox and glutathione abnormalities (GSH).</p>
</fn>
<fn id="TFN6">
<label>5</label>
<p id="P60">Molecular substrates affecting the hypothalamic-pituitary-adrenal axis (HPA) and glucose/insulin pathways (glucose/insulin) are broadly grouped. Broader metabolic abnormalities including lipid metabolism are labeled “metabolic.”</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>